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Abstract 
INTRATUMORAL STING ACTIVATION SENSITIZES POORLY IMMUNOGENIC 
CANCERS TO CHECKPOINT BLOCKADE IMMUNOTHERAPY 
Casey Ager, B.S. 
Advisory Professor: Michael A. Curran, Ph.D. 
Unprecedented durable tumor regression can be achieved in patients with checkpoint 
blockade immunotherapy, yet these responses are rare and are not observed in all tumor 
types. Castration resistant prostate cancer (CRPC) and pancreatic adenocarcinoma 
(PDAC) are two common lethal cancers that remain refractory to checkpoint blockade, 
requiring development of new therapeutic approaches to promote responsivity in patients 
with these diseases. Both CRPC and PDAC are characterized by an immunosuppressive 
tumor milieu rich in cells of the myeloid lineage, which regulate T cell activity in many ways 
independent of the coinhibitory receptor axis. We investigated whether activation of acute 
inflammatory signaling through the cytosolic DNA sensing pathway component stimulator 
of interferon genes (STING) could reprogram tumor associated macrophages (TAMs) and 
myeloid derived suppressor cells (MDSCs) to support rather than suppress T cell activity, 
converting CRPC and PDAC to settings in which checkpoint blockade can be effective. 
To this end, we established therapeutic synergy between cyclic dinucleotide (CDN) 
STING agonists and checkpoint modulating agents in the multi-focal TRAMP-C2 murine 
model of CRPC, and described how the balance between systemic efficacy and local 
pathology can be balanced by modifying CDN dosing frequency. We characterized a 
novel STING agonist IACS-8803, which possesses potent stimulatory activity and 
therapeutic efficacy in vitro and in vivo relative to known natural and synthetic clinical CDN 
compounds. We described the phenotypic and functional effects of CDNs on suppressive 
MDSCs and TAMs of murine and human origin in the in vitro setting, and utilized high 
parameter flow cytometry to validate these changes in the tumor microenvironment upon 
local CDN injection. Utilizing a novel transplantable model of orthotopic PDAC, we confirm 
that intra-pancreatic delivery of 8803 can synergize with checkpoint blockade to 
significantly prolong survival in a highly refractory setting. Together, these studies lay the 
groundwork for translation of CDNs in combination with checkpoint blockade for patients 
with CRPC and PDAC. 
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Chapter 1: Introduction  
The theory of cancer immunosurveillance was first proposed by Thomas and Burnet in 1957, 
and posits that the host’s immune system is capable of specifically sensing and disposing of 
malignant cells bearing “non-self” genetic alterations. Despite historical records of the use of 
heat-attenuated bacteria as “immunotherapy” by Coley dating back to the late 19th century, 
this theory was largely rejected until two major intellectual advances in the late 20th century. 
Schreiber and colleagues definitively showed that cancer could be surveilled by the immune 
system, and that the interplay between immune cells and tumors could endow cancer cells 
with immune-evasive characteristics (1). Additionally, Allison and colleagues identified a key 
mechanism by which tumors counteract productive immunosurveillance, and produced both 
preclinical and clinical evidence that modulation of this immune regulatory pathway could 
liberate the immune system to regress advanced cancer (2, 3). These advances ushered in a 
new era in oncology, with immunotherapy being elevated amongst the three traditional pillars 
of cancer therapy; surgery, chemotherapy, and radiation. Over the past decade, immune 
checkpoint blockade therapies have been evaluated and FDA approved to treat an array of 
cancers, and unprecedented durable responses can now be achieved for patients that were 
recently without any hope of a cure. However, many patients still fail to respond to current 
immunotherapies, and some malignancies including prostate and pancreatic cancer remain 
almost entirely refractory. In the following chapter, I aim to (i) provide an overview of the 
current understanding of why tumors respond or fail to respond to immunotherapy, with a 
focus on prostate and pancreatic cancers, (ii) discuss the role of myeloid cells as mediators 
of immune suppression in the tumor microenvironment, and (iii) review the stimulator of 
interferon genes (STING) pathway and discuss its potential role in modulating tumor myeloid 
cells and sensitizing refractory cancers to immunotherapy. 
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1.1: Tumor Immunogenicity: Beyond “Hot” and “Cold” 
The ultimate goal of clinical oncology is to identify and prescribe for each patient the 
most efficacious therapeutic modality available based upon objective, observable 
characteristics of a patient’s disease. Cancer is not one disease but many; tumors differ not 
only across tissues, but tumors of the same histology can differ drastically in nature. Thus, a 
major goal of cancer research is to discover which molecular and cellular traits of a tumor are 
most informative for guiding clinical decisions and predicting how patients will respond to 
therapy. Traditionally, tumors are grouped according to histology, as malignancies that arise 
from a common tissue tend to share common traits. Within a given histology, tumors are 
classified according to their size and the extent to which they have metastasized. Classical 
TNM staging involves characterizing a patient’s disease by the size of the primary tumor (T), 
the number and location of lymph nodes that contain cancer (N), and the degree to which 
disease has metastasized to distal regions of the body (M). Algorithms exist to guide clinicians 
to chemotherapeutic, surgical, or radiation interventions based upon specific TNM status. 
While TNM staging is practical, accessible, and built upon decades of clinical research, 
our increasing understanding of the genetic basis of cancer and its interaction with the host is 
illuminating novel avenues for classifying tumors in specific but non-traditional ways. For 
example, a number of targeted therapies have been designed that attack specific oncogenic 
pathways found in many tumors. Thus, mutational analysis of a patient’s tumor can reveal a 
specific mutation such as BRAF V600E that can be directly targeted regardless of tumor 
histology with much greater therapeutic potential than standard TNM-guided therapy (4). The 
acceptance of immunotherapy at the clinical level has added even greater complexity, as a 
patient’s response to immune-based interventions can be related to both tumor genetics as 
well as the dynamic composition of the tumor immune microenvironment. Patients with the 
optimal combination of immune and genetic factors can achieve unprecedented durable tumor 
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regressions never before seen in previously-terminal cancers, however these patients remain 
relatively rare. Thus, there is great interest in understanding what characteristics define a “hot” 
tumor that is primed to respond to immunotherapy in contrast to “cold” tumors that do not 
respond, so that therapeutic approaches can be designed to render more tumors sensitive to 
therapy.  
This section aims to provide a discussion of the key genetic, molecular, and cellular 
factors that are thought to contribute to “hot” and “cold” tumors in general, and provide a 
summary of two clinically “cold” tumors studied in this dissertation: castration resistant 
prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC). 
 
1.1.1: Defining Characteristics of “Hot” and “Cold” Tumors 
Tumor Antigenicity. The human immune system is fundamentally fashioned to distinguish 
“self” from “non-self.” Specifically, both innate and adaptive immune cells are trained to ignore 
or protect any and all self tissues, yet express receptors that together are theoretically able to 
recognize any possible protein epitope not found natively within the host. For example, viruses 
contain genetic material encoding proteins that differ in sequence and structure compared to 
human proteins; thus these non-self protein epitopes can serve as targets for host immune 
cells. Though cancer is indeed derived from native host tissue, it becomes malignant through 
the obligatory accumulation of genetic mutations that ultimately alter cellular function. As 
these mutated gene products by definition differ in protein sequence compared to their 
unmutated healthy forms, they can theoretically be recognized by the immune system as 
“altered-self” targets, making cancer an immunologically visible disease. Therefore, the 
number and nature of mutations carried by a given tumor dictates its antigenicity, which in 
turn impacts the likelihood of an immune response being generated against it. 
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 The idea that tumors by nature possess antigens that are targets of immune 
surveillance was first proposed in the mid 20th century by Burnet and Thomas (5), however 
not until the turn of the century were there proper experimental tools to decisively confirm the 
theory. Experimental confirmation of the concept of immunosurveillance (1) garnered interest 
in defining what antigens the immune system specifically recognizes in cancer. Early work 
defined many “shared” tumor antigens, which represent non-mutated molecules aberrantly 
overexpressed in cancer relative to normal tissue. These antigens have been studied as 
targets for vaccination, however endogenous immunity against them is limited due to 
mechanisms of central and peripheral immune tolerance that protect against autoimmune 
responses to self tissues. More recently, the advent of next-generation genetic sequencing 
together with immunogenic peptide epitope prediction algorithms has facilitated the 
identification of bona fide tumor-specific mutated antigens, termed neoantigens. In contrast to 
shared tumor antigens, neoantigens are found only in tumor cells and not in healthy tissues, 
thus T cell responses can be generated against them without the barrier of overcoming central 
tolerance. It has been clearly demonstrated in both mice and humans that neoantigens can 
be targeted by T cells and that checkpoint blockade immunotherapies can enhance the 
function of these neoantigen-specific T cells (6, 7). Therefore, there is currently significant 
interest in understanding how tumor mutational burden influences neoantigen quantity and 
quality, in order to develop clinically informative associations between tumor antigenicity and 
response to immunotherapy. 
 In theory, the more genetic mutations a tumor possesses, the greater the probability it 
will contain targetable neoantigens available for immune surveillance. In support of this theory, 
there is a compelling clinical observation that tumors which commonly arise due to carcinogen 
exposure tend to exhibit relatively high response rates to immunotherapy. For instance, 
melanoma and lung cancer – associated with exposure to UV light and cigarette smoke, 
5 
 
respectively – on average possess very high somatic mutation rates of around 10 mutations 
per megabase of DNA (8). Indeed, these cancers were the first to receive FDA approval for 
checkpoint blockade immunotherapies (9, 10). Interestingly, in a later study correlating tumor 
mutational burden with response to immunotherapy, Yarchoan and colleagues found that the 
median value of 10 coding somatic mutations per megabase generally separates tumors with 
high response rate (>25%) from tumors with lower response rates (<20%)(11). While 
carcinogen exposure is a common harbinger of high mutational burden in human cancer, 
defects in DNA damage repair machinery can additionally contribute to “hypermutated” tumor 
genomes. A small percentage of patients across all cancer types possess defects in the DNA 
mismatch repair (MMR) pathway, which senses and repairs single nucleotide mutants or 
minor insertions and deletions that occur during DNA replication (12). In colorectal cancer, 
nearly 15% of patients carry tumors with MMR defects, resulting in a hypermutation phenotype 
called microsatellite instability (MSI) (13). While colorectal cancer is historically refractory to 
immunotherapy, patients with MSI exhibit response rates analogous to those seen in patients 
with metastatic melanoma. In a landmark phase II study of pembrolizumab in metastatic 
colorectal cancer, MSI patients exhibited a response rate of 40%, while none of the 18 
microsatellite stable patients responded (14). These results were rapidly generalized to any 
patients with MMR deficiency, and pembrolizumab was shown to be similarly effective 
regardless of histology (15). These findings precipitated FDA approval of pembrolizumab for 
any patient with MMR defects; the first ever tissue-agnostic approval of a cancer therapy 
based on MMR biomarker testing. Together, these clinical observations suggest that tumors 
with high mutational burden are more likely to be immunologically “hot” and possess higher 
response rates to immunotherapy. 
 While the correlation between tumor mutational burden and response to 
immunotherapy is strong, it is not perfect. For example, after melanoma and lung cancer, 
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kidney cancer was the third to receive FDA approval for checkpoint blockade targeting PD-1, 
however it is characterized by a relatively low median mutation rate of ~3 mutations per 
megabase (8). A growing body of evidence suggests that not all mutations equally engender 
relevant neoantigens; rather, the specific nature of the somatic genetic alteration may 
influence its relative immunogenicity. An early observation in support of this was provided by 
Snyder et al, who performed whole exome sequencing on malignant and healthy tissue from 
64 melanoma patients that received ipilimumab or tremelimumab. In this study, tumor 
mutational load was not sufficient to predict response to immunotherapy; however, a specific 
neoantigen “landscape” was found uniquely in responders, and constituted a strong predictive 
marker of response (7). The authors mapped this signature to short 4 amino acid tetrapeptide 
motifs found within immunogenic neoantigen peptides, which may by sequence and structure 
have a greater tendency to form high-affinity interactions with host T cell receptors. While the 
feasibility of identifying a similar neoantigen signature has proven controversial in other 
datasets (16), these results provide a mechanistic hypothesis to explain why neoantigens may 
differ in immunogenicity. A recent study by Turajlic and colleagues comprehensively probed 
whole-exome sequencing data from The Cancer Genome Atlas to characterize neoantigens 
arising from single nucleotide variants as well as small insertions and deletions (indels). The 
authors found that frameshifts resulting from indel alterations are nine times more likely to 
generate neoantigen peptides that are strong predicted binders to host MHC compared to 
single nucleotide variants (17). Furthermore, they determined that kidney cancer possesses 
the highest frequency of indel mutations, which may explain its sensitivity to checkpoint 
immunotherapy despite its low average tumor mutational load (8). These data further suggest 
that, with regard to antigenic epitopes, there may exist a spectrum of “non-selfness,” with 
some genetic alterations engendering more immunogenic epitopes than others. A precise 
mechanistic explanation for this has not yet been described in the field, however algorithms 
7 
 
to predict high-quality non-self neoantigens have been reported. Using a unique cohort of 
pancreatic cancer patients with extremely long-term survival, Balachandran and colleagues 
described a neoantigen quality model that predicts patient survival based upon homology 
between their expressed neoantigens and infectious disease-related epitopes, and 
demonstrated that this model predicts survival with greater accuracy than a model that 
associates immunogenicity with the number of tumor neoantigens (18). Based upon these key 
observations, it is becoming clear that the mere quantity of neoantigens is not sufficient to 
fully predict whether a tumor will be immunologically “hot”; rather, the quality of those antigens 
must also be taken into account to more accurately predict a tumor’s immunogenicity. 
 
Tumor Microenvironment. While tumor antigens provide the necessary means of detection 
for an immune response against cancer, the eradication of a tumor ultimately relies on the 
capacity for immune cells to exert potent and specific cytolytic effector functions at the tumor 
site. This is no small task, as the human immune system is endowed with a wealth of 
regulatory mechanisms to suppress or prevent untoward damage of self tissue. In the local 
battle for survival that occurs upon immune recognition of cancer, it is evident that immune 
killing creates an evolutionary pressure that selects for outgrowth of tumor clones that 
summon these mechanisms to locally disable the immune response (19). As early as 1997, it 
was known that cancer cells bearing a targetable antigen could grow progressively while non-
malignant skin grafts bearing the same antigen could be rejected in the same host (20). These 
observations suggested that it is tumor-mediated locoregional control of immune response, 
rather than systemic immune dysfunction, that allows for outgrowth of antigenic tumors. 
Therefore, it follows that an understanding of the relevant components of the tumor immune 
microenvironment (TME) and how they interact can aid in predicting whether a tumor will 
respond or is actively responding to immunotherapy. 
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 In most cases, cytotoxic CD8 T cells are the indispensable mediators of immune-
mediated tumor rejection, thus the prevalence of CD8 T cells in a tumor ought to have 
prognostic or predictive value in cancer. Early studies quantifying T cell numbers in colorectal 
tumor biopsies found that a greater density of infiltrating CD8 T cells correlates with both 
earlier stage disease and the absence of metastatic invasion (21, 22). Incredibly, a simple 
histopathological algorithm termed the Immunoscore which enumerates the total number of 
CD3+ and CD8+ T cells in the center and periphery of a tumor has high prognostic value in 
these patients, and outperforms both TNM staging and MSI status in predicting recurrence as 
well as survival in colorectal cancer (23, 24). While the Immunoscore remains to be validated 
in other histologies, independent reports have associated CD8 T cell infiltration with tumor 
stage, recurrence rate, or survival in melanoma (25, 26), ovarian cancer (27, 28), head and 
neck cancer (29), liver cancer (30), bladder cancer (31), and gastrointestinal stromal tumors 
(GIST) (32). Therefore, a high density of CD8 T cells within the tumor core is a generalizable 
characteristic of immunologically “hot” tumors across many human cancers. 
 Given the critical import of CD8 T cells in controlling cancer progression and lethality, 
it is important to understand how and why tumors become T cell-infiltrated. Interestingly, a 
recent report by Spranger et al suggests that the prevalence of CD8 T cells in melanoma is 
not related to the number of nonsynonymous somatic mutations in a given tumor, and these 
findings could be generalized across solid tumors in the TCGA database (33). These data 
suggest that the majority of solid tumors likely possess sufficient neoantigen burden to support 
a T cell response, thus the capacity or failure to achieve CD8 T cell infiltration is chiefly 
determined by molecular and cellular characteristics of the tumor microenvironment. Gene 
expression analysis of human tumors bearing differing levels of T cell infiltration have hinted 
that a foundational determinant underlying the presence of CD8 T cells is the host type I 
interferon response (34). Historically associated with antiviral immunity, type I interferons in 
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cancer are critical for facilitating myeloid activation in the sterile tumor microenvironment. 
Specifically, IFN-β released in the microenvironment acts upon Batf3-lineage dendritic cells 
(DCs), and signals through the IFN-α/βR and Stat1 to induce a transcriptional program 
associated with antiviral antigen presentation (35). These DCs, characterized by expression 
of the surface markers CD8α or CD103 in mice and CD141 in humans (36), are capable of 
tumor antigen cross presentation, which allows for priming of CD8 T cells against tumor 
antigens exogenously acquired by tumor DCs. Moreover, type I interferons trigger release of 
chemokines by myeloid cells including CCL5 and CXCL10 that are required to recruit CD8 T 
cells to the tumor bed (37, 38). Mice deficient in type I interferon signaling or Batf3-lineage 
DCs thus exhibit deficiencies in T cell infiltration and spontaneous immunity against otherwise 
immunogenic tumors (34, 38-40). Therefore, the presence of type I interferon signaling and 
Batf3-lineage DCs capable of tumor antigen cross presentation are critical determinants of 
immunologically “hot” tumors bearing CD8 T cell infiltration.  
 If priming and recruitment of tumor antigen-specific CD8 T cells are necessary 
characteristics of immunogenic “hot” tumors, then it follows that any factors that interfere with 
T cell priming, recruitment, or cytolytic function at the microenvironment can contribute to 
poorly immunogenic “cold” tumors. Again, given the evolutionary emphasis on immune 
regulation to avoid autoimmunity, such mechanisms are numerous and diverse in the human 
immune system. Broadly, these immunoregulatory influences can be conceptually grouped 
into three categories; immune suppression, immune exclusion, and immune ignorance (Fig 
1). 
 Suppression of CD8 T cell cytolytic function can be achieved by a number of cell types 
often present in the tumor microenvironment, and occurs through modulation of T cell 
signaling, polarization, and metabolic fitness. After activation, T cells will begin to express an 
array of coinhibitory receptors including CTLA-4, PD-1, LAG-3, Tim-3, and TIGIT, among 
10 
 
  
Figure 1: The “Hot” vs “Cold” tumor paradigm. Tumor immunogenicity is broadly 
determined by tumor antigen burden and the composition and quality of the tumor immune 
microenvironment. Represented are human solid tumors ranked in rough order of relative 
immunogenicity, as well as the multiple mechanisms by which tumors can be 
immunologically “cold.” It should be emphasized that multiple mechanisms can be present 
and relevant at the level of a given tumor type as well as within an individual patient’s 
tumor. 
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others. Ligation of these receptors generally suppresses signaling downstream of the T cell 
receptor (TCR) and costimulatory receptors, limiting T cell function and longevity (41). 
Specifically, PD-1 is thought to be a dominant coinhibitory factor for T cells within the tumor 
microenvironment (42). PD-1 signals through SHP1 and SHP2 phosphatases to 
dephosphorylate and inactivate ITAM motifs on CD28, and additionally removes phosphate 
groups that are required for the function of downstream TCR signaling proteins such as ZAP70 
and PI3K (43-45). Expression of the ligands for PD-1 (PD-L1 and PD-L2) can be found on 
both myeloid cells infiltrating tumors (46), and on tumor cells themselves, and can be further 
induced on these cells in response to T cell-derived IFN-γ (47, 48). These observations 
provide rationale for the blockade of T cell coinhibitory molecules in cancer, an approach 
which has revolutionized clinical management of cancer over the past decade. However, a 
number of other T cell suppressive mechanisms exist in the TME that occur independently of 
coinhibitory checkpoint receptors. Many of these are the product of immune cells that possess 
an anti-inflammatory influence in cancer, including FoxP3+ regulatory T cells (Tregs), myeloid 
derived suppressor cells (MDSCs), and tumor associated macrophages (TAMs). Three critical 
immunosuppressive mechanisms include the presence of suppressive cytokines that limit 
inflammatory T cell function and longevity, the production of reactive oxygen and nitrogen 
species that have toxic effects on cytotoxic T cells, and the enzymatic catalysis of T cell-
essential nutrients. As suppressive myeloid cells are key contributors to these methods of T 
cell inhibition in the TME, the above mechanisms will be reviewed in detail in the next chapter. 
Overall, an increased density of coinhibitory ligands in the TME together with the coordinated 
actions of Tregs, MDSCs, and TAMs can render the TME a hostile environment for the survival 
and functional fitness of CD8 T cells. 
 Immune exclusion involves the construction of physical or metabolic barriers that 
preclude access of CD8 T cells to some or all of the tumor bed. For circulating T cells primed 
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in secondary lymphoid organs against tumor antigens, neovascular tumor endothelium 
presents the first barrier to T cell entry. Whereas healthy endothelium facilitates T cell 
extravasation into tissues through clustered expression of adhesion molecules such as ICAM1 
and VCAM1, aberrant tumor neovasculature often displays reduced expression of these 
proteins (49) and aberrant expression of inhibitory ligands such as PD-L1 and PD-L2 (50, 51), 
anti-adhesive molecules such as endothelin B receptor (52), or apoptosis-inducing ligands 
such as TRAIL and FasL (53). Thus, the tumor vasculature can suppress T cell infiltration into 
tumors by promoting anergy or outright apoptosis in circulating T cells. If extravasation through 
the neovasculature is permitted, T cells often encounter stromal barriers at the tumor site. 
Mesenchymal fibroblasts have been shown to be immunosuppressive in many tumors (54), 
and possess the capacity to lay down thick webs of extracellular matrix composed of collagen, 
fibrinogen, laminin, and other glycoproteins. The dense patterns of ECM present in many 
tumors can either block T cell entry or interfere with chemotaxis, thus inhibiting T cell entry 
into the tumor bed (55, 56). Blockade of chemokine signals that recruit cancer-associated 
fibroblasts (CAFs) can boost T cell access and sensitize tumors with dense stroma to immune-
based therapies (57), however outright depletion of CAFs has had mixed results in mouse 
and man, with some reports suggesting stromal depletion can accelerate tumor progression 
and metastasis (58). Absent stromal barriers to T cell chemotaxis, many tumors possess 
regions which are metabolically incompatible with T cell survival. Segments of a tumor that 
are spatially separated from sufficient vasculature can be deeply hypoxic, and limited access 
to oxygen promotes immunosuppressive phenotypes in both T cells and myeloid cells through 
activation of the hypoxia-responsive signaling protein Hif1α (59-61). Elimination of 
intratumoral hypoxia through hypoxia-activated pro-drug therapy or respiratory hyperoxemia 
can restore T cell infiltration and sensitize tumors to immunotherapy (62, 63). Therefore, 
exclusion of T cells from the tumor via non-permissive neovasculature, dense ECM 
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deposition, or intratumoral hypoxia can contribute significantly to a poorly-immunogenic, “cold” 
tumor phenotype. 
 Immune ignorance chiefly involves a failure of the innate immune system to sense the 
presence of a tumor, as innate antigen presenting cells such as DCs are required to prime a 
T cell response against cancer. In this context, tumors with exceptionally low mutational 
burden may possess an insufficient number of quality neoantigens to contain an epitope 
capable of being targeted by host T cells. While this has been postulated to contribute to the 
poorly immunogenic nature of genetically engineered murine models (GEMMs) (64), it is 
unclear whether this is a relevant mechanism for human tumors that naturally develop over 
long periods of time, where chromosomal instability makes the accumulation of some number 
of passenger mutations essentially inevitable. An alternative explanation is that host DCs may 
be shielded from tumors, denying them access to tumor antigens to utilize for T cell priming. 
An interesting mechanism for this was provided by Spranger and colleagues, who found that 
human melanoma tumors that lack T cell infiltration exhibit activation of the WNT/β-catenin 
signaling pathway. Analysis of the effects of β-catenin signaling revealed an inhibition of the 
cytokine CCL4, which is utilized to recruit Batf3-lineage DCs to the tumor microenvironment 
(65). Thus, oncogenic signaling through the WNT/β-catenin pathway can further promote 
tumor progression by precluding recruitment of DC populations required to mount antitumor 
T cell immunity. As this pathway is active in other cancers beyond melanoma, it may constitute 
a generalizable mechanism of immune ignorance across histologies (66).  
In summary, the success or failure of an antitumor immune response is governed in 
large part by the dynamic composition and character of the tumor microenvironment. 
Immunogenic “hot” tumors tend to be characterized by robust infiltration of CD8 T cells which 
have been primed by Batf3-lineage DCs activated by type I interferon to mediate tumor 
antigen cross-presentation. In contrast, poorly immunogenic “cold” tumors are either devoid 
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of T cells through immune ignorance or immune exclusion, or possess functionally inept T 
cells through the concerted actions of immunosuppressive cells and coinhibitory ligands within 
the tumor microenvironment. In the future, coordinate analysis of both microenvironmental 
immune factors together with tumor antigen burden may be a unique method to 
comprehensively approximate tumor immunogenicity and provide powerful prognostic and 
predictive value (67). 
 
1.1.2: Castration Resistant Prostate Cancer (CRPC); a Quintessential “Cold” Tumor 
Biology and Clinical Management of CRPC. Prostate cancer is the most commonly 
diagnosed cancer in men, and is one of the leading causes of male death in western countries 
(68). Of the 164,690 men predicted to be diagnosed with prostate cancer this year, nearly 
80% will present with localized disease (68), which is relatively indolent and associated with 
good prognosis. Active surveillance through PSA screenings and MRI screening – in place of 
traditional interventions including radical prostatectomy, radiotherapy, or brachytherapy – is 
sufficient to allow for a 1% risk of death over 10 years for these low risk patients (69, 70). 
However, around 35% of prostate cancer patients either treated or monitored for localized 
disease will eventually exhibit increases in serum PSA levels associated with disease 
progression, and require further therapy (71). Unfortunately, serum PSA is the only 
standardized method for monitoring prostate tumor progression, as imaging techniques of the 
organ are insufficient to provide definitive diagnoses. The first-line intervention for advanced 
prostate cancer patients is surgical or chemical castration through use of antiandrogens such 
as bicalutamide. While temporary control of PSA is common with this therapy, eventual 
progression to metastatic castration-resistant disease is inevitable given sufficient time. In 
contrast to localized disease, metastatic castration resistant prostate cancer (mCRPC) is an 
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incurable disease with a 5-year survival rate of 29% (68). Most commonly, these patients see 
metastatic spread to bone or distal lymph nodes, though involvement of visceral organs such 
as the liver can occur and is associated with more aggressive disease (72, 73). Traditionally, 
chemotherapy with docetaxel is the standard of care for these patients (74, 75), however in 
the last decade a number of novel therapies have been successfully evaluated in large 
randomized studies including an autologous vaccine sipuleucel-T (76), hormonal agents 
abiraterone (77, 78) and enzalutamide (79-81), the novel taxane cabazitaxel (82, 83), and a 
bone metastasis targeting radionuclide radium-223 (84, 85).  
 Genetic and molecular classification of mCRPC has proven a difficult task, due to the 
rare but complex genetic alterations associated with the disease. The mCRPC genome 
generally exhibits a low mutation rate of 2 mutations per megabase, with common mutations 
targeting tumor suppressor genes TP53, PTEN, and SPOP, as well as components of the 
androgen receptor (AR) signaling pathway (86, 87). Copy number alterations are also 
relatively infrequent, but target common pathways such as PTEN, MYC, and AR (88). A 
characteristic quality of advanced prostate cancer is the presence of complex coordinated 
chromosomal translocations, termed “chromoplexy” to represent a rewiring of the genome 
(89). Specifically, mCRPC contains frequent gene fusions involving members of the ETS 
transcription factor family, which often fuse with components of the AR signaling pathway such 
as TMPRSS2 (90, 91). This has led to an effort to classify tumors based upon the presence 
of ETS fusions, as common mutations in genes such as PTEN, TP53, SPOP, or SPINK1 tend 
to be enriched in either ETS-positive or ETS-negative tumors (86, 92-94). Unfortunately, these 
common alterations are not amenable to available targeted therapeutic approaches, rendering 
personalized therapy using clinical genomics currently untenable for patients with mCRPC. 
 
Immunotherapy for CRPC. Inflammation is linked to prostate carcinogenesis, suggesting the 
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host immune system interacts with and plays a role in the initiation and progression of CRPC 
(95, 96). To date, the most commonly evaluated and only successful immune-based 
interventions in CRPC are therapeutic vaccines. The first therapeutic vaccine created for 
prostate cancer was GVAX, which initially consisted of autologous irradiated prostate cancer 
cells retrovirally engineered to produce GM-CSF (97), though for large randomized studies 
allogeneic cell lines LNCaP and PC3 were utilized in place of autologous tissue (98, 99). 
Unfortunately, two phase III studies of GVAX for CRPC were halted early due to lack of 
efficacy in the treatment arms (100), preventing clinical approval of GVAX as a single agent 
therapy. An alternative vaccine, Sipuleucel-T, is a live cell-based vaccine consisting of 
autologous monocytic DCs differentiated with a fusion peptide containing GM-CSF and a 
prostate antigen prostatic acid phosphatase (PAP). In a phase III study of men with mCRPC, 
Sipuleucel-T extended survival 4.1 months compared to placebo, despite having no significant 
effect on PSA or time to disease progression (76). Based on these results, Sipuleucel-T 
received FDA approval for mCRPC in 2010. However, some controversy clouds these data, 
as patients age 65 or older in the placebo arm of the trial appear to have exhibited 
uncharacteristically short survival relative to historical controls, which may have skewed the 
survival data in favor of the Sipuleucel-T arm (101). Additionally, the cellular product infused 
into patients in the placebo arm was kept without supportive cytokine at 2-8oC during the 
culture period in which GM-CSF-PAP was added to the cultured monocytic DCs in the 
treatment arm, thus the quality (or lack thereof) of the “placebo” infusion product has been 
questioned (101). Despite these allegations, Sipuleucel-T remains the only FDA-approved 
immunotherapy for prostate cancer patients. A number of other vaccines have reached late-
phase clinical investigation, including a poxvirus-based vaccine named ProstVac-VF (102). A 
large phase III study of this vaccine was recently halted however due to futility upon interim 
analysis (103). Together, vaccine approaches have been rigorously evaluated clinically in 
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prostate cancer but to date have demonstrated little or marginal benefit in comparison to 
chemotherapy or androgen modulating therapies. 
 Given the unprecedented clinical success of monoclonal antibodies targeting T cell 
coinhibitory checkpoints CTLA-4 and PD-1 in metastatic melanoma, lung cancer, and 
numerous other tumor types, there has been significant interest in evaluating checkpoint 
blockade immunotherapy in CRPC. To date, two phase III studies have been completed 
evaluating ipilimumab in men with mCRPC. The first trial evaluated ipilimumab in combination 
with low-dose radiation versus radiation and placebo (104), while the second trial tested 
ipilimumab or placebo in earlier-stage chemotherapy-naïve patients (105). Neither study 
demonstrated a significant enhancement in survival in the treatment arms, thus ipilimumab 
has not received FDA approval for CRPC. However, close analysis of the data illuminates 
trending advantages in either overall survival or progression-free survival in the respective 
studies, suggesting ipilimumab as a single agent may possesses marginal, non-negligible 
efficacy in prostate cancer. In light of this, ipilimumab is currently being evaluated in 
combinatorial regimens together with vaccines such as Sipuleucel-T (106) or ProstVac-VF 
(NCT02506114), or with androgen deprivation therapies including leuprolide, goserelin, or 
degarelix (NCT01377389). Blockade of PD-1 is additionally being evaluated in CRPC, based 
in part upon the observation that approximately 32% of mCRPC tumors test positive for PD-
L1 expression (107). Preliminary data from the first large-scale evaluation of pembrolizumab 
in patients with docetaxel-refractory CRPC show a meager response rate of 9% in patients 
with RECIST-measurable disease (108). However, higher response rates are observed in 
patients with mutations in DNA repair genes such as BRCA1/2 or ATM, indicating biomarker 
evaluation for mutations in DNA repair genes, MMR genes, or MSI status can be beneficial in 
finding rare patients capable of responding to PD-1, as seen in other tumor types. Fortunately, 
a relatively high proportion of patients (~12%) are believed to bear this hypermutated 
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phenotype in CRPC (109). Additionally, PD-1 blocking agents are being utilized in the 
combination setting with vaccines (110), androgen deprivation therapy (111), or together with 
CTLA-4 blockade (112). It remains to be seen whether these combinatorial regimens will 
prove successful in a setting where single agent immunotherapy has largely failed, or whether 
altogether novel approaches are required to benefit patients with CRPC. One such novel 
approach may be targeting of prostate tumor myeloid cells such as TAMs or MDSCs. A critical 
relationship has recently been established between MDSCs and CRPC cells, wherein MDSCs 
secrete factors such as IL-23 to promote AR-signaling and tumor survival even in the presence 
of antiandrogen therapies (113), while additionally facilitating suppression of cytotoxic T cell 
responses. As such, the use of myeloid-targeting therapies appears to sensitize prostate 
tumors to checkpoint blockade (114, 115). A critical question for the field going forward – 
addressed in more detail later in this dissertation – is how to most effectively modulate tumor 
myeloid cells to optimally synergize with checkpoint blockade, and whether these approaches 
will translate into effective clinical management of human CRPC. 
 Together, prostate cancer is a largely manageable disease at early stages, however 
progression to its metastatic, castration-resistant form results in incurable disease. Thus far, 
greater understanding of the complex genomic landscape in CRPC has not translated to 
effective targeted therapy. Moreover, the first generation of clinical immune-based 
interventions have provided either modest or negligible benefit, resulting in the classification 
of CRPC as an immunologically cold tumor. Future success in this disease requires better 
prognostic and predictive biomarkers to select patients likely to respond to available 
treatments, more rationally-designed combination approaches, and development of novel 
therapeutic regimens aimed at targeting tumor myeloid cells to convert the prostate tumor 
microenvironment from “cold” to “hot.” 
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1.1.3: Pancreatic Ductal Adenocarcinoma (PDAC); a Uniquely “Cold” Tumor 
Biology and Clinical Management of PDAC. Pancreatic ductal adenocarcinoma (PDAC) is 
perhaps the most lethal of all common cancers, with a number of defining characteristics that 
act in concert to produce a highly metastatic, largely uncontrollable disease. Symptoms 
associated with early-stage localized pancreatic tumors – such as stomach pain, appetite loss, 
or back pain – are diffuse and non-specific, thus early detection of PDAC is rare. Even for 
high-risk patients with hereditary predisposition to PDAC, there remains no accepted 
screening method due to a lack of sensitivity and specificity in traditional techniques including 
imaging or quantification of serum tumor markers such as CA19-9 (116, 117). As a result, only 
10% of PDAC patients are diagnosed with localized disease, whereas the overwhelming 
majority present with metastatic tumor burden (68). Surgery is the only therapy with curative 
potential in PDAC, however it is reserved for the minority of patients with resectable or 
borderline resectable disease, and even among these early-stage surgical candidates the rate 
of relapse is nearly 90% and 5-year overall survival is low (~20%) (118). For patients with 
unresectable PDAC, chemotherapy is the current standard of care. Gemcitabine has been the 
primary chemotherapeutic for PDAC since the late 1990s, when it demonstrated superiority 
over fluorouracil in extending median overall survival from 4.4 to 5.6 months (119). More 
recently, two unique combinatorial regimens have been approved for use based upon 
superiority over gemcitabine in randomized phase III studies; the first a multi-drug cocktail 
consisting of fluorouracil, oxaliplatin, leucovorin, and irinotecan (FOLFIRINOX) (120), and the 
second a two-drug combination consisting of gemcitabine and albumin-bound paclitaxel (nab-
paclitaxel) (121). While these two regimens have not been evaluated in a head-to-head clinical 
study, it appears that FOLFIRNOX may be marginally more effective, as Conroy et al report 
a median overall survival of 11.1 months for patients receiving FOLFIRINOX, versus 8.5 
months in patients receiving gemcitabine and nab-paclitaxel in the study reported by Von Hoff 
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et al. However, FOLFIRINOX is substantially more toxic, thus clinically it is generally reserved 
for patients under 76 years of age with excellent performance status (122). Despite these 
recent advances, the long-term outlook for patients with PDAC remains quite poor, as the 
overall median survival rate remains 8 months. This grim reality necessitates the design of 
novel interventions based upon the unique genetic and microenvironmental characteristics of 
the disease. 
 One of the central defining characteristics of PDAC is the presence of activating 
mutations in the KRAS oncogene. Analysis of the earliest detectable PDAC precursor lesions, 
termed pancreatic intraepithelial neoplasias (PanINs), show that KRAS is mutated in more 
than 90% of these lesions (123), suggesting oncogenic KRAS is a critical initiator of PDAC 
tumorigenesis. Additional common mutations found in 50-80% of patients occur in TP53, 
CDKN2A, or SMAD4 tumor suppressors. These mutations are often found in later-stage 
PanINs, suggesting they occur after initial KRAS activation and are necessary for progression 
into PDAC (124-126). This concept has been corroborated with genetically engineered mouse 
models bearing pancreas-specific expression of oncogenic KRAS in the presence or absence 
of mutated or null alleles of TP53, Ink4a/CDKN2A, or SMAD4. Mice expressing a constitutively 
active KRASG12D allele develop PanIN lesions, but only rarely progress to invasive metastatic 
PDAC (127). Concurrent expression of KRASG12D and inactivated TP53, Ink4a/CDKN2A, or 
SMAD4 results in rapid formation of invasive PDAC with complete penetrance (124, 128, 129). 
In contrast, enforced expression of mutated TP53, Ink4a/CDKN2A, or SMAD4 in the absence 
of KRASG12D does not lead to observable disease (125, 130). Thus, oncogenic KRAS is 
required for initiation of PDAC precursor lesions, which then acquire additional loss of TP53, 
Ink4a/CDKN2A, or SMAD4 to progress to invasive PDAC in mice. Given the critical role of 
these four genes in PDAC tumorigenesis and their presence in essentially all PDAC patients, 
approaches to target them specifically would be ideal. Unfortunately, no therapies currently 
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exist to restore function of mutated TP53, CDKN2A, or SMAD4, and oncogenic KRAS retains 
the fateful designation “undruggable” (131). Thus, targeted therapy is not a tenable option for 
PDAC patients at this time. 
 Extensive desmoplasia is an additional defining histological characteristic of PDAC 
tumors that promotes tumor progression and drug resistance. It has been estimated that 
malignant cells compose only 10% of the PDAC tumor microenvironment, the rest consisting 
of both cellular and non-cellular constituents. The non-cellular extracellular matrix found 
densely deposited within PDAC lesions contains proteins such as collagen, fibronectin, and 
laminin, in addition to numerous and diverse glycosylated proteins. It is thought that a 
population of pancreas-resident myofibroblasts termed pancreatic stellate cells (PSCs) are 
largely responsible for the generation of this proteinaceous milieu (122, 132). Malignant PDAC 
cells participate in crosstalk with PSCs through production of cytokines such as TGF-β, FGF, 
HGF, EGF, and PDGF (133, 134), which stimulate stromal matrix deposition by PSCs (135). 
This in turn promotes tumor progression, creating a positive feedback loop accelerating matrix 
deposition and tumor invasion (136). In addition, dense desmoplasia restricts the tumor 
vasculature, resulting in a hypovascular state in which diseased pancreas in mouse and man 
possesses a mere 25% of the average vessel density found in normal tissue (137). This 
functionally limits drug perfusion into the tumor bed (137), and further results in the formation 
of deeply hypoxic regions within the tumor tissue (138). Not only does hypoxia itself feedback 
to stimulate a stronger desmoplastic reaction (139), it also promotes tumor migration and 
metastasis (140). Oncogenic KRAS supports metabolic adaptations by PDAC tumor cells to 
survive within these hypoxic zones, promoting Warburg-like anaerobic glycolysis (141), 
increased macropinocytotic uptake of environmental nutrients (142), autophagy (143), and 
upregulation of Nrf2 to maintain cellular redox states (144). In contrast, hypoxia blunts the 
antitumor immune response, creating sites of immune privilege inaccessible to cytotoxic T 
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cells that are metabolically sensitive to oxygen deprivation (63), while fortifying 
immunosuppressive phenotypes in tumor myeloid populations (60, 145). Therefore, 
adaptation to hypoxia in highly desmoplastic, hypovascular tumor regions affords PDAC cells 
a safe haven from cytotoxic therapies and immune cells, resulting in drug resistance and rapid 
progression to metastatic disease. 
 Finally, hematopoietic cells are an additional critical component of the PDAC tumor 
stroma that largely contribute to – rather than contradict – its designation as an 
immunologically “cold” tumor. Characterization of the tumor-infiltrating immune milieu in GEM 
models of PDAC such as the Kras+/G12DTP53+/R172HPdx1-Cre (KPC) mouse has profoundly 
advanced our knowledge of the dynamic interactions between the host immune system and 
PDAC from early stages through to metastatic disease. A landmark study by Clark and 
colleagues described the tendency of PDAC tumors to recruit CD45+ immune cells even at 
pre-malignant PanIN stages, which further increases upon progression to invasive PDAC 
(146). This immune infiltrate is largely composed of classically immunosuppressive cell types 
including Tregs, TAMs, and MDSCs. Interestingly, PanIN lesions efficiently recruit 
macrophages, while MDSCs accumulate in later stage disease. The authors describe a 
striking mutually exclusive relationship between CD11b+Gr-1+ MDSC and CD3+CD8+ T cells 
in PDAC tumors, suggesting suppressive MDSCs may contribute to immune exclusion in 
PDAC (146). Recruitment of immunosuppressive MDSC can be attributed largely to tumor-
intrinsic oncogenic KRAS signaling, which causes PDAC cells to secrete cytokines and growth 
factors that mobilize and polarize MDSC including GM-CSF (147, 148) and IL-6 (149). In 
support of this, blockade of tumor GM-CSF production significantly reduces MDSC 
accumulation, restoring CD8 infiltration into the TME (147, 148). Macrophages also exhibit a 
mutually exclusive relationship with CD8 T cells in PDAC (146), and have in some instances 
been shown to exclude T cell infiltration in a way resembling the activity of cancer associated 
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fibroblasts (150). Macrophages are thought to arise from two distinct sources in PDAC: 
circulating monocytes that are recruited to the TME and differentiate into TAMs in situ, or from 
a pool of embryonically-derived tissue resident macrophages that possess self-renewing 
capacity (151). While macrophages are known to possess both immunosuppressive and pro-
tumorigenic roles in PDAC (152), a recent report by Zhu et al suggests that these dual roles 
are mediated by individual TAM compartments, rather than by monocyte-derived TAMs alone 
as previously thought (153, 154). Specifically, monocyte-derived TAMs in PDAC exhibit a 
gene expression profile in line with immunosuppression, while embryonically-derived resident 
macrophages predominantly contribute matrix remodeling factors to facilitate local 
desmoplasia (151). While further studies are required to thoroughly unravel the complex 
biology of macrophage plasticity and function in PDAC, it is clear that TAMs and MDSCs 
together contribute significantly to PDAC tumor progression, local immunosuppression, and 
therapeutic resistance. Therefore, the PDAC myeloid compartment is a major target for 
development of novel therapeutics. 
 
Immunotherapy for PDAC. To date, traditional immunotherapy has not proven successful in 
clinical management of PDAC, however a number of novel combinatorial approaches are on 
the horizon supported by compelling preclinical evidence of efficacy. As in prostate cancer, 
the first immunotherapies for PDAC consisted of cancer vaccines, including GVAX, an 
allogeneic irradiated whole cell vaccine expressing GM-CSF (155). GVAX has progressed to 
phase II testing in combination with other regimens, including chemoradiation in the adjuvant 
setting (156), low-dose cyclophosphamide (157), or cyclophosphamide plus CRS-207, a live-
attenuated Listeria monocytogenes based vaccine (158). Though these studies report high 
tolerability and generation of mesothelin tumor antigen-specific CD8 T cells, median survival 
rates remain at 6 months for advanced patients (158). Three other vaccines have been 
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evaluated unsuccessfully in randomized phase III trials: peptide vaccines targeting telomerase 
(159) or VEGFR2 (160), or an allogeneic irradiated whole cell vaccine expressing α1,3-
galactosyltransferase (161). While these trials additionally report generation of CD8 T cells 
against vaccine antigens, no significant clinical benefit has been observed, suggesting 
significant barriers remain preventing cytotoxic regression of PDAC tumors.  
 Checkpoint blockade has been tested in small phase I studies alone or in combination 
with chemotherapy, however meager results have prevented progression to large-scale trials. 
Ipilimumab was first tested in a phase II study of 27 patients with metastatic or locally 
advanced PDAC, with no patients exhibiting disease response by RECIST criteria (162). 
Similarly, no responses were seen in 14 PDAC patients treated with a PD-L1 blocking 
antibody in a phase I study (163). Recent trials have evaluated checkpoint blockade in 
combination with chemotherapy, including two phase I studies combining CTLA-4 blocking 
antibodies with gemcitabine (164, 165). While temporary stable disease was achieved in a 
number of patients in these studies, the observed RECIST response rates did not exceed 
historical controls for gemcitabine monotherapy. Interestingly, a recent phase I study tested 
nivolumab in combination with gemcitabine and nab-paclitaxel, and reported partial responses 
or stable disease in 12 of 17 patients (166). While not definitive given the small sample size, 
these results may indicate efficacy by checkpoint blockade agents when utilized in potent 
combinatorial regimens. Additionally, rare PDAC patients with MMRd have been shown to 
respond favorably to PD-1 blockade (15), further suggesting checkpoint blockade can be of 
benefit in this disease given optimal antigenic conditions. 
 A new generation of immunotherapeutic agents are currently in early-stage testing for 
PDAC based on rational targeting of key elements in the PDAC tumor stroma. Many of these 
approaches target myeloid cells, due to their high prevalence in PDAC tumors and potent 
immunosuppressive abilities. As such, these myeloid-based therapies will be reviewed in the 
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next chapter of this dissertation. In addition to myeloid cells, however, cancer associated 
fibroblasts (CAFs) and their matrix-depositing functions are being targeted in PDAC, in large 
part because of their immunosuppressive and immune excluding effects. While outright 
depletion of CAFs has proven controversial, with some studies reporting tumor progression 
upon depletion whereas others report tumor control (58, 137, 167), Feig and colleagues found 
that FAP+ CAFs produce large amounts of the chemokine CXCL12, which is associated with 
T cell exclusion from the PDAC tumor bed (57). Blockade of CXCR4, the receptor for CXCL12, 
results in increased T cell infiltration and sensitization of KPC tumors to checkpoint blockade. 
It is currently unclear why blockade of this chemokine results in paradoxical T cell recruitment, 
however there are reports of CXCL12 possessing a chemorepulsive effect at high 
concentrations (168). Regardless, an inhibitor of CXCR4 is being evaluated in two phase I 
studies in pancreatic, ovarian, and colorectal cancers (NCT03277209, NCT02179970). An 
additional approach involves targeting of focal adhesion kinase (FAK), a signaling protein that 
regulates the cellular response to contact with extracellular matrix constituents (169). Hong 
and colleagues discovered FAK expression in PDAC to correlate with immunosuppressive 
microenvironments as measured by low CD8 T cell density and high granulocytic infiltrates 
(170). Inhibition of FAK results in delayed tumor growth kinetics in KPC mice and a decreased 
prevalence of Tregs, MDSCs, and TAMs, and thus sensitizes refractory KPC tumors to 
checkpoint blockade (170). Based in part on these data, a number of FAK inhibitors are under 
clinical evaluation in phase I and II studies for patients with PDAC, with a number of trials 
combining FAK inhibition with pembrolizumab (NCT02546531, NCT02758587), or 
chemotherapy (NCT02428270, NCT02651727). Though immune modulation has proven 
insufficient to provide survival benefit for patients with PDAC to date, the coming decade holds 
great promise for successful translation of rationally-designed combination regimens that may 
finally provide longer-term hope for patients with this dreaded disease. 
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1.1.4: Summary 
While immunotherapy has delivered unprecedented clinical benefit to some patients with 
some tumor types, the majority of patients treated with immune modulating agents fail to 
achieve durable responses. Moreover, some tumor types remain almost universally refractory. 
Increased understanding of the malignant antigens recognized by the immune system is 
improving our ability to educate our own immune systems against cancer, while investigation 
into the complex network of interactions between immune cells and non-immune cells in the 
tumor microenvironment is informing our ability to identify patients poised to respond or not to 
therapy. Advanced prostate and pancreatic cancers remain among the most challenging 
indications, yet novel rationally-designed therapeutic approaches are on the clinical horizon 
that may finally render these cancers sensitive to therapy. Therapeutic modulation of tumor 
myeloid cells is one such approach. In light of their complex biology and the myriad roles these 
cells play in cancer, the next section will review the etiology, function, and therapeutic 
targeting of myeloid cells in cancer. 
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1.2: Myeloid Immunosuppression: A Critical Barrier to Antitumor Immunity 
The term “myeloid” cell refers to any cell of primitive or definitive hematopoietic origin 
which descends from the common myeloid progenitor cell. This common myeloid progenitor 
can give rise to two daughter lineages, one a precursor of megakaryocytes and erythrocytes 
(MEP), and the other a precursor of monocytes and granulocytes (171). Cells descending 
from the granulocyte/monocyte progenitor include polymorphonuclear neutrophils, basophils, 
and eosinophils, and mononuclear monocytes, macrophages, and dendritic cells. Together, 
these cells largely compose the innate arm of the immune system. These cells are generally 
highly adaptive and are readily programmed by a multitude of dynamic environmental signals 
in their local niche, and thus have wide-ranging roles in physiology from host defense to 
maintenance of tissue integrity and homeostasis.  As a result of this plasticity, they are also 
implicated in a number of disease states including heart disease, obesity, diabetes, allergy 
and autoimmunity, and cancer (172). 
Chronic inflammation is a long-recognized hallmark of cancer that is both a result of 
and contributor to the phenotype and function of myeloid cells in cancer (173, 174). Systemic 
inflammation interferes with normal myelopoiesis in terms of both the quantity and quality of 
myeloid cells produced, resulting in unique circulating myeloid populations that can seed the 
tumor environment and modulate tumor growth and the host response to cancer. Moreover, 
the complex metabolic and cellular milieu of the tumor microenvironment can further program 
myeloid cells to participate in largely normal physiological processes – such as those 
reminiscent of wound repair – that paradoxically serve to promote tumor immune evasion, 
invasion, and metastatic dissemination. The high plasticity characteristic of myeloid cell 
biology is both a blessing and a burden; it provides therapeutic potential for reprogramming 
myeloid function towards tumor-antagonistic functions, yet results in a complex biology that 
confounds identification and validation of optimal therapeutic approaches. The aim of this 
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section is to review the ontogeny and function of two major classes of myeloid immune cells 
in the context of cancer, and discuss the current state of the art in targeting myeloid cells for 
cancer therapy. 
 
1.2.1: Ontogeny of Myeloid Derived Suppressor Cells and Tumor Associated Macrophages 
Myeloid Derived Suppressor Cells. An enigmatic population of myeloid cells in cancer 
capable of apparent immune suppression but lacking in definitive phenotypic marker 
expression was first identified in the 1970s (175). Not until the turn of the century, however, 
were there sufficient technological tools and understanding of hematopoiesis to accurately 
describe the identity and nature of these cells. An early definitive phenotype arose with 
identification of the Gr-1 epitope recognized by the RB6-8C5 antibody (176), which was later 
shown to bind both Ly6G and Ly6C markers on granulocyte/monocyte lineage cells in mice 
(177). Cells co-expressing CD11b and Gr-1 were shown to be elevated in the context of 
cancer (178), immunosuppressive (179-181), and dependent on myeloid colony stimulating 
factors such as GM-CSF for accumulation in the blood or spleen (180, 182). These cells were 
shown to phenotypically resemble monocytes and granulocytes, but were accepted as a 
unique population due to their immature nature and potent immunosuppressive function (183). 
Thus, myeloid derived suppressor cells (MDSCs) constitute a unique population of myeloid 
cells characterized in large part by immunosuppressive function in pathologic contexts such 
as cancer. 
 Fundamentally, MDSCs consist of immature myeloid precursor cells derived from the 
common myeloid progenitor that have not completed differentiation into mature monocytes or 
granulocytes, such as neutrophils. As such, MDSCs can be separated into two main cell types; 
monocytic MDSCs (MO-MDSC) or polymorphonuclear MDSCs (PMN-MDSC), based upon 
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phenotypic and morphologic resemblance to monocytes or neutrophils, respectively (184). 
The generation of MDSCs in pathological conditions such as cancer is thought to require two 
discrete signals; first, colony stimulating factors such as GM-CSF, G-CSF, or SCF-1 are 
required to induce myelopoiesis to expand a pool of immature myeloid progenitors (180, 185, 
186). Second, low-level chronic inflammatory signals drive aberrant activation of these 
precursor cells, which halts their differentiation and supports transcriptional programming 
towards immunosuppressive phenotypes (187). The concerted actions of GM-CSF and IL-6 
have been described to promote MDSC differentiation and accumulation in a number of tumor 
models (147, 188-190), which has shed light on the signaling pathways governing the MDSC 
phenotype. IL-6 is known to induce phosphorylation, homodimerization, and nuclear 
translocation of STAT3. Thus, inhibition of STAT3 with tyrosine kinase inhibitors such as 
sunitinib (191) or by genetic ablation (192, 193) can reduce accumulation of suppressive 
MDSCs in tumors, while ablation of SOCS3, a negative regulator of STAT3, can have the 
opposite effect (194). STAT3 likely governs multiple aspects of MDSC biology from 
mobilization (195) and differentiation (196) to immunosuppression through induction of Nox2 
(197) and arginase (198). In addition, GM-CSF and IL-6 can induce C/EBPβ, a transcription 
factor that also been implicated as a critical mediator of MDSC differentiation (199). Like 
STAT3, C/EBPβ can regulate expression of arginase and Nox2, implicating this factor in 
MDSC suppressive function (199). Additional pathways thought to be involved in MDSC 
differentiation include IRF8 (200, 201), Notch signaling (202), RB1 (203, 204), and 
adenosinergic signaling (205, 206). Moreover, suppressive activity of MDSCs may further be 
bolstered by signaling through STAT6 (207, 208), NF-κB (209, 210), PGE2/COX2 (211, 212), 
and the ER stress response transcription factor CHOP (213). Given the diverse chronic 
inflammatory stimuli capable of naturally generating MDSCs in vivo, together with the inherent 
cellular diversity within this pool of pathologically-activated myeloid precursors, MDSCs are 
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fundamentally heterogeneous cells with context-specific phenotype and function in cancer. 
 
Tumor Associated Macrophages. The earliest postulations of cellular immunity, dating back 
to the work of Elie Metchnikoff in the late 19th century, described the function of phagocytic 
cells as a means of host defense, rendering macrophages among the first immune cells ever 
studied (214). Macrophages have been a central focus of observation and investigation ever 
since, and continue to surprise and confound researchers with their remarkable range of 
phenotypes and functions in both homeostatic and pathological states across almost all 
tissues. Early on, it was assumed that all macrophages present in human tissue were derived 
from circulating monocytes produced via “definitive” hematopoiesis in the bone marrow (215). 
Classically, these circulating monocytes express Ly6C and CCR2 in mice (CD14 in humans) 
in contrast to patrolling monocytes that express CX3CR1 (CD16 in humans) and rarely 
extravasate into tissues to undergo differentiation (216, 217). However, macrophages can 
also develop during “primitive” hematopoiesis occurring in the yolk sac during embryonic 
development, and these macrophages have recently been shown to seed many tissues and 
remain as resident macrophages where they are maintained by in situ self-renewal through 
adulthood (218-220). Interestingly, absent fate mapping manipulations, tissue resident 
macrophages in a given tissue are indistinguishable from macrophages recently differentiated 
from recruited circulating monocytes; a testament to the remarkable plasticity of this cell 
lineage in responding to loco-regional cues within the tissue (221). Upon inflammatory insult, 
macrophages will expand in tissues either through in situ proliferation of tissue resident 
macrophages (222, 223) or through recruitment and differentiation of circulating monocytes 
(216), and the relative contribution of these two cellular sources is likely governed by the tissue 
itself and the nature of the inflammatory signal. In cancer, tumor associated macrophages 
(TAM) are generally thought to undergo continual replacement by circulating monocytes or 
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MO-MDSCs, however recent studies suggest there may be unique temporal or functional 
contributions by TAMs of definitive or primitive origin. For example, Franklin and colleagues 
report in the MMTV-PyMT breast cancer model that early expansion of macrophages in the 
TME is the result of proliferation by tissue resident macrophages, however long-term TAM 
accumulation requires contribution from the monocyte pool (153). Moreover, Zhu et al report 
that TAMs in the KPC model of PDAC are derived from both primitive and definitive 
hematopoiesis, and that monocyte-derived TAMs may primarily participate in 
immunosuppression, while tissue resident TAMs promote local desmoplasia (224). Future 
studies are needed to illuminate with greater clarity the relative contributions of monocyte-
derived and tissue resident macrophages across cancers, as tissue-specific programming is 
likely to play a role in dictating this balance.  
 A plethora of distinct factors contribute to macrophage recruitment, differentiation, and 
polarization during homeostasis and in the context of cancer. Fundamentally, signaling 
through the CSF-1 receptor is the critical factor supporting macrophage differentiation and 
survival. This receptor binds both CSF-1 (225) and IL-34 (226), with both cytokines likely 
contributing to the generation and stability of the macrophage pool. Loss of CSF-1R signaling 
through genetic ablation or pharmacologic inhibition results in a drastic reduction in TAMs, 
suggesting CSF-1R signaling is critical for macrophage recruitment and longevity in the TME 
(227-229). Moreover, the chemokine CCL2 provides a critical recruitment signal for circulating 
monocytes to enter the tumor bed and differentiate into TAMs (216, 230), although additional 
factors such as VEGF can contribute to this recruitment (231). Differentiation of circulating 
monocytes into TAMs appears to involve Notch pathway signaling, specifically through the 
transcription factor RBPJ (153). Additionally, MO-MDSCs can serve as an additional source 
of TAMs (60). Kumar and colleagues report that under hypoxia MO-MDSCs engage the 
hypoxia-inducible factor Hif-1α to induce CD45 tyrosine phosphatase activity, which 
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downregulates STAT3 and results in differentiation of MO-MDSCs into TAMs within hypoxic 
zones (232). Upon differentiation, macrophages integrate numerous environmental signals to 
generate a context-dependent phenotype and function (233). The “M1/M2” paradigm has 
been created in an attempt to define these phenotypes, and, while useful, this paradigm is 
widely accepted as an oversimplification of macrophage diversity in vivo (234). The 
“classically activated” M1 macrophage phenotype is induced by IFN-γ and LPS, while the 
“alternatively activated” M2 phenotype is induced by IL-4 and IL-13, mirroring the Th1/Th2 
cytokine paradigm in T cell biology (235). These factors drive distinct transcriptional programs 
characterized by unique transcription factor usage (STAT1 and NF-κB versus STAT6 and 
Myc), cytokine output (IL-12 versus IL-10), metabolic enzyme production (iNOS versus 
arginase), and surface molecule expression (CD80 and CD86 versus CD163 and CD206) 
(174, 236, 237). These phenotypes have been considered extremes along a spectrum of 
macrophage diversity, however characterization of multiple “flavors” of alternatively activated 
macrophages has challenged the linear spectrum model of macrophage identity (238). Thus, 
the M1/M2 phenotypes may be considered landmark hues within a color wheel of interrelated 
identities (Fig 2). This plasticity presents a challenge in understanding the critical factors that 
polarize TAMs in cancer, as unique anatomical cues and tumor-derived factors in different 
models can dynamically modulate TAM phenotype and function (154). Therefore, high-
dimensional analysis of tumor myeloid cell transcriptional and phenotypic characteristics at 
the single cell level will be required to fully understand the complex nature and function of 
TAMs in any given cancer tissue (239-241). 
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Figure 2: Models of macrophage polarization and plasticity. Classical M1/M2 
nomenclature utilizes a linear spectrum model, with LPS/IFNγ stimulated M1 macrophages 
and IL-4/IL-13 stimulated macrophages as extremes along the spectrum of possible 
phenotypes. A more complex view of macrophage plasticity is represented by the color 
wheel model, where multiple landmark phenotypes exist in a non-linear, interrelated 
fashion. This model is likely more accurate in describing the broad range of macrophage 
phenotypes present in tumors across tissues. 
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1.2.2: Mechanisms of T Cell Immunosuppression by MDSCs and TAMs 
Myeloid infiltration in cancer is increasingly appreciated as a negative prognostic 
marker across many histologies and is thought to underlie resistance to immunotherapy. 
Immunosuppressive activities by MDSCs and TAMs are diverse and context-specific, in line 
with the general theme of myeloid biology. Though unique in ontogeny and phenotype, TAMs 
and MDSCs exhibit many overlapping functional properties in the TME, thus this section will 
be organized according to the individual mechanisms of immune suppression by myeloid 
cells, and specific contributions from individual subsets of TAMs or MDSCs will be highlighted 
therein. 
 
Nutrient Deprivation. Catabolism or sequestration of macromolecular nutrients can have 
immunomodulatory effects, especially on cytotoxic T cells (242). Interestingly, despite the 
array of environmental metabolites involved in sustaining T cell effector function, only two 
main amino acid catabolism pathways are common among myeloid cells in cancer, targeting 
arginine and tryptophan. As a corollary, cysteine sequestration has been observed in MDSCs, 
however the generalizability of this observation has not been demonstrated (243). Arginine 
catabolism by myeloid cells is largely controlled by the enzymes arginase-1 and iNOS, which 
create distinct byproducts and are generally expressed in different cell types. Arginase 
hydrolyzes arginine to form ornithine and urea, compounds that are thought to be relatively 
indolent in regard to T cell function, though a potential suppressive role of ornithine has been 
reported (244, 245). Arginase is often expressed within tumor-infiltrating MO-MDSCs, PMN-
MDSCs, and TAMs, and is thought to function primarily by denying T cells access to this 
critical environmental metabolite. T cells deprived of arginine exhibit a profound deficiency in 
proliferative capacity, concomitant with downregulation of the CD3ζ chain of the T cell receptor 
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(246-248). Furthermore, in the absence of arginine T cells fail to induce key cell cycle 
regulators and thus stall in the G0-G1 phase (249, 250). Interestingly, arginase activity may 
promote MDSC accumulation in some circumstances (251), suggesting a positive feedback 
loop between arginine metabolism and MDSC recruitment may exist. Arginase expression is 
mainly controlled by Th2-type cytokines including IL-4 and IL-13, which engage STAT6 to 
drive arginase gene transcription in association with C/EBPβ in macrophages (252, 253). 
Additionally, activation of Hif1-α in hypoxic conditions results in arginase upregulation in 
MDSC (60). In contrast, iNOS catabolizes arginine to form citrulline, NADPH, and nitric oxide 
(NO). Unlike arginase, iNOS is induced by Th1-type cytokines such as IFN-γ, leading to the 
classification of iNOS as a marker of M1-like macrophages (254). The value of iNOS 
expression in the tumor myeloid compartment is likely context dependent, as it is associated 
with beneficial inflammatory macrophage polarization, yet can contribute to T cell suppression 
through release of toxic NO species by MDSCs, as discussed below (60). 
 Tryptophan catabolism in mammals is primarily mediated by the enzymes indoleamine 
2,3-dioxygenase-1 (IDO1), IDO2, and TDO, with IDO1 the predominant enzyme expressed in 
cancer (255). These enzymes break down tryptophan to form a metabolite N-formyl-
kynurenine, which itself constitutes a molecule with immunomodulatory properties (256). 
Thus, both tryptophan deprivation and downstream catabolite formation contribute to the 
immunosuppressive function of IDO in the TME. IDO was discovered as an interferon-
inducible protein (257), so in cancer IDO often acts as a counter-regulatory mechanism 
induced in response to cytotoxic T cell function (48). Both MDSCs and TAMs can express 
IDO (258, 259), and tumor-intrinsic IDO expression can enhance MDSC accumulation in 
tumors (260). Similar to the effects of arginine depletion, IDO1-mediated depletion of 
tryptophan causes growth arrest in T cells, which was shown to involve the amino acid sensing 
pathway GCN2 (261, 262). In addition, kynurenine products activate the aryl hydrocarbon 
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receptor (AHR) (256, 263), which can downregulate the TCR CD3ζ chain or induce outright 
apoptosis in T cells (264, 265). In light of these observations, therapeutic targeting of both 
IDO1 and arginase are being attempted in preclinical and clinical studies at this time, and will 
be reviewed later in this chapter. 
 
Free Radical Species. Free radicals consist of an atom or group of atoms that possess 
unpaired electrons. These molecules arise as normal byproducts of biochemical reactions, 
and when not properly reduced are by nature extremely reactive species, stealing electrons 
from surrounding molecules to initiate a chain reaction of free radical generation that can 
damage or decay macromolecular structures within or around a cell. The most common free 
radicals produced by myeloid cells are reactive oxygen species (ROS) including superoxide 
(O2•-) or reactive nitrogen species (RNS) such as nitric oxide (NO) (266). Myeloid ROS 
production is mediated by NADPH oxidase (Nox1) and arginase-1 (Arg1), while RNS are 
primarily produced by iNOS (266). In general, it is thought that MO-MDSCs and TAMs are the 
predominant producers of RNS, while PMN-MDSCs primarily produce ROS (267, 268). When 
Nox1/Arg1 and iNOS are active in the same location, superoxide and NO species will react 
together spontaneously to form peroxynitrite (ONOO-), one of the strongest oxidizing agents 
found in vivo (269, 270). In normal physiology, ROS/RNS are utilized by both macrophages 
and neutrophils to kill bacteria or helminths, however in cancer these pathways can interfere 
with T cell recruitment, antigen recognition, and T cell viability. 
 Peroxynitrite species react irreversibly with four amino acids; methionine, cysteine, 
tryptophan, and tyrosine in a process called nitration (266, 271). Nitration of proteins in the 
TME can be detected with antibodies that detect nitrotyrosine, which was shown to correlate 
with MDSC numbers in human tumors (272). Chemokines such as CCL2 can be nitrated, 
interfering with T cell recruitment to both murine and human prostate tumors (273). 
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Interestingly, given the role of CCL2 in chemotaxis of both T cell and myeloid populations, 
nitro-CCL2 seems to selectively interfere with CD8 T cell recruitment, while myeloid cells and 
Tregs remain able to infiltrate either through retained binding to nitro-CCL2 or through other 
redundant chemotactic pathways (273). Additionally, nitration of tumor MHC molecules can 
interfere with peptide binding, preventing presentation of tumor antigen for recognition by CD8 
T cells (274). In this study, Lu and colleagues report that MDSC are the major contributors of 
peroxynitrite species compared to macrophages or tumor cells across a number of human 
and murine tumor types (274).  On the other side of the equation, nitration of the T cell receptor 
or the CD8 surface molecule can also occur (275). These modifications further interfere with 
TCR binding to peptide-MHC complexes on the surface of tumor cells, resulting in T cell 
hyposensitivity in the TME (276). Thus, MHC nitration by MDSCs can prevent T cell 
cytotoxicity independent of anergy induction or suppression of T cell effector capacity. 
Nevertheless, excessive exposure to peroxynitrite in the TME can render T cells dysfunctional 
regardless of antigen detection efficiency, through suppression of IL-2 signaling or outright 
toxicity (277, 278). Therefore, the concerted actions of MDSCs and TAMs to induce ROS/RNS 
in the TME can lead to local nitration of critical surface markers and chemokines to selectively 
interfere with CD8 T cell recruitment, longevity, and tumor-specific cytotoxicity. 
 
Immunosuppressive Ligands. Both MDSCs and TAMs express a wide variety of surface 
molecules and secreted factors that can suppress local T cell responses through both direct 
and indirect mechanisms (174). Indirect mechanisms involve recruitment or polarization of 
suppressive cell types, such as Tregs. For example, MDSCs and TAMs can recruit Tregs 
through release of chemokines that act on CCR5 and CCR6 (279, 280), and expand Tregs 
locally through direct antigen presentation (281, 282) or release of TGF-β, a critical mediator 
of Treg differentiation (283). Moreover, MDSCs and TAMs can participate in mutual crosstalk, 
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reinforcing suppressive phenotypes through complementary cytokine signals. For example, 
IL-10 production by MDSCs can promote TAM polarization towards an M2-like phenotype 
associated with NO production and reduced TNF-α release (284). Moreover, through cell-
contact dependent interactions MDSCs can reduce IL-12 expression in TAMs, while TAMs 
further promote IL-10 production by MDSCs (285). Together, these complex interactions can 
fortify the immunosuppressive stroma, creating a local extrinsic barrier to antitumor T cell 
function. 
 In contrast, a number of cytokines and surface ligands expressed by TAMs and 
MDSCs act directly on T cells to suppress their effector functions. Cytokines such as TGF-β 
and IL-10 derived from MDSCs or TAMs – in addition to their indirect effects described above 
– can directly suppress CD8 T cell cytotoxicity. TGF-β exposure induces downregulation of 
key effector molecules in CD8 T cells including perforin, granzyme B, IFN-γ, and Fas ligand 
(286), reduces IL-2 signaling and cell cycle regulators needed for proliferation (287), and is 
associated with T cell exclusion from the tumor bed (288). IL-10 also contributes to the 
suppression of T cell proliferation by regulating costimulatory signaling through CD28 (289). 
Thus, TGF-β and IL-10 are together considered powerful mediators of peripheral T cell 
tolerance (290, 291). Furthermore, ligation of PD-1 on T cells by the coinhibitory ligands PD-
L1 or PD-L2 is a common mechanism of direct T cell suppression in cancer. MDSCs are 
known to express PD-L1 in both murine and human tumors (292, 293), and expression may 
be more pronounced on PMN-MDSCs relative to MO-MDSCs (294). This ligand is functional, 
as antibody blockade of PD-L1 can reduce contact-dependent T cell suppression by PMN-
MDSCs in ex vivo assays (294). Moreover, TAMs are similarly observed to express PD-L1 in 
murine models (295) as well as a number of human tumor types (296-298). Expression of PD-
L1 can occur at a greater magnitude on TAMs compared to tumor cells, and thus can 
contribute to escape of immunogenic tumors from T cell-mediated killing (299). Therefore, in 
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addition to metabolic or redox-related T cell suppression through depletion of environmental 
nutrients and release of ROS/RNS species, TAMs and MDSCs can express a number of cell 
surface or secreted ligands which are capable of suppressing antitumor T cell responses 
through indirect or direct mechanisms. 
 
1.2.3: Therapeutic Targeting of MDSCs and TAMs in Cancer 
Myeloid Derived Suppressor Cells. Given the potent immunosuppressive capacities of 
MDSCs and their negative association with clinical outcome or response to therapy in patients 
with a range of different tumor types (300), MDSCs present an attractive target for therapeutic 
intervention. Such approaches to date have targeted MDSCs in three ways; blockade of 
MDSC recruitment, interference with MDSC differentiation and survival, or inhibition of 
immunosuppressive functions. The canonical chemokine receptors governing monocyte and 
neutrophil chemotaxis are CCR2 and CXCR2, respectively. Blockade of CXCR2 has been 
tested preclinically, with efficacy as single agent or in combination with chemotherapy or 
checkpoint blockade in PDAC (301), ovarian (302), and colorectal cancers (303). Based on 
these data, a small molecule inhibitor of CXCR2 is being evaluated in patients with mCRPC 
(NCT03177187). Inhibition of CCR2 has been evaluated clinically in combination with 
FOLFIRINOX in a phase Ib trial of patients with borderline resectable or locally advanced 
PDAC, with 49% of patients showing objective response by RECIST to the combination 
therapy (304). Interestingly, individual depletion of MO-MDSCs and TAMs by CCR2 blockade 
or PMN-MDSCs by CXCR2 inhibition can lead to compensatory myelopoiesis, in which the 
untargeted myeloid population will be recruited to the tumor in greater numbers (305). Thus, 
blockade of both CCR2 and CXCR2 may be necessary for optimal clinical benefit. Additionally, 
CCR5 expression has been described on both MO-MDSCs and PMN-MDSCs, and may 
describe a highly suppressive subset of MDSCs (306). This observation illuminates the high 
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level of redundancy in the immune chemokine receptor network on myeloid cells, which 
presents a challenge even to combination approaches. Thus, it remains to be seen whether 
chemokine receptor modulation will be a tenable approach to significantly ameliorate myeloid 
suppression in human cancers. 
 In addition to inhibiting recruitment, MDSC numbers can be reduced in cancer through 
interference with MDSC differentiation, direct induction of apoptosis, or maturation into DCs 
or other mature myeloid populations. One such approach with both preclinical and clinical 
testing involves all-trans retinoic acid (ATRA), a derivative of vitamin A. ATRA promotes 
maturation of myeloid precursors into DCs through upregulation of glutathione synthase (307, 
308), and when used therapeutically effectively reduces the number of MDSCs in tumor-
bearing hosts (309). This effect has been seen in a small study evaluating ATRA with IL-2 in 
18 patients with metastatic renal cell carcinoma, where ATRA improved the MDSC:DC ratio 
(310). Recently, ATRA was evaluated in combination with ipilimumab in a phase II study of 
patients with melanoma, where it reduced the number and suppressive function of MDSCs, 
while increasing the frequency of circulating mature myeloid populations. However, the overall 
clinical benefit of this approach was not fully reported (311), thus it remains to be seen whether 
ATRA will synergize with immunotherapy in the clinical setting. A similar approach consists of 
inhibition of STAT3, which plays a major role in MDSC differentiation and suppressive 
programming. A number of STAT3-targeting therapies are currently under design and 
preclinical evaluation, and it appears that this approach can promote maturation of MDSCs 
into inflammatory DC populations (312). In contrast, direct depletion of MDSCs by apoptosis 
can be achieved in a number of ways. In response to ER stress, MDSCs upregulate TRAIL 
receptors relative to normal monocyte and neutrophil populations. Targeting of these 
receptors can thus induce apoptosis somewhat selectively in the MDSC compartment (313). 
Furthermore, targeting of S100A8 and S100A9 with engineered peptides can induce MDSC 
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depletion with greater efficiency than Gr-1 targeting antibodies in mice (314). Interestingly, 
many chemotherapies when given at low doses can cause preferential apoptosis in the MDSC 
compartment, including gemcitabine (315), 5-fluorouracil (316), docetaxel (317), and 
doxorubicin (318). Clinical evaluation of these approaches alone and together with 
immunotherapies is needed to reveal which will most effectively counter MDSC suppression 
and synergize with immunotherapy in patients. 
 Finally, the immunosuppressive programs utilized by MDSCs can be targeted to 
reduce their suppressive influence in the tumor microenvironment. For example, ROS/RNS 
production by MDSCs can be indirectly inhibited by a synthetic triterpenoid CDDO-Me, which 
also induces expression of Nrf2 to promote survival under redox insult (319). Similarly, 
nitroaspirin can reduce NO production by MDSCs (320). Arginase expression in MDSCs can 
be reduced by inhibitors of COX-2 (211) or PDE-5, providing an opportunity for highly-utilized 
clinical compounds tadalafil or sildenafil to be used therapeutically in cancer patients (321, 
322). As such, tadalafil has shown efficacy in patients with head and neck cancer and multiple 
myeloma (323, 324). Another clinical compound with an unexpected role in MDSC biology is 
entinostat, an epigenetic modulator that inhibits class I histone deacetylase (325). This 
approach may have additional effects on TAMs as well, as is common among therapies 
targeting general mechanisms of myeloid-mediated immunosuppression (326). Together, a 
number of approaches are currently under preclinical and clinical investigation to target MDSC 
localization, function, and viability in cancer. Preclinical and clinical studies will be required to 
unravel which approaches are optimal across histologies, especially in the combination setting 
to enhance T cell-targeted immunotherapies. 
 
Tumor Associated Macrophages. Like MDSCs, TAMs possess potent immunosuppressive 
capabilities and are often associated with poor clinical outcome or response to therapy in 
42 
 
patients with many tumor types (327). The predominant means of targeting TAMs to date 
involves modulation of the CSF-1:CSF-1R signaling axis, given the dominant and exclusive 
role of this pathway in macrophage differentiation, stability, and alternative polarization. In a 
number of murine models and in some human tissues, tumor cells directly secrete large 
amounts of CSF-1 (228, 328-330), presumably to establish local immune privilege and to 
receive protumorgenic signals. Blockade of CSF-1R signaling through antibody blockade or 
small molecule inhibition of CSF-1R-associated tyrosine kinase activity leads to both 
reductions in the frequency of intratumoral TAMs and repolarization of residual macrophages 
towards inflammatory phenotypes (152, 330). This inflammatory reprogramming of the tumor 
microenvironment induces expression of T cell checkpoint ligands in the tumor 
microenvironment, thus combination of CSF-1R inhibition with CTLA-4 and PD-1 engenders 
strong therapeutic effects in mice with orthotopically implanted PDAC (330). In addition, CSF-
1R inhibitors have shown preclinical synergy with other conventional therapeutic modalities 
including androgen depletion in prostate cancer (331) or chemotherapy in PDAC (332) and 
breast cancer (333). Interestingly, patients with rare diffuse-type tenosynovial giant-cell 
tumors (dt-GCT) show nearly universal overexpression of CSF-1R due to characteristic 
chromosomal amplifications at the CSF-1 locus (229). Thus, in a phase I study CSF-1R 
blockade induced objective responses in 86% of patients, and 2 of 28 patients achieved 
complete responses (334). Currently, there are over 20 clinical trials ranging from phase I to 
phase III evaluating CSF-1R inhibition as single agent or in combination with chemotherapy, 
radiation, or immunotherapy across most solid tumors and some hematologic malignancies 
(335). However, outside of dt-GCT, response rates have been quite modest, though the 
efficacy of CSF-1R in the combination setting remains to be seen (336). While CSF-1R 
inhibition allows for macrophage-specific targeting, a number of other pathways play important 
roles in TAM differentiation and polarization, providing other promising – if less specific – 
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therapeutic avenues. The γ isoform of PI3K was recently described to be a critical molecular 
switch in controlling immunosuppressive macrophage phenotypes in PDAC and other cancers 
(337). Like CSF1R inhibition, pharmacologic blockade of PI3Kγ reprograms TAMs to support 
CD8 T cell function while inhibiting stromal desmoplasia and associated tumor metastasis 
(338), and in other tumor models PI3Kγ inhibition can potentiate checkpoint blockade (339). 
Based on these data, an inhibitor of PI3Kγ is currently in phase I evaluation across advanced 
solid tumors (NCT02637531). In addition, RORγ was recently shown to regulate myelopoiesis, 
contributing to both TAM differentiation and M2-like polarization, as well as MDSC 
accumulation in human and murine tumors (340). Greater prioritization of TAM-targeting 
therapies in clinical studies should reveal in the coming years which myeloid signaling 
pathways are the most promising therapeutic targets in cancer. 
 Macrophage plasticity is generally disadvantageous in cancer, as tumors efficiently 
polarize macrophages to support tumor growth and immune evasion. However, a growing 
body of work supports the idea that macrophage plasticity also presents a unique therapeutic 
opportunity. TAMs are often the most prevalent immune population within tumors; if 
repolarized from tumor-supporting to tumor-antagonistic, they could present a significant 
“trojan horse” approach to turn a tumor’s defenses against itself. The most striking example 
of this concept to date involves an agonistic antibody targeting the myeloid stimulatory 
receptor CD40. In a study by Beatty et al, the authors report CD40 agonism leading to T cell-
independent, macrophage-mediated tumor cytotoxicity in PDAC tumor-bearing KPC mice, 
presumably through release of reactive oxygen or nitrogen species and tumor cell 
phagocytosis (341). PDAC is known to possess a large and heavily immunosuppressive 
myeloid infiltrate, thus inflammatory repolarization by agents such as αCD40 could in theory 
be quite powerful by turning the vast reservoir of TAMs against the tumor. An agonistic 
antibody targeting human CD40 has progressed through phase I testing (341, 342) and is 
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currently being evaluated in a phase II study in PDAC in combination with gemcitabine and 
nab-paclitaxel in the adjuvant or neoadjuvant setting (NCT02588443). As with any immune 
agonist, CD40-targeting antibodies can exhibit toxicities due to systemic elaboration of 
inflammatory cytokines, thus the balance between efficacy and toxicity will be critical in 
determining the clinical feasibility and success of this approach. An alternative approach to 
CD40 activation involves activation of innate pattern recognition receptors such as Toll-like 
receptors (TLRs). The most common TLRs targeted for TAM repolarization in cancer include 
nucleic acid detectors TLR3 (polyI:C; synthetic dsRNA analog), TLR7/8 (imidazoquinoline; 
synthetic ssRNA analog), and TLR9 (ODN1826; synthetic CpG-rich dsDNA). These agents 
generally facilitate NF-κB activation through classical MyD88 or TRIF signaling downstream 
of the respective TLR, and upon local delivery can induce expression of proinflammatory 
cytokines such as TNFα, IL-12, IL-6, and to a lesser extent IFN-β (343-346). Clinical 
translation of these agonists is underway, with over 50 trials established for phase I/II testing 
in many solid tumors (347). Interestingly, a more recently characterized pattern recognition 
receptor STING – which is critical for innate detection of cytosolic DNA species – was shown 
to be essential for innate recognition and response to immunogenic tumors, while TLR 
signaling was dispensable (348). Whether agonists of STING can promote TAM repolarization 
and exhibit therapeutic activity in myeloid-rich tumors such as CRPC and PDAC is a main 
focus of investigation in this dissertation, and will be reviewed in detail below.  
 
1.2.4: Summary 
Tumor associated macrophages and myeloid derived suppressor cells are heterogeneous cell 
populations with a vast array of context-dependent functions in cancer. This complex biology 
has presented a challenge in describing the nature of these cells across tumor types in mouse 
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and man, and has delayed development of therapies aimed at reducing or modulating their 
functions. However, recent investigation has revealed potent immunosuppressive and tumor-
promoting roles for these cells, and has elevated them as key barriers precluding efficacy of 
both conventional cancer therapy as well as exciting new immunotherapies. Prioritizing 
myeloid-targeting trials in the coming years should illuminate optimal methods for myeloid 
modulation in cancer, and, when utilized in combinatorial regimens, these agents bring hope 
of converting refractory, non-responding patients to responders in tumors currently considered 
terminal. 
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1.3: STING: A Powerful Activator of Innate Immunity in the Tumor Microenvironment 
In contrast to adaptive immune cells, which undergo genetic rearrangement and 
hypermutation to express individualized receptors with exquisite specificity for a given antigen, 
innate immune cells recognize generalized molecular patterns unique to non-self pathogens 
or states of cellular distress through expression of germline-encoded pattern recognition 
receptors (PRRs). Conserved families of PRRs have been described, including the 
membrane-bound Toll-like Receptors (TLR) and C-type Lectin Receptors (CLR), and the 
endosomal NOD-like Receptors (NLR) and RIG-like Receptors (RLR). These families encode 
numerous unique receptors capable of sensing an array of molecular structures that are 
essential to the viability or pathogenesis of non-self pathogens, or are associated with the 
host stress response to infection or tissue damage.  
Particular attention is devoted to nucleic acid sensing, as nucleic acids are 
indispensable for essentially all viruses and bacteria, and genetic material from these 
pathogens can be readily discriminated from mammalian DNA and RNA. For example, TLR9 
senses unmethylated cytidine-phosphate-guanosine (CpG) rich DNA sequences, as bacteria 
lack the epigenetic machinery needed to undergo CpG methylation that is normally found in 
the mammalian genome. In addition to unique physical characteristics, aberrant cellular 
compartmentalization of nucleic acids can also constitute a sign of infection or stress. The 
presence of double-stranded DNA in the cytoplasm has long been known to induce innate 
immune activation, for example (349). However, the specific PRRs required for the detection 
of and response to cytoplasmic DNA in mammalian cells eluded discovery until recent years. 
Work by Barber and Chen described the cyclic GMP-AMP synthase (cGAS) – stimulator of 
interferon genes (STING) pathway as the major innate detection system for cytosolic DNA, 
and these studies revealed STING to be a potent activator of Type I interferon production in 
both hematopoietic and non-hematopoietic cells. In light of studies by Gajewski and others 
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associating a Type I interferon gene signature with an immunologically “hot,” or T cell-inflamed 
tumor microenvironment, efforts are underway to investigate the potential for therapeutic 
STING activation to induce Type I interferons within immunologically “cold” non-T cell-
inflamed tumors.  
This section aims to describe the discovery of the cGAS-STING pathway, summarize 
current knowledge regarding the role of STING in antitumor immunity, and discuss the use of 
STING agonists as therapies in both mouse and man. 
 
1.3.1: Discovery and Characterization of the cGAS-STING Pathway 
Discovery of STING. A fundamental component of the host response to viral infection is 
induction of type I interferons including IFN-α and IFN-β. By the early 2000s, a number of 
PRRs capable of inducing type I interferons in response to viral RNA and DNA had been 
identified, including membrane-bound TLR3 and TLR9, which detect the presence of 
endosomal double-stranded viral RNA and unmethylated CpG DNA, respectively (350, 351). 
Additionally, a number of cytoplasmic RNA helicases including RIG-I and MDA5 were 
described to detect and induce interferon responses to viral RNA present in the cytosol (352, 
353). However, the host response to viral double-stranded non-CpG DNA was known to occur 
independent of TLR9 signaling (349, 354), suggesting the presence of an undescribed DNA 
sensor capable of sensing viral DNA in the cytoplasm.  
 Contemporaneous reports by Ishikawa, Zhong, and Jin in 2008 identified the 
TMEM173 gene product STING (also known as MITA, ERIS, MPYS) as a novel component 
of innate immune signaling. Interestingly, the first report of STING by Jin et al found STING in 
association with MHC-II as a mediator of apoptotic signaling in lymphoma, which remains a 
cryptic function of STING that has not been further substantiated (355). In both studies by 
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Ishikawa and Zhong, however, STING was identified in expression cloning screens for a 
robust capacity to mediate release of IFN-β upon overexpression in 293T cells (356, 357). 
These studies implicated IRF3, IRF7, TBK1, and NF-κB in signaling downstream of STING, 
which were known to be involved in the interferon response to non-CpG DNA. This, together 
with the observation that STING-deficient mouse embryonic fibroblasts (MEFs) exhibit 
increased susceptibility to infection by the DNA virus herpes simplex virus 1 (HSV1) 
established STING as a putative DNA sensor. At the time, a number of cytosolic DNA sensors 
including DAI, AIM2, IFI16, and DDX41 had been identified, however none were uniquely 
required for the type I interferon response to non-CpG DNA. In a subsequent study, Ishikawa 
provided conclusive evidence that STING is essential for induction of IFN-β following exposure 
to cytosolic DNA, using STING-deficient MEFs, macrophages, and dendritic cells to 
demonstrate a lack of interferon release following transfection with viral DNA (HSV1, HSV2, 
Ad5), bacterial DNA (E. coli, Listeria monocytogenes), and synthetic DNA species (non-CpG 
immunostimulatory DNA, poly-dAT:dAT, poly-dGC:dGC) (358). Of note, STING-deficient cells 
retained TLR9-mediated responses to CpG-containing DNA as well as TLR3-mediated 
responses to poly(I:C) RNA analogues, suggesting STING-mediated nucleic acid signaling 
and TLR-mediated nucleic acid signaling are discrete and independent entities (358). 
Together, these reports identified STING as a critical component of the mammalian type I 
interferon response to cytosolic DNA. 
 Given this critical role for STING in cytoplasmic DNA sensing, it was initially thought 
that STING was a direct sensor of non-CpG DNA. However, early reports did not demonstrate 
an obvious association between STING and DNA. Bearing four transmembrane domains, 
STING was found to localize to the endoplasmic reticulum (ER) as well as the ER-associated 
mitochondrial membrane, and upon activation translocate through the golgi apparatus to 
perinuclear endosomal structures, which serve as foci of STING signaling (358, 359). While 
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the long C-terminal domain of STING is oriented towards the cytosol where it can theoretically 
sense extra-nuclear DNA, this restricted localization profile is uncommon among known DNA 
sensors, which are generally non-membrane-bound cytosolic proteins. In support of this, 
Sauer and Burdette identified cyclic dinucleotides – rather than DNA – as direct ligands of 
STING (360, 361). Using a forward genetic approach in mice mutagenized with N-ethyl-N-
nitrosourea, Sauer identified a point mutation in STING which abolished responsivity of mice 
to L. monocytogenes infection due to a lack of response to the bacterial second messenger 
nucleotide cyclic di-GMP (CDG) (361). Burdette utilized this null STING allele (termed 
goldenticket; STINGgt) to definitively describe STING as a sensor of cyclic dinucleotides (360). 
Interestingly, in this study Burdette identified an additional R231H point mutant of murine 
STING which was not stimulated by CDG, but could induce IFN-β in response to DNA 
transfection. This suggested the presence of an additional DNA sensor capable of generating 
a novel and unique agonist of STING in response to cytoplasmic DNA. 
 
Discovery of cGAS. To identify the elusive molecule capable of activating STING in response 
to cytosolic DNA, Wu et al developed a cell-free assay to evaluate lysates from DNA-
transfected L929 fibroblasts for ligands capable of inducing STING-mediated IRF3 
homodimerization. Through both chromatography and STING-based affinity purification, they 
identified by mass spectrometry a dinucleotide cyclic GMP-AMP (cGAMP) which could bind 
and activate STING (362), including the R231 isoform identified previously which did not 
respond to CDG. This was the first description of a cyclic dinucleotide produced endogenously 
within a metazoan cell. Using a complex fractionation strategy of DNA-transfected L929 
extracts, the same group identified a highly conserved but uncharacterized enzyme with 
sequence and structural homology to the human oligoadenylate synthase (OAS1), a member 
of the nucleotidyltransferase family of enzymes. This novel enzyme, termed cyclic GMP-AMP 
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synthase (cGAS), was found to bind DNA and catalyze the synthesis of cGAMP, which 
induced IRF3 dimerization and IFN-β production in multiple cell types in a manner dependent 
on STING expression (363). This study was closely followed by three others which confirmed 
cGAS as a DNA sensor capable of synthesizing cGAMP (364-366). Further, these reports 
refined the description of cGAS enzymatic activity, as initial mass spectrometry analysis of 
cGAMP failed to distinguish the non-canonical G(2’5’)pA(3’5’) “mixed” phosphodiester linkage 
present in cGAS-synthesized cGAMP, in contrast to the G(3’5’)pA(3’5’) canonical linkage in 
cGAMP produced by bacterial cGAMP synthases. Together, these reports conclusively 
identified cGAS as a novel DNA sensor capable of inducing type 1 interferon responses to 
cytoplasmic, non-CpG DNA through synthesis of a novel CDN bearing mixed phosphodiester 
linkages which potently activates STING. 
 
The cGAS-STING Signaling Pathway. The cGAS-STING pathway is an essential, non-
redundant means of cellular nucleic acid sensing with critical roles in anti-viral immunity, 
autoimmunity, and tumor immunity, as described herein. Both STING and cGAS are highly 
conserved proteins with ancestral homologs described in anemone, suggesting this pathway 
evolved as an early means of host defense over 500 million years ago (367, 368). In contrast 
to other nucleic acid sensors such as TLR9, which is expressed predominantly in rare 
plasmacytoid dendritic cells and B cells, STING and cGAS exhibit a broad expression pattern 
and are found across hematopoietic cells in addition to non-immune endothelium, epithelial 
tissues, neurons, and fibroblasts. 
 Signaling through the cGAS-STING pathway is precipitated by the presence of 
cytosolic double-stranded DNA (dsDNA) species, which serve as cellular danger signals by 
providing scaffolds for cGAS oligomerization and resulting catalytic activity. Under normal 
conditions, dsDNA is compartmentalized within the nucleus or mitochondria, thus the 
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presence of cytosolic dsDNA can be indicative of infection by intracellular bacteria or viruses, 
endogenous genotoxic stress or chromosomal instability (369-372), or necrotic cell death by 
neighboring cells that release unprocessed DNA (348, 373-375). Binding of cGAS to dsDNA 
occurs along the phosphate-sugar backbone of the minor groove of B-form DNA, allowing 
binding to occur in a sequence-independent manner (376, 377). Once bound, cGAS covers 
approximately 20 DNA base pairs (bp), allowing cGAS to recognize short dsDNA fragments. 
However, at low DNA concentrations approximating physiological conditions during viral 
infection, cGAS activity is correlated with dsDNA fragment length, with a minimum size of 40 
bp required for activation (378, 379). Monomeric binding of cGAS to dsDNA does not result 
in catalytic activity; rather, dimerization of two cGAS:dsDNA units induces cGAS activation 
(380). While this cGAS2-DNA2 complex formation is a thermodynamically unfavorable 
process, it facilitates “ladder-like” binding of additional cGAS dimers, resulting in cooperative 
formation of cGAS2n-DNA2 complexes (378). This cooperative binding acts to amplify the 
downstream 2’3’-cGAMP signal, and likely explains the dsDNA length-dependent activity of 
cGAS under physiological conditions. A number of stress-related nucleic acid binding proteins 
such as TFAM and HMGB are known to bind and induce “U-turn-like” structures in DNA, which 
can nucleate cGAS2n-DNA2 complexes and bypass the unfavorable cGAS2-DNA2 structure 
under stress conditions (378). Of note, the DNA length-dependency of cGAS is more 
pronounced with the human form of the enzyme relative to that found in other mammalian 
cells, owing to two amino acid substitutions on the DNA-binding surface of human cGAS that 
permit preferential binding to longer DNA sequences (381). This demonstrates a potential 
evolutionary emphasis on selective activation in humans, as opposed to highly sensitive 
activation as seen in lower species (381). Recently, Du et al found that high-order cGAS-DNA 
structures undergo phase separation to form liquid-like “droplets” within the cytosol, which 
concentrate and amalgamate available cGAS-DNA complexes to optimize cGAMP production 
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efficiency upon reaching a threshold concentration of cytosolic DNA (382). Thus, catalytic 
activation of cGAS upon binding cytosolic DNA is a complex process with unique regulatory 
mechanisms that promote selective activation under conditions of cellular stress or infection. 
 Upon activation by dsDNA, cGAS undergoes a conformational change that exposes 
its catalytic domain to undergo a two-step reaction by which free ATP and GTP nucleotides 
are converted to 2’3’-cGAMP, a high-affinity ligand for STING. At the basal state, STING exists 
as a monomer localized to the endoplasmic reticulum (ER) membrane due to RYR and RIR 
signal sequences surrounding its four N-terminal transmembrane domains (359). Two STING 
monomers are required to bind a single cyclic dinucleotide such as 2’3’-cGAMP, and this 
binding-induced dimerization facilitates activation of downstream signaling. Specifically, 
seating of 2’3’-cGAMP into the binding pocket of the cytoplasmic portion of STING dimers 
causes a closing of the two “wing-like” C-terminal arms and the formation of a β-sheet lid that 
covers the dinucleotide. This conformational change is associated with a novel trafficking 
pattern, whereby active STING dimers translocate from the ER through the golgi apparatus 
and form perinuclear endosomal structures in a process that resembles autophagosome 
formation (358, 383). These endosomal punctae serve as foci of STING signaling, which 
involves recruitment of the inhibitor of κB kinase (IKK) family member TANK-binding kinase 1 
(TBK1), which associates with the S366 residue of STING, resulting in autophosphorylation 
on S172 of TBK1 (384, 385). Upon autophosphorylation, TBK1 is activated to phosphorylate 
the C-terminal portion of STING at S353, S358, and S379 residues (385). This 
phosphorylation event is thought to promote recruitment of interferon regulatory factor 3 
(IRF3), which then is phosphorylated by TBK1 at S385/S386 and T404/S405 to mediate rapid 
IRF3 dimerization. Additionally, in association with tumor necrosis factor receptor-associated 
factor 6 (TRAF6), TBK1 induces NF-κBp65/RelA activation through the IKKαβ activation loop  
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Type I Interferon 
Production 
Figure 3: The canonical STING signaling pathway. STING is activated by cyclic 
dinucleotide molecules, which are either derived from bacteria (c-di-GMP/c-di-AMP) or 
from the cytoplasmic DNA sensor cGAS (cGAMP) following detection of viral- or host-
derived DNA in the cytosol. Upon binding cyclic dinucleotides, activated STING trafficks 
through the golgi to perinuclear endosomes, where it recruits TBK1 to activate downstream 
signaling components IRF3 and NF-κB (not shown). This signaling promotes robust type I 
interferon production, in addition to acute anti-viral inflammation-associated gene 
transcription. 
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(386). As a result, activated IRF3 and NF-κB/p65 undergo rapid translocation into the nucleus, 
where they act in concert to drive anti-viral gene transcription, predominantly characterized 
by induction of type I interferons (Fig 3). While STING-mediated activation of NF-κB/p65 
promotes “canonical” NF-κB signaling, activated STING is also capable of mediating non-
canonical NF-κB signaling in a TBK1-independent manner, which involves interactions with 
TRAF3 to promote IKKα-mediated activation of NF-κBp52 (386). Furthermore, activated 
STING was shown to physically associate with STAT6, which can be phosphorylated on S407 
by TBK1, leading to homodimerization and nuclear translocation to induce a specific repertoire 
of chemokines including CCL2, CCL20, and CCL26 (387). Therefore, while canonical STING 
signaling results in potent type I interferon release due to the coordinated activation of IRF3 
and NF-κBp65, STING does engage other non-canonical signaling pathways to achieve a 
robust acute pro-inflammatory program upon cellular infection or therapeutic activation.  
 
1.3.2: Role of the STING Pathway in the Antitumor Immune Response 
STING in Spontaneous Tumor Immunity. Immune control of cancer generally requires the 
generation of a cytotoxic CD8 T cell response, as these cells are in most circumstances the 
central mediators of tumor cell cytolysis. Naïve CD8 T cells capable of specifically sensing 
tumor antigens can only gain cytolytic effector function after priming by professional antigen 
presenting cells (APCs), however, as these cells alone are capable of delivering the 
costimulatory signals required to unleash effector programs in CD8 T cells following 
recognition of cognate tumor antigen through MHC-peptide-TCR engagement. Thus, proper 
APC function is a critical rate-limiting step in the process of generating antitumor T cell 
responses. In 2005, a study by Dunn et al demonstrated a critical role for type I interferons 
(IFN-α/β) in establishing tumor immune surveillance, and the cellular target of IFNα/β was 
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mapped to host hematopoietic cells (39). Contemporaneous reports by Diamond and Fuertes 
et al in 2011 identified a unique lineage of dendritic cells (DCs) driven by the Batf3 
transcription factor as the specific cellular target of IFN-α/β, as the action of IFN-α/β on these 
cells was required to facilitate CD8 T cell priming and accumulation within tumors (34, 388). 
These DCs are characterized by expression of cell surface markers CD8α or CD103, and are 
thought to play a critical role in tumor antigen cross-presentation, a unique process by which 
exogenous tumor antigens are internalized and shunted away from the MHC class II peptide 
processing pathway and loaded on to MHC class I, allowing professional APCs to induce CD8 
priming with exogenous, rather than endogenous, antigens. However, at the time it was 
unclear what stimulus induced IFNα/β and resulting cross-presentation activity by Batf3-
lineage DCs, as the sterile tumor microenvironment was thought to be bereft of traditional 
pathogen associated molecular patterns (PAMPs) only present during viral or bacterial 
infection. 
 To identify the innate signaling pathway capable of mediating sterile activation of 
Batf3-lineage DCs in the context of cancer, Woo et al implanted immunogenic B16-SIY tumors 
into mice lacking key components of TLR signaling (MyD88, TRIF, TLR4, or TLR9), antiviral 
RNA signaling (MAVS), purinogenic signaling (P2x7R), or STING signaling (STING, or IRF3).  
Of all pathways tested, only host STING and IRF3 were required for generation of a tumor 
specific CD8 T cell response and resulting regression of implanted tumors (348). Tumor DNA, 
rather than any other component of the B16 tumor extract, was sufficient to induce IFN-β in 
DCs in vitro, and using imaging cytometry, DCs carrying tumor-derived DNA were identified 
in the tumor microenvironment. These same cells exhibited increased levels of IFN-β 
transcripts relative to DCs from lymph nodes or spleen. Thus, DNA from dying tumor cells 
constitutes a key danger associated molecular pattern (DAMP) capable of inducing STING-
mediated type I interferon responses within the sterile tumor microenvironment (348). A 
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following study by Klarquist et al confirmed a role for STING in mediating both antitumor and 
autoimmune responses following uptake of DNA from dying cells (373). In inducible models 
of colorectal cancer and glioma, STING deficiency was associated with enhanced tumor 
growth relative to wild type animals, further suggesting STING signaling can counteract tumor 
progression (389, 390). Interestingly, epigenetic silencing of both STING and cGAS promoters 
has also been described in human colorectal carcinoma and melanoma (391, 392), and HPV 
viral oncoproteins E7 and E1A have been shown to bind STING and block its activation (393). 
This apparent evolutionary pressure to limit STING expression or function further supports a 
protective role for STING-mediated IFNα-β responses in limiting tumorigenesis. Therefore, 
STING activation in host DCs following sensing of tumor-derived DNA and the associated 
IFNα/β response is a critical rate-limiting step in the induction of cytolytic CD8 T cell responses 
against cancer. 
 
STING in Radiation Therapy. Localized tumor irradiation has long been utilized in cancer 
therapy because of its ability to induce genotoxic stress in chromosomally-unstable malignant 
cells, leading to tumor cell death. Various immune cell populations are also susceptible to 
radiation therapy (RT), which initially led many to believe that RT efficacy is unrelated to host 
immune function (394). However, recent studies suggest the efficacy of RT is in fact 
dependent on the immune system, as ablative radiation is largely ineffective in 
immunodeficient mice (395). Further, RT can induce adaptive immune responses and act 
synergistically with checkpoint blockade (395, 396). Delineation of the cGAS-STING pathway 
and its role in cellular DNA sensing led to the hypothesis that radiation-induced DNA damage 
may constitute a DAMP capable of promoting innate sensing of irradiated tumors and resulting 
induction of adaptive antitumor immunity. Deng et al provided evidence for this hypothesis, 
using mice with genetic deficiencies in innate immune signaling pathways to demonstrate that 
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STING and cGAS are uniquely required for the antitumor efficacy of RT (397). Exposing 
tumors to ablative RT results in cGAS-STING mediated production of IFN-β primarily by tumor 
CD11c+ DCs, presumably due to sensing of tumor DNA released upon radiation-induced 
necrotic cell death. This has been confirmed by the observation that induced expression of 
the DNA exonuclease three prime repair exonuclease 1 (TREX1) in irradiated tumors 
degrades cytosolic DNA and attenuates RT-induced activation of the cGAS-STING pathway 
(398). Interestingly, TREX1 induction is highly dependent on radiation dosing, with high doses 
applied in single fractions between 12 and 18 Gy constituting a threshold level capable of 
inducing physiologically-relevant levels of the exonuclease. However, repeated administration 
of low-dose radiation does not cause TREX1 upregulation, and appears optimal for inducing 
cGAS-STING mediated IFN-β induction, Batf3-lineage DC cross-presentation, and resulting 
priming of adaptive immune responses (398). It is intriguing to note that a collection of clinical 
case studies reporting systemic regression of metastatic cancer following local irradiation of 
a single primary lesion – termed the “abscopal” effect – utilized this fractionated low-dose 
approach (399-402). A number of these reports involved the use of fractionated RT together 
with checkpoint blockade immunotherapy, suggesting the vaccine-like immune potentiating 
effects of cGAS-STING activation in tumor DCs can prime adaptive immune responses that 
can be bolstered by other immune modulators. Therefore, the cGAS-STING pathway plays a 
critical role in the immune-potentiating effects of RT, and fine-tuning clinical RT protocols to 
optimize STING activation may result in superior clinical activity especially when combined 
with checkpoint blockade immunotherapy. 
 
STING in Non-Myeloid Tumor Stroma. Most early studies that have validated STING as a 
critical component of the antitumor immune response describe its function in promoting 
IFNα/β responses in Batf3-lineage DCs, as this promotes tumor-specific CD8 T cell priming 
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(348, 373). However, cGAS and STING are widely expressed among cells of the 
hematopoietic lineage as well as non-hematopoietic tissues, and engagement of this pathway 
can have unique effects depending on the cell type in which it is acting. For example, while 
STING activation fortifies DC survival and antigen presentation function, a number of reports 
have suggested an inhibitory role for STING activation within T cells. Even before the cGAS-
STING pathway was described, it was known that bacterial cyclic dinucleotides such as CDG 
could inhibit proliferation of Jurkat T cells (403). More recently, a collection of studies provided 
evidence of STING signaling triggering T cell-intrinsic IRF3-mediated IFNα/β production, 
which was associated with decreased proliferative capacity, increased cellular stress, and pro-
apoptotic gene expression (404-406). Specifically, these studies together report unique 
engagement of proapoptotic genes such as BAX (406), PUMA, and BIM (405), genes 
associated with the unfolded protein response including Bip/HSPA5 and GADD34 (406), and 
genes associated with the TP53 pathway (405). However, these studies utilized non-canonical 
forms of STING activation including the highly cell-permeable small molecules 5,6-
Dimethylxanthenone-4-acetic acid (DMXAA) or 10-carboxymethyl-9-acridanone (CMA), or 
enforced expression of a constitutively active form of STING bearing the V155M point 
mutation. Therefore, despite these insights, it remains to be determined whether physiologic 
STING activation within the confines of the tumor microenvironment following cGAS-mediated 
DNA sensing or therapeutically-administered cyclic dinucleotide agonists is sufficient to 
significantly attenuate T cell proliferation or survival. 
 DNA damage is known to upregulate expression of stress-related ligands such as 
NKG2D on tumor cells in a STING-dependent fashion, which serve as activation signals for 
cytotoxic natural killer (NK) cells (407, 408). While type I interferons are known to be essential 
for NK cell homeostasis and antitumor effector functions (409), few studies have deeply 
probed the effects of STING activation on NK cell cytotoxicity in tumors. Data from Takashima 
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et al suggest that STING signaling in both B16D8 melanoma tumor cells and host 
hematopoietic cells contribute to NK cell recruitment, possibly through chemokines CXCL10 
and CCL5 (410). While NK cell recruitment correlated with suppression of tumor growth in this 
model, it was not determined whether NK cell function was absolutely required for the 
response, or clearly dependent on STING signaling. In an in vitro system evaluating 
cetuximab-mediated NK-DC crosstalk against HPV+ head and neck squamous cell carcinoma 
(HNSCC) cell lines, Lu et al found cGAMP able to synergize with cetuximab to enhance 
human NK cell expression of HLA-DR and IFN-γ, markers of NK cell activation (411). Further, 
Kim et al reported a role for NK cell function in the efficacy of STINGVAX, a GM-CSF-secreting 
cellular vaccine formulated with CDN. These data also suggested CDN are capable of 
elaborating IFN-γ production by NK cells (412). Together, studies suggest STING activation 
can promote NK cell cytotoxicity against cancer, however it remains to be definitively shown 
to what extent the efficacy of CDN is dependent on NK function, and in which tumor indications 
STING-mediated NK cell activation is required. 
 In addition to infiltrating lymphocytes, STING is also highly expressed in tumor 
endothelial cells (413). In an early study evaluating the efficacy of intratumoral cGAMP in 
melanoma, Demaria and colleagues found that within 5 hours of injection, tumor endothelial 
cells are the highest producers of IFN-β, in both murine and human tumor extracts (414). 
Additionally, using endothelial cell lines and purified DC populations in vitro, they 
demonstrated a greater responsivity of endothelial cells to tumor DNA and cGAMP as 
measured by IFN-β mRNA induction. These data are seemingly in conflict with the notion that 
activation of Batf3-lineage DCs is central for the antitumor efficacy of STING agonists, 
however this study does not demonstrate a sufficiency for endothelial cells in promoting 
cGAMP-mediated immunity in mice deficient for Batf3. In addition, these experiments utilized 
lipofectamine-encapsulated cGAMP for both in vitro and in vivo experiments, rather than 
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naked CDNs as is used in the majority of preclinical studies as well as in early clinical trials 
for STING agonists. Lipid formulation may lead to preferential uptake of CDNs by endothelial 
cells which would not occur using naked CDN. Thus, this study does not disprove a role for 
STING-mediated DC activation in antitumor immunity elicited by CDNs, but identifies 
endothelial cells as an additional unexpected cellular source of STING-induced IFN-β in the 
tumor microenvironment. 
 
1.3.3: Current Knowledge of the Therapeutic Utility of STING Agonists in Cancer 
Classes of STING Agonists. There is currently significant interest in the development of 
agonistic ligands for STING for therapeutic use in cancer. While STING is traditionally known 
to bind and undergo activation in response to cyclic dinucleotide molecules, the first STING 
agonist tested as an anti-cancer agent was a small molecule compound 5,6-
Dimethylxanthenone-4-acetic acid (DMXAA), which underwent preclinical and clinical 
evaluation before the STING pathway was identified. DMXAA was initially developed as an 
analog of flavone-8-acetic acid (FAA), which in 1989 demonstrated potent antitumor effects 
against multiple murine tumor models (415). This activity was initially ascribed to effects on 
the tumor vasculature, however later studies showed additional requirements for immune 
activation by DMXAA, including induction of IFN-β in tumor macrophages and DCs and 
recruitment of CD8 T cells (416-419). At the time, it was known that FAA – the parent 
compound of DMXAA – failed in clinical trials due to a lack of activity against human cells 
(420), yet DMXAA was rapidly translated to clinical evaluation due to its significantly enhanced 
potency in murine models relative to FAA (421, 422). DMXAA progressed through phase I 
and II trials (423) before failing in definitive randomized phase III studies (424). These 
disappointing results were explained following identification of the cGAS-STING pathway, as 
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it was determined that DMXAA binds and potently activates murine STING, but does not bind 
or stimulate human STING due to the presence of a single amino acid substitution in the 
human protein (365, 425, 426). DMXAA remains useful as a tool for inducing STING activation 
in murine models, however it is better utilized as a cautionary tale to properly study the 
mechanisms of action of potential therapies on cells of human origin before translation into 
large-scale clinical trials. 
 Despite the checkered past of DMXAA, great interest remains in the study of cyclic 
dinucleotides as therapeutic STING agonists in mouse and man. The most basic CDNs first 
evaluated as preclinical agents for cancer are cyclic di-GMP (CDG) and cyclic di-AMP (CDA), 
which consist of two nitrogenous purine nucleobases cyclized by canonical 3’-5’ 
phosphodiester linkages. These molecules are utilized uniquely as second messenger 
molecules in bacteria, and thus serve as immune PAMPs indicative of bacterial infection. 
Bacterial CDG exhibits a Kd of 1.21µM for STING homodimer binding, and this relatively weak 
binding is an exothermic process (366). CDG and CDA are readily hydrolyzed by 
phosphodiesterase enzymes, potentially limiting their potential bioavailability as therapeutic 
molecules (427, 428), although the specific hydrolases expressed by humans able to degrade 
bacterial CDNs have not been rigorously described. The central weakness of bacterial CDNs 
as therapeutic compounds in humans relates to their inability to activate unique isoforms of 
the STING gene that are commonly expressed in the human population. Specifically, an allele 
bearing arginine to histidine substitution at residue 232 (R232H) of STING found in 
approximately 14% of humans exhibits reduced binding and activation in response to bacterial 
CDNs (429, 430). Thus, bacterial CDNs are relatively weak agonists of STING and are unlikely 
to be translated as clinical compounds due to an inability to broadly activate all naturally-
occurring isoforms of STING found in the human population. 
 In contrast, the metazoan CDN 2’3’-cyclic GMP-AMP (2’3’-cGAMP) is a structurally 
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unique molecule allowing for high-affinity binding to all human STING alleles. Unlike CDG and 
CDA, 2’3’-cGAMP is cyclized by a non-canonical G(2’5’)pA(3’5’) phosphate bridge, commonly 
described as a “mixed” phosphodiester linkage (364-366). This mixed linkage structure is 
unique to metazoan CDNs, and endows the molecule with a flexibility not found in bacterial 
CDNs. This allows 2’3’cGAMP to bind more deeply within the CDN binding groove of 
dimerized STING and mediate conformational changes in the protein associated with 
enhanced activation. These include a narrowing of the C-terminal wing-like arms of STING, 
which draw together nearly 20 Å closer than occurs after CDG binding, and the formation of 
a β-sheet lid that covers the CDN binding pocket (366). Additionally, the free 3’OH present on 
the GMP residue of 2’3’-GAMP interacts specifically with the serine 162 residue of STING, 
which enhances the affinity of this interaction (366). As a result, 2’3’-cGAMP exhibits a Kd of 
approximately 4 nM with dimerized STING, nearly an order of magnitude greater binding 
affinity than that of CDG (366). The mixed linkage of 2’3’-cGAMP additionally confers binding 
to the R232H allele of human STING and permits downstream signaling, unlike bacterial 
CDNs (429, 430). However, the mixed linkage structure of 2’3’-cGAMP does not render the 
CDN resistant to phosphodiesterase cleavage, as Li et al identified an enzyme ecto-nucleotide 
pyrophosphatase/phosphodiesterase (ENPP1) capable of specifically hydrolyzing 2’3’-
cGAMP (431). ENPP1 deficiency in murine lung fibroblasts resulted in enhanced IFN-β 
production in response to 2’3’-cGAMP and HSV infection, demonstrating ENPP1 is able to 
exert regulatory control over 2’3’-cGAMP responses in vivo. Therefore, 2’3’-cGAMP is a high 
affinity ligand for all naturally-occurring STING isoforms in mouse and man, yet its in vivo 
potency can be limited due to sensitivity to enzymatic hydrolysis. 
 Synthetic analogs of naturally-occurring CDNs represent a novel class of STING 
agonists designed for high stability, affinity, and specificity for STING isoforms in the 
therapeutic setting. A critical modification that enhances CDN stability is the inclusion of sulfur 
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residues within the phosphate bridge, as such phosphorothioate diester linkages inhibit 
hydrolysis by phosphodiesterases (432, 433). Inclusion of bisphosphorothioate linkages within 
2’3’-cGAMP inhibits cleavage by ENPP1, and does not negatively affect STING binding or 
activation (431). Furthermore, unique bisphosphorothioate diastereomers possess subtle 
differences in potency, as Corrales et al report that RP-RP diastereomers elicit greater IFN-β 
release by THP-1 monocytes than RP-SP forms (429). Based upon these insights, the 
synthetic CDN ML-RR-S2-CDA is currently being investigated as the first-in-class STING 
targeting therapeutic in clinical trials (NCT02675439, NCT03172936). Together, these studies 
identify mixed linkage CDNs bearing bisphosphorothioate bridges of RP-RP diastereometry as 
ideal therapeutic CDNs with high stability due to phosphodiesterase resistance, robust per-
molecule potency due to high STING affinity, and broad applicability to stimulate all common 
isoforms of STING found in mouse and man. 
 
Preclinical Evaluation of STING Agonists in Cancer. In the decade since the cGAS-STING 
pathway was identified and characterized, a wealth of data has been generated evaluating 
each class of STING agonist as a cancer therapy across a broad array of common preclinical 
tumor models. The earliest reports of CDNs in cancer utilized the bacterial compound CDG 
as an adjuvant to potentiate the therapeutic effect of cancer vaccines. Chandra et al 
incorporated CDG as an adjuvant for an attenuated Listeria monocytogenes-based vaccine 
expressing the MAGE-b antigen for use in the 4T1 murine breast cancer model, and found 
CDG capable of suppressing metastasis, boosting CD8 T cell responses, and stimulating IL-
12 production by MDSCs when combined with vaccine (434). Interestingly, this early report is 
one of the only studies to date identifying specific effects of CDNs on MDSCs. The adjuvant-
like effects of CDG in boosting tumor-specific CD8 T cells was confirmed in a similar study 
evaluating CDG in combination with a “TriVax” strategy of poly-IC, CD40 agonist antibody, 
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and a modified gp100 peptide in the B16-F10 model of murine melanoma (435). While these 
early studies utilized CDG in combination with other potential innate stimulators, Hanson et al 
demonstrated that nanoparticle encapsulation of CDG alone can result in robust adjuvant 
properties by suppressing systemic diffusion and promoting accumulation of the compound 
within lymph nodes, allowing for more profound expansion of viral specific T cells and antibody 
titers relative to naked CDN or other common adjuvants (436). These studies established an 
early framework for the use of CDNs in cancer, demonstrating potent adjuvant-like properties 
of CDG including activation of myeloid antigen presenting cells, induction of antigen specific 
CD8 T cells, the possibility of unique formulations for enhanced efficacy, and a broad 
applicability to diverse histologies including breast cancer and melanoma. 
 While CDNs were rapidly accepted as potent adjuvants in both viral and cancer 
vaccine models, the next conceptual advancement in the field involved the idea of in situ 
vaccination; that intratumoral delivery of a CDN can directly facilitate antigen-specific T cell 
priming in the absence of an a priori designed vaccine. Support for this idea was provided in 
contemporaneous reports by Woo and Klarquist et al who discovered a role for the cGAS-
STING pathway in controlling the innate immune response to tumor-derived DNA DAMPs, 
suggesting natural STING activation in this context is necessary and sufficient to induce 
antigen specific antitumor T cell-mediated immunity, as the tumor and its associated antigen 
repertoire act as an intrinsic vaccine (348, 373). In light of this, the first report of in situ 
vaccination through intratumoral CDN delivery was provided by Ohkuri and colleagues, who 
locally administered CDG into orthotopically implanted GL261 gliomas. Despite the technical 
challenge associated with this model, they found CDG capable of eliciting CCL5 and CXCL10 
cytokines within the intracranial space, recruiting both CD8 and CD4 T cells that were capable 
of fully regressing of gliomas in half of mice tested (389). Perhaps the seminal report of in situ 
vaccination through intratumoral CDN injection came from Corrales et al, who generated novel 
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synthetic CDNs of high potency relative to CDG and evaluated the efficacy of local CDN 
administration in murine models of B16 melanoma, 4T1 breast cancer, and CT26 colon 
carcinoma (429). This study identified ML-RR-S2-CDA and provided the first evidence of 
superior therapeutic effects of this bisphosphorothioate modified CDN as monotherapy in 
treating established B16-F10 tumors relative to CDG, 2’3’-cGAMP, and ODN1668, a DNA-
based agonist of TLR9. Furthermore, Corrales et al demonstrated local delivery of ML-RR-
S2-CDA could mediate regression not only of locally-injected tumors, but also was sufficient 
to achieve control of synchronously-implanted distal uninjected 4T1 or CT26 lesions. Similar 
effects have been observed in the field of radiation oncology, as in rare cases local irradiation 
of a primary lesion can be followed by spontaneous regression of systemic disease. Termed 
the “abscopal effect,” this is largely thought to be an immune-mediated phenomenon, and 
likely involves STING activation in response to radiation-induced tumor DNA release (397). 
Thus, in situ vaccination by local CDN administration can induce curative T cell responses 
that are not just localized to the environment of the injected lesion, but are capable of 
circulating throughout the host and exerting cytolytic immune pressure on uninjected lesions 
such as distal metastases. 
 Building upon these insights, there has been great interest in incorporating CDNs into 
rationally-designed combinatorial approaches based upon complementary mechanisms of 
action between CDNs and other immunotherapies. For example, an existing antitumor T cell 
repertoire is thought to be a prerequisite for response to checkpoint blockade immunotherapy, 
thus agents like CDNs that are capable of boosting tumor-specific CD8 T cell frequencies are 
likely to act synergistically with checkpoint blockade. In addition, the interferon response 
characteristically associated with STING activation is known to induce expression of 
coinhibitory receptor ligands including PD-L1 (48), providing rationale to coordinately block 
the PD-1:PD-L1 axis upon intratumoral CDN therapy. Fu and colleagues were the first to 
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report the combination of PD-1 blockade with a STING-based therapeutic. Formulating ML-
RR-S2-CDA into a GM-CSF-secreting irradiated cellular vaccine (STINGVAX) reduced growth 
kinetics of various tumor models including B16 melanoma, TRAMP-C2 prostate cancer, and 
CT26 colon carcinoma, however only the combination of STINGVAX with αPD-1 was 
sufficient to induce outright tumor regression (437). This study was followed by another 
demonstrating synergy between local ML-RR-S2-CDG with PD-L1 blockade in the MOC1 
model of head and neck squamous cell carcinoma (438). However, ML-RR-S2-CDG was 
ineffective in controlling another model of the same histology, MOC2, which was characterized 
as a non-T-cell-inflamed tumor. While the basis for this lack of efficacy was not explicitly 
determined, a similar report in the tolerized neu/N model of HER-2+ breast cancer suggested 
that rationally combining ML-RR-S2-CDA with additional T cell coinhibitory and costimulatory 
molecules including αPD-L1 and αOX40 could convert non-responding tumors to responders, 
highlighting the capacity for CDNs to potentiate checkpoint modulation to promote cytolytic T 
cell immunity in the face of pre-existing T cell tolerance (439). CDNs have additionally been 
utilized in combination with agonists of 4-1BB (114) or GITR (440), innate agonists such as 
TLR9 (441) or TLR7/8 (440), and radiation therapy (442). Thus, rational combinatorial 
approaches incorporating CDNs with other immunotherapies can display therapeutic synergy 
and are attractive for use even in immunologically “cold” tumors. 
 Despite the therapeutic benefits associated with STING-mediated acute inflammation 
in cancer, excessive or prolonged engagement of this pathway can also lead to inflammatory 
pathologies. A number of groups have observed robust local ulceration in tumors exposed to 
CDNs, regardless of the tumor model or mouse strain under investigation (114, 442, 443). In 
line with the initial description of DMXAA as a vascular remodeling agent, local CDN 
administration appears to promote leakage or outright collapse of neovascular endothelium 
within hours of injection (442). This is associated with a potent early elaboration of 
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inflammatory cytokines including IFN-β, TNFα, IL-6, and CCL2, and has been described as 
hemorrhagic necrosis (442). Interestingly, this necrosis occurs in mice which lack adaptive 
immune cells (RAG-/-) or interferon signaling (IFNαR-/-), but is reduced in mice deficient in 
TNFα (443).  Blockade of TNFα at the time of CDN injection also suppresses this pathology, 
suggesting STING-induced TNFα is central to local hemorrhagic necrosis (442). While even 
excessive necrotic responses generally result in formation of an eschar that resolves over 
time, such pathology can be a source of infection for patients with superficial disease, or could 
have more complex and lasting effects if present at an injected visceral tumor. Data presented 
in this dissertation suggest that reduced dosing of CDNs can limit observed necrosis without 
significantly blunting therapeutic efficacy, and that the extent to which ulceration is observed 
can be related to both CDN dose and tumor size at the time of injection (114). Thus, balancing 
the immune promoting effects of CDNs with potential inflammatory necrotic pathology will be 
critical for successfully translating CDNs into clinical compounds.  
 
1.3.4: Summary 
The cGAS-STING pathway is central to innate immune responses in the context of bacterial 
infection, viral invasion, and cancer. STING activation liberates potent type I interferon release 
through the TBK1-IFR3 pathway, and also engages NF-κB signaling to produce a broad array 
of inflammatory cytokines, chemokines, and surface receptors across cells of both 
hematopoietic and non-hematopoietic origin. Cyclic dinucleotide agonists of STING are thus 
attractive candidates for cancer therapy, owing to their capacity to mediate in situ vaccine-like 
responses upon local injection by activating local myeloid cells, leading to enhanced antitumor 
T cell immunity even in immunologically “cold” tumors. 
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Chapter 2: Methodology 
Mice 
 Male C57BL/6 and B6(Cg)-Tyrc-2J/J albino mice were purchased from The Jackson 
Laboratory, and STINGGt/Gt mice were a kind gift from the Dr. Kimberly Schluns. Mice were 
approximately 5 to 8 weeks old at the time of use. All mice were housed in accordance with 
the Association for Assessment and Accreditation of Laboratory Animal Care and NIH 
standards. All experiments were conducted according to protocols approved by the University 
of Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee. 
Cell Lines 
 The TRAMP-C2 tumor cell line was provided by Dr. Norman Greenberg and all 
experiments in this manuscript were performed using passage 21-22 tumor cells. TRAMP-C2 
cells were maintained as previously described (444). The mT4-2D cell line was a kind gift from 
Dr. David Tuveson (445), and cells were maintained in complete DMEM containing 10% fetal 
bovine serum (Gibco), 100 U/mL penicillin, 100 mg/mL streptomycin sulfate, and 2mM L-
glutamine. THP-1 Dual and J774-Dual reporter cells were obtained from InvivoGen and 
cultured according to manufacturer’s instructions. HEK-Blue reporter cells were a kind gift 
from Dr. Simon Yu at the University of Texas MD Anderson Institute for Applied Cancer 
Science (IACS) and cultured in cDMEM supplemented with zeocin (100µg/mL) and blasticidin 
(30µg/mL) for antibiotic selection.  
Cyclic Dinucleotides 
 Cyclic di-GMP (CDG) and 2’3’ cyclic GMP-AMP (cGAMP) were purchased from 
InvivoGen and reconstituted in water according to manufacturer’s instructions. ML-RR-CDA 
was synthesized by Wuxi AppTec and reconstituted in water. IACS-8803 was designed in 
collaboration with the University of Texas MD Anderson Cancer Center and synthesized by 
Wuxi AppTec, and was reconstituted in water or PBS for in vitro or in vivo use. 
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Antibodies and Chemotherapy 
 Antibodies used in in vivo studies were purchased from BioXCell or Leinco 
Technologies and were administered via intraperitoneal (IP) injection or intratumoral (IT) 
injection as indicated at the following concentrations: anti-CTLA-4 (9H10; 100μg IP, 50μg IT), 
anti-PD-1 (RMP1-14; 250μg IP, 50μg IT), anti-4-1BB (3H3; 200μg IP, 50μg IT). Flt3L-Ig (Flt3L; 
Bio X Cell) was administered IT at 50μg per mouse, or 200μg per mouse where described. 
Chemotherapy agents gemcitabine (Gemzar®; Eli Lily) and nab-paclitaxel (Abraxane®; 
Celgene) were obtained from the University of Texas MD Anderson pharmacy and were 
reconstituted according to manufacturer’s instructions. Both agents were administered IP at 
120mg/kg. Antibodies used for flow cytometry were obtained from BD Biosciences, 
BioLegend, or Roche. 
STING Reporter Cell Assays 
All STING reporter cell assays were conducted according to manufacturer’s protocols. 
In short, CDN or control agonists were added at desired concentrations in 20µl PBS to desired 
wells of flat-bottom 96-well plates. HEK-Blue, J774-Dual, THP-1 Dual, or THP-1 parental cell 
lines were harvested, washed, counted, and resuspended for addition of 5x104 – 1x105 cells 
per well in 180µl recommended media. Cells were incubated with CDN for 20-24 hours, when 
supernatants were harvested for luciferase or SEAP assays using QuantiLuc® or 
QuantiBlue® solutions according to manufacturer’s instructions. For ELISA, THP-1 parental 
cells were incubated with CDN for 72 hours, then supernatants were harvested and IFNβ 
levels were quantified using the PBL Human IFNβ ELISA kit according to manufacturer’s 
protocols.  
MDSC Generation and T Cell Suppression Assays  
Bone marrow was isolated from naïve male C57BL/6 mice through aspiration of the 
femur and/or tibia as described. Red blood cells were lysed using RBC lysis buffer (Sigma), 
70 
 
and 4x106 cells were plated in 10mL in non-TC treated 10cm petri dishes (Falcon) in RPMI 
containing 10% FBS, 100 U/mL penicillin, 100mg/mL streptomycin sulfate, recombinant 
mouse GM-CSF (40ng/mL; BioLegend) and IL-6 (40ng/mL; BioLegend), and 2-
Mercaptoethanol (β-ME; 55µM) to induce MDSC differentiation. After 4 days in culture, BM-
MDSC suspension cells were harvested, washed with cRPMI to remove cytokine, and re-
plated in 10mL cRPMI with no cytokine at 4x105 cells/mL in 10cm petri dishes. CDN were 
added at 1-10µg/mL as indicated for 24-48 hour repolarization. 
For suppression assays, naïve splenocytes were obtained from male C57BL/6 mice, 
and CD8 T cells were isolated by negative selection with the Miltenyi Mouse CD8 T Cell 
Isolation Kit. CD8 T cells were labeled with CellTrace CFSE (ThermoFisher) as described 
(446). 1x105 CFSE-labeled CD8 T cells were plated at indicated ratios with unstimulated or 
repolarized BM-MDSC in 200µl cDMEM containing 10% FBS, 50U/mL IL-2, 27.5µM β-ME, 
and 2µg/mL αCD28 (clone 37.51; BioLegend) in round bottom 96-well plates coated with 
αCD3 (BioXCell clone 145-2C11; coated overnight at 10µg/mL in PBS at 4oC). After 72-96 
hours, CD8 T cells were analyzed for CFSE dilution by flow cytometry. 
Human Macrophage Generation  
Healthy donor buffy coats were obtained from the University of Texas MD Anderson 
Cancer Center Blood Bank. Peripheral blood mononuclear cells were isolated by ficoll 
gradient centrifugation (Histopaque 1077; Sigma), and CD14+ monocytes were isolated by 
negative selection using the Miltenyi Classical Monocyte Isolation Kit. Monocytes were 
differentiated into M2c macrophages as described (447). In short, monocytes were plated in 
T25 flasks (1x106 cells/mL) in RPMI containing 20% FBS and 100ng/mL recombinant human 
M-CSF for 6 days, with a media refresh on day 4. On day 6, media was replaced, with the 
addition of recombinant human TGF-β (10ng/mL) and IL-10 (10ng/mL). On day 8, adherent 
cells were washed with PBS and cultured with cRPMI + 100ng/mL M-CSF + 10µg/mL 
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indicated CDN for repolarization over 72 hours. Adherent macrophages were harvested with 
Detachin cell detachment solution (Genlantis) for downstream applications. All recombinant 
human cytokines were purchased from PeproTech and reconstituted according to 
manufacturer’s instructions. 
Luminex and RPPA Sample Preparation  
Repolarized human M2c macrophages or murine BM-MDSC were generated as 
described above. Supernatants from repolarized cultures were isolated, spun to remove 
contaminating cells, then frozen at -80o. All harvested supernatants were thawed on ice and 
were analyzed with the Cytokine & Chemokine 36-Plex Mouse ProcartaPlex or 
Cytokine/Chemokine/Growth Factor 45-Plex Human ProcartaPlex Panels 
(Invitrogen/ThermoFisher) using a Luminex MAGPIX® machine according to manufacturer’s 
instructions. For RPPA, a minimum of 1x106 cells were washed twice with cold PBS, and dry 
pellets were stored at -80o. Cell lysis and analysis was conducted at the University of Texas 
MD Anderson Functional Proteomics RPPA Core Facility.  
Subcutaneous Tumor Implantation and Treatment  
Mice were implanted at day 0 on one flank with 2.5x105 mT4-LA or mT4-LS cells, or 
on both flanks with 1 x 106 TRAMP-C2 cells. Refer to indicated figures for exact treatment 
schedules. Tumor volumes were measured with calipers to define the largest length (a), width 
(b), and height (c), and volumes were calculated as (a x b x c). 
Orthotopic Pancreatic Tumor Implantation and IVIS Imaging 
Subconfluent cultures of mT4-2D, mT4-LA, or mT4-LS were harvested with 0.05% 
trypsin, washed with PBS, and resuspended at desired concentration in ice cold PBS 
containing 30% Matrigel (Corning) by volume for implantation. Each mouse was anesthetized 
through isoflurane inhalation and was administered 3µg buprenorphine hydrochloride 
analgesic (Sigma) by intraperitoneal injection. Following sterilization of the surgical field with 
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70% isopropyl alcohol, a small (~1-2cm) incision was made on the left flank skin as well as 
the underlying peritoneal lining. Blunt-end forceps were used to access the spleen and 
accompanying pancreas. 50µl of cell suspension or CDN solution was administered into the 
head of the pancreas using a U-40 insulin syringe with 29.5 gauge needle. The peritoneal 
wound and surrounding skin were cleaned with betadine antiseptic swabs, and the wound 
was closed using 4-0 absorbable sutures (Oasis) for the peritoneal incision and the Autoclip 
Wound Closing System for the skin (Braintree Scientific). Mice were allowed to recover under 
a heat lamp until displaying normal ambulance, and were monitored daily for signs of pain or 
discomfort. Wound clips were removed 10-14 days following application. 
Mice were imaged weekly to monitor tumor growth using an IVIS® Spectrum in vivo 
imaging system (PerkinElmer). Mice were anesthetized with isoflurane and received 200µl D-
Luciferin (15mg/mL in PBS; GoldBio) by IP injection. Bioluminescent images were acquired 
11-12 minutes following administration of D-Luciferin. All imaging was conducted in the 
University of Texas MD Anderson Small Animal Imaging Facility. 
Flow Cytometry Analysis of Tumor Immune Infiltrates  
1 x 106 TRAMP-C2 cells were mixed with 30% collagen matrix (Matrigel, BD) and 
implanted at day 0 on both flanks. Mice received treatment when tumors reached ~200mm3 
volume, on days 31, 35, and 39, and were sacrificed on day 42. Following euthanasia, primary 
tumors were harvested, massed, and finely diced into 70µm filters within 6cm petri dishes. 
Diced tumors were enzymatically digested in a 37o incubator for 30 minutes in digestion media 
consisting of X-Vivo15 media (Lonza) supplemented with collagenase H (1mg/mL; Sigma) 
and DNAse (160µg/mL; Roche), then tumors were physically mashed through 70µm filters to 
create single cell suspensions. Total cells were counted, then live immune cells were purified 
by ficoll gradient centrifugation (Histopaque 1119; Sigma). Samples were fixed overnight and 
permeabilized using the FoxP3/Transcription Factor Staining Buffer Set 
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(eBioscience/ThermoFisher) for staining with fluorescently labeled antibodies in 96-well U-
bottom plates. Stained samples were analyzed using a BD LSRII or X-30 prototype flow 
cytometer. 
  mT4-2D or mT4-LA cells were harvested with 0.05% trypsin, washed with PBS, 
counted, and resuspended in ice cold PBS containing 30% Matrigel for implantation of 2.5x105 
cells in 100µl subcutaneously or 3.5x104 cells in 50µl orthotopically as described. Mice were 
treated with intratumoral CDN, checkpoint blockade antibodies, or chemotherapy according 
to treatment schedules included in associated figures. Preparation of tumor samples for flow 
cytometry was completed as described above. 
  
74 
 
Chapter 3: Intratumoral STING Activation with T-Cell Checkpoint Modulation 
Generates Systemic Antitumor Immunity 
 
This work is based upon “Intratumoral STING Activation with T-cell Checkpoint Modulation 
Generates Systemic Antitumor Immunity” by Ager et al. July 25 2017 Cancer Immunology 
Research  DOI: 10.1158/2326-6066.CIR-17-0049. It is presented with permission from 
Cancer Immunology Research and the American Association for Cancer Research (AACR). 
 
3.1: Introduction 
Therapeutic blockade of T-cell coinhibitory receptors CTL-associated antigen 4 
(CTLA-4) and programmed death 1 (PD-1) is sufficient to promote durable immune-mediated 
tumor regression across multiple cancers in mouse and man. Neither ipilimumab (anti-CTLA-
4) nor nivolumab (anti-PD-1), however, provide clinical benefit in the setting of castration-
resistant prostate cancer (CRPC) (448, 449). Prostate cancer is the second leading cause of 
cancer-related death in men, and patients with CRPC have a median overall survival of 14 
months, highlighting the urgent need for alternative immunotherapeutic approaches for this 
disease (450). Preclinical models of prostate cancer, including the transgenic 
adenocarcinoma of the mouse prostate (TRAMP) mouse and its derivative TRAMP-C2 
implantable cell line (444),  reveal two major barriers to antitumor immunity in CRPC: (i) poor 
CD8+ T-cell infiltration into the prostate tumor microenvironment (TME), and (ii) robust 
infiltration of immunosuppressive myeloid populations including tumor associated 
macrophages (TAM) and myeloid derived suppressor cells (MDSC). Given the well-described 
means by which TAM and MDSC impede T-cell infiltration and effector function independent 
of the CTLA-4/PD-1 axes (451), therapies which deplete or biologically reprogram TAM and 
MDSC may render the prostate TME amenable to T-cell activity. Absent these barriers to T-
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cell infiltration and function, we hypothesize that CRPC patients would be likely to experience 
durable benefit from T-cell checkpoint blockade. 
In this study, we pursued a rational approach to design and evaluate multi-modal 
therapies for CRPC consisting of antagonistic antibodies targeting T-cell coinhibitory 
receptors CTLA-4 and PD-1, agonistic antibodies targeting the T-cell costimulatory receptor 
4-1BB, and agonistic molecules targeting myeloid activation pathways including stimulator of 
interferon genes (STING) or FMS-like tyrosine kinase 3 (Flt3). Our lab previously established 
synergistic relationships between anti-CTLA-4 and anti-PD-1 antibodies, owing to their non-
redundant roles in regulating central T-cell priming and peripheral effector function (452). 
These data preceded successful phase III trials and subsequent FDA approval of this 
combination in patients with metastatic melanoma (453, 454). Additionally, we described 
complementary effects of CTLA-4 blockade with concomitant ligation of the stimulatory 
receptor 4-1BB, which promotes CD8+ T-cell survival, proliferation, and TH1 cytokine 
production (455). In each setting, combination therapies were maximally effective in the 
context of an irradiated cellular vaccine secreting Flt3-ligand (Flt3L). Known for its classical 
role in promoting survival, proliferation, and differentiation of hematopoietic progenitors, Flt3L 
can induce dendritic cell (DC) chemotaxis and conversion to a CD8α+CD103+ phenotype 
associated with cross-presentation and robust T-cell priming potential (456, 457). In contrast, 
Flt3L also promotes differentiation of plasmacytoid dendritic cells, which can exert tolerogenic 
effects in cancer through induction of regulatory T cells (Treg) and limit the efficacy of Flt3L 
as a cancer immunotherapy (458).  
The cytosolic nucleic acid sensor Stimulator of Interferon Induced Genes (STING) acts 
to promote tumor-specific T-cell responses by activating interferon secretion and 
costimulatory ligand expression by myeloid cells after uptake of tumor cell-derived DNA, and 
is indispensable for spontaneous rejection of immunogenic cancers (348). Cyclic dinucleotide 
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agonists of STING activate macrophages and DC in vitro and have demonstrated therapeutic 
utility alone and in combination with checkpoint blockade across multiple tumor models (429, 
437). 
Using mice bearing bilaterally-implanted TRAMP-C2 tumors, we found that 
intratumoral STING activation with the dinucleotide cyclic di-GMP (CDG) mediates regression 
of injected tumors, but fails to elicit systemic “abscopal” immunity targeting distal lesions. 
Triple checkpoint modulation with anti-CTLA-4, anti-PD-1, and anti-4-1BB, however, converts 
intratumoral CDG into a potentiator of systemic immunity capable of rejecting distal, uninjected 
lesions. In contrast, intratumoral Flt3L augments the benefit of triple checkpoint modulation, 
but only when administered locally at each lesion. Given the potential toxicity of anti-CTLA-4, 
anti-PD-1, and anti-4-1BB combination therapy, we investigated whether intratumoral 
administration of this combination at low doses could serve as a safer alternative to systemic 
antibody therapy. These studies demonstrate that curative abscopal immunity can be 
generated against multi-focal TRAMP-C2 when local triple checkpoint modulation is used in 
combination with intratumoral CDG. This therapeutic synergy is associated with infiltration of 
tumor-specific T cells and enhanced ratios of CD8+ T cells to Treg, MDSC, and TAM, as well 
as pronounced downregulation of the M2 macrophage marker CD206 on TAM. Alternatively, 
Flt3L failed to mobilize abscopal immunity in combination with triple checkpoint modulation, 
likely due its expansion of CD4+ Teff and Treg populations with similar potency to CD8+ T cells 
at local and distal lesions. We observed dose-dependent skin pathology in mice receiving 
intratumoral CDG in combination with triple checkpoint blockade, although the therapeutic 
benefit of this combination appears modestly (but not significantly) dose-dependent. These 
data support the development of combinatorial strategies targeting adaptive and innate 
immune populations in prostate cancer, and inform the design of dosing strategies for STING 
agonists and checkpoint modulators to maximize clinical benefit while minimizing undue 
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toxicity. 
3.2: Results 
3.2.1: Intratumoral CDG potentiates systemic checkpoint modulation in TRAMP-C2 
In both clinical and preclinical settings, prostate cancer remains refractory to 
checkpoint blockade therapy targeting CTLA-4 or PD-1. To identify combinatorial strategies 
capable of sensitizing prostate tumors to immunotherapy, we augmented our checkpoint 
blockade cocktail of antagonistic anti-CTLA-4 and anti-PD-1 antibodies with an agonistic 
antibody targeting 4-1BB, a costimulatory receptor of the Tumor Necrosis Factor Receptor 
(TNFR) superfamily which promotes CD8+ T-cell survival and cytotoxic effector function (459). 
We next investigated whether intratumoral STING activation using the STING agonist c-di-
GMP (CDG) can potentiate checkpoint modulation by promoting in situ vaccine-like 
augmentation of T-cell priming and pro-inflammatory reprogramming of the murine prostate 
tumor myeloid compartment. Mice were challenged with 1x106 TRAMP-C2 cells on both 
flanks, and received three doses of therapy every four days beginning when tumors were 
palpable on day 14.  Tumor growth and survival were monitored until tumors reached 
1000mm3 (Fig. 4A). We found that as a single agent, intratumoral CDG mediated rejection of 
essentially all locally injected tumors; however, CDG failed to elicit a systemic immune 
response capable of clearing distal, uninjected lesions (Fig. 4B-C; Supplementary Fig. S1). 
Although systemic triple checkpoint modulation with anti-CTLA-4, anti-PD-1, and anti-4-1BB 
demonstrated efficacy in this model, curing both bilateral tumors in 40% of mice, we found 
that concurrent administration of CDG and immunotherapeutic antibodies, even at a single 
lesion, induced complete bilateral tumor rejection in ~75% of mice (Fig. 4D). This revealed a 
therapeutic synergy between CDG and our antibody cocktail, and demonstrated the abscopal 
potential of CDG when combined with systemic checkpoint modulating therapies. 
78 
 
 
  Figure 4: Local CDG potentiates IP checkpoint modulation against bilateral TRAMP-C2. (A) Five to eight-week-old C57BL/6 mice were challenged with 1x106 TRAMP-C2 cells 
on both flanks, and were treated on days 14, 18, and 22 post-implantation with 
intraperitoneal (IP) checkpoint modulators and/or intratumoral (IT) CDG at either the right 
(R) or both right and left flank tumors (R&L). (B) Percent of mice tumor free at each flank, 
(C) tumor growth kinetics, and (D) overall survival over the treatment period are shown. 
Mice were deemed moribund when tumor volume reached 1000 mm3. Data is cumulative 
of n = 3 experiments with 5 mice per group. Statistical significance for survival was 
calculated using the Gehan-Breslow-Wilcoxon test. ns = not significant, * = P < 0.05, ** = 
P < 0.01, *** = P < 0.001, **** = P < 0.0001. 
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Supplemental Figure S1: Individual tumor growth curves; IP antibody + IT agonists. 
Individual tumor growth kinetics at the injected (right) and contralateral (left) flanks of mice 
treated with systemic (IP) antibody cocktail and/or intratumoral (IT) myeloid agonists. 
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3.2.2: Intratumoral Flt3L at each lesion potentiates systemic checkpoint modulation in 
TRAMP-C2 
Given our previous work combining checkpoint blockade with irradiated cellular 
vaccines secreting Flt3L (460), and the potential for Flt3L to act as a chemotactic and 
differentiation factor for DCs, we also chose to evaluate the capacity of intratumoral Flt3L to 
potentiate triple checkpoint modulation in our bilateral TRAMP-C2 model (Fig. 5A). In contrast 
to CDG, intratumoral Flt3L exhibited modest local efficacy as a single agent, yet achieved 
curative responses in ~15% of mice (Fig. 5B-D). Similar to CDG, Flt3L synergized with triple 
checkpoint modulation to cure 75% of mice in this model; however, this maximal response 
required intratumoral administration of Flt3L at each tumor (Fig. 5D). Therefore, in optimal 
conditions, Flt3L and CDG were capable of potentiating triple checkpoint modulation with 
similar efficacy, curing up to 75% of mice with multi-focal, poorly immunogenic TRAMP-C2 
tumors. When combined with systemic checkpoint modulators, however, only the STING 
agonist mobilized abscopal immunity.  
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Figure 5: Local Flt3L potentiates IP checkpoint modulation against bilateral TRAMP-
C2. (A) Five to eight-week-old C57BL/6 mice were challenged with 1x106 TRAMP-C2 cells 
on both flanks, and were treated on days 14, 18, and 22 post-implantation with 
intraperitoneal (IP) checkpoint modulators and/or intratumoral (IT) Flt3L at either the right 
(R) or both right and left flank tumors (R&L). (B) Percent of mice tumor free at each flank, 
(C) tumor growth kinetics, and (D) overall survival over the treatment period are shown. 
Mice were deemed moribund when tumor volume reached 1000 mm3. Data is cumulative 
of n = 3 experiments with 5 mice per group. Statistical significance for survival was 
calculated using the Gehan-Breslow-Wilcoxon test. ns = not significant, * = P < 0.05, ** = 
P < 0.01, *** = P < 0.001, **** = P < 0.0001. 
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3.2.3: Intratumoral checkpoint modulation and CDG mobilizes abscopal immunity 
In the clinic, individual checkpoint modulators can trigger severe, dose-limiting 
immune-related adverse events in many patients (461). Colitis, pruritus, fatigue, and rash are 
toxicities associated with anti-CTLA-4 and anti-PD-1. Agonistic antibodies targeting 4-1BB are 
associated with rare instances of fatal hepatotoxicity (462-464). Therefore, combinatorial 
strategies to target CTLA-4, PD-1, and 4-1BB must be sub-optimally dosed or administered 
in a manner that limits systemic toxicity while preserving therapeutic potency. Based on a 
number of studies investigating intratumoral administration of checkpoint modulators including 
anti-CTLA-4 (465, 466), we asked whether intratumoral administration of low-dose 
combination checkpoint modulation with anti-CTLA-4, anti-PD-1, and anti-4-1BB could prime 
local and systemic immunity against bilateral TRAMP-C2, and whether concomitant local 
STING activation with CDG could further potentiate these effects.  
Mice bearing 14-day established bilateral TRAMP-C2 tumors received three 
intratumoral injections of therapy only at the right flank tumor four days apart (Fig. 6A). In this 
setting, intratumoral low-dose anti-CTLA-4, anti-PD-1, and anti-4-1BB mediated regression of 
~50% of injected tumors, but failed to engender systemic immunity against distal lesions (Fig. 
6B-D; Supplementary Fig. S2). Concurrent administration of CDG augmented the abscopal 
potential of local checkpoint modulation, however, promoting abscopal regression of distal 
lesions and bilateral tumor rejection in up to 52% of mice. Although not statistically significant 
with the number of mice tested, we observed a trend toward a dose-dependent increase in 
efficacy with additional CDG doses in potentiating local checkpoint modulation (Fig. 6D). 
Thus, we conclude that CDG can enhance the curative abscopal potential of intratumoral anti-
CTLA-4, anti-PD-1, and anti-4-1BB against bilateral TRAMP-C2 in a dose-dependent manner. 
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Figure 6: Intratumoral combination CDG and checkpoint modulation mobilizes 
abscopal responses against distal TRAMP-C2. (A) Five to eight-week-old C57BL/6 mice 
were challenged with 1x106 TRAMP-C2 cells on both flanks, and were treated on days 14, 
18, and 22 post-implantation with intratumoral CDG and/or checkpoint modulators at the 
right flank tumor only. (B) Percent of mice tumor free at each flank, (C) tumor growth 
kinetics, and (D) overall survival over the treatment period are shown. Mice were deemed 
moribund when tumor volume reached 1000 mm3. Data is cumulative of n = 3-4 
experiments with 5-10 mice per group. Statistical significance for survival was calculated 
using the Gehan-Breslow-Wilcoxon test. ns = not significant, * = P < 0.05, ** = P < 0.01, 
*** = P < 0.001, **** = P < 0.0001. 
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Supplemental Figure S2: Individual tumor growth curves; IT antibody + IT agonists. 
Individual tumor growth kinetics at the injected (right) and contralateral (left) flanks of mice 
treated with intratumoral (IT) antibody cocktail and/or IT myeloid agonists. 
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3.2.4: Intratumoral combination therapy with CDG elicits skin pathology 
In the course of the experiments described above, we observed an inflammatory 
reaction provoked at the injection site in mice receiving intratumoral administration of CDG 
together with anti-CTLA-4, anti-PD-1, and anti-4-1BB. Within two days of the final therapeutic 
injection, we observed accumulation of dark, bloody fluid in and around the tumor site that 
yielded to ulceration, scabbing, and eventual resolution after 2-3 weeks. This pathology 
required concomitant local administration of CDG and checkpoint modulators, as no ulceration 
occurred following CDG or checkpoint modulation therapy alone. This effect was dose-
dependent with respect to the number of CDG doses, with mild inflammation and no ulceration 
observed in mice that received one or two CDG doses (Fig. 7A). Tumor size at the time of 
therapy may also play a role in determining the extent of ulceration, as injection of larger, 28-
day established TRAMP-C2 tumors resulted in reduced ulceration generally localized to the 
tumor core and not evident in the surrounding skin (Fig. 7B). Given that three concurrent 
doses of CDG with intratumoral anti-CTLA-4, anti-PD-1, and anti-4-1BB was associated with 
ulcerative pathology at the injection site yet delivered little survival benefit over one or two 
concurrent CDG doses (Fig. 6D), it may be prudent to limit STING agonist dosing in the 
combination setting in order to maximize therapeutic benefit while minimizing adverse event 
frequency and severity.  
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  Figure 7: Intratumoral CDG with checkpoint modulation invokes dose-dependent 
and tumor size-dependent ulcerative pathology at the tumor site. (A) Photographs of 
representative mice treated as described in Fig. 3 were taken six days following final 
intratumoral injection (Day 28), when ulceration is most intense, and two weeks later during 
the resolution phase (Day 42). (B) Mice bearing either 14-day or 28-day established 
TRAMP-C2 tumors were given three intratumoral injections of CDG with anti-CTLA-4, anti-
PD-1, and anti-4-1BB every four days for a total of three injections, according to normal 
protocol. Photographs of ulceration were taken 2 (Day 24) and 6 (Day 28) days following 
final intratumoral injection. 
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3.2.5: Flt3L with checkpoint modulation failed to generate abscopal immunity 
Using the treatment schedule described in Fig. 8A, we evaluated whether local Flt3L 
could mobilize abscopal immunity against TRAMP-C2 when combined with intratumoral triple 
checkpoint modulation. In contrast to CDG, we found that Flt3L failed to synergize with local 
checkpoint modulation in mediating systemic tumor immunity, delivering no survival benefit 
over anti-CTLA-4, anti-PD-1, and anti4-1BB alone (Fig. 8B-D). Given the possibility that the 
therapeutic potency of our human Flt3L-Ig protein could be limited by sub-optimal receptor 
binding affinity and generation of neutralizing antibodies, we tested a saturating dose of 200μg 
per injection (Fig. 8B-D; Flt3L 3x “HIGH”), and found that, although local efficacy against the 
injected tumor was increased, abscopal immunity failed to improve. Of all mice treated we 
noted that the incidence of relapse was higher in groups that received intratumoral Flt3L 
compared to groups treated with CDG, although the results were not statistically significant, 
and time to relapse was not disparate between these groups (Supplementary Fig. S3). 
Although these data suggest that in situ vaccination with Flt3L was inferior to CDG in the 
context of checkpoint modulation, we wished to further confirm that this discrepancy was a 
generalizable phenomenon and not dependent on tumor size at the time of injection. To 
address this, we asymmetrically implanted mice with TRAMP-C2 to obtain 28-day established 
tumors (~200mm3) on the right flank and 14-day established tumors (~20mm3) on the left flank 
before beginning local treatment (Supplementary Fig. S4A). Though the long engraftment 
period led to variability in both tumor size at the right flank and engraftment efficiency of distal 
tumors by the time of treatment, we were able to observe more effective local control of large 
TRAMP-C2 tumors following in situ delivery of combination checkpoint modulation and CDG 
in comparison to local checkpoint antibodies and Flt3L.  Despite the inferior regression of the 
injected lesion, Flt3L did show an equivalent capacity to 3xCDG to promote abscopal 
responses targeting the smaller, uninjected tumor on the opposite flank (Supplementary Fig. 
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S4B). Together, we conclude that CDG is superior to Flt3L in potentiating local checkpoint 
modulation to induce both local control and to mobilize abscopal effects against TRAMP-C2 
tumors. 
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Figure 8:  Intratumoral combination Flt3L and checkpoint modulation does not 
mobilize abscopal responses against distal TRAMP-C2. (A) Five to eight-week-old 
C57BL/6 mice were challenged with 1x106 TRAMP-C2 cells on both flanks, and were 
treated on days 14, 18, and 22 post-implantation with intratumoral Flt3L and/or checkpoint 
modulators in the right flank only. (B) Percent of mice tumor free at each flank, (C) tumor 
growth kinetics, and (D) overall survival over the treatment period are shown. Mice were 
deemed moribund when tumor volume reached 1000 mm3. Data is cumulative of n = 3-4 
experiments with 5 mice per group. Statistical significance for survival was calculated using 
the Gehan-Breslow-Wilcoxon test. ns = not significant, * = P < 0.05, ** = P < 0.01, *** = P 
< 0.001, **** = P < 0.0001. 
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Supplemental Figure S3: Tumor relapse rates. Overall comparison of tumor relapse 
rates between mice exposed to CDG vs Flt3L treatments. Relapse was defined as any 
tumor that initially grew to at least 25mm3 in volume that regressed below 25mm3, then 
relapsed to grow again above 25mm3. (A) Number of relapses across all mice treated with 
CDG vs Flt3L. (B) Comparison of relapse rate between CDG-treated and Flt3L-treated 
mice. Relapse rate is defined elapsed time between the day of regression (when initial 
tumor shrunk below 25mm3) and the day at which the relapsed tumor mass passed the 
indicated volume. (C) Raw data used to calculate relapse rates. Statistical significance was 
calculated using Student’s T test. 
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Supplemental Figure S4: Asymmetric TRAMP-C2 tumor growth kinetics. (A) To obtain 
large (~200mm3) right flank tumors for IT injection, mice were implanted on day   -14 with 
1x106 TRAMP-C2 on the right flank, were implanted on day 0 with 1x106 TRAMP-C2 on 
the left flank, and treatment occurred on days 14, 18, and 22. (B) Tumor growth kinetics 
on the injected right flank and uninjected left flank are shown. Due to some variation in 
tumor size at the right flank during the long 28-day engraftment period, below is shown 
normalized tumor growth as a percentage of tumor size at day 14. 
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3.2.6: High parameter analysis of TRAMP-C2 immune contexture in response to local therapy 
To further understand the biological mechanisms driving response to intratumoral 
therapy at both injected and distal TRAMP-C2 tumors, as well as the differential capacity of 
CDG and Flt3L to potentiate local checkpoint modulation, we utilized 18-color flow cytometry 
to phenotype and functionally characterize the immune composition of bilateral TRAMP-C2 
tumors following intratumoral therapy. As local CDG injection of 14-day established TRAMP-
C2 mediates rapid, complete regression leaving minimal tumor tissue for analysis, we allowed 
tumors to establish for 31 days before initiating therapy, performing intratumoral injections on 
right flank tumors on days 31, 35, and 39, and harvesting all tumors on day 42 (Supplementary 
Fig. S3).  
At baseline, TRAMP-C2 tumors are dominated by a dense myeloid infiltrate consisting 
of CD11b+F4/80+Gr-1- tumor associated macrophages (TAM) and CD11b+Gr-1+ myeloid 
derived suppressor cells (MDSC; Fig. 9B). T cells constitute only 5% of all CD45+ cells, and 
are composed of roughly even proportions of CD8+ cytolytic T lymphocytes (CTL), 
CD4+FoxP3- effector T lymphocytes (Teff) and CD4+FoxP3+ regulatory T cells (Treg; Fig. 9C). 
Intratumoral CDG administration enhanced CD8+ T-cell infiltration of injected tumors, and 
caused local accumulation of CD11b+Gr-1+F4/80neg granulocytes, likely indicating neutrophil 
infiltration (Fig. 9D; Supplementary Fig. 6). In contrast, intratumoral Flt3L elicits increased 
CD11c+CD11b- dendritic cell (DC) accumulation, yet triggered expansion of Treg in both 
injected and uninjected tumors (Fig. 9B,C). Intratumoral checkpoint modulation enhanced the 
proportion of T cells infiltrating TRAMP-C2 tumors, and diminished the Treg pool, likely 
through antibody-dependent cellular cytotoxic (ADCC) depletion of αCTLA-4 coated Treg 
(467). Concurrent administration of CDG and checkpoint modulating antibodies further 
enhanced CD8+ T-cell accumulation at each tumor, resulting in favorable CD8:Treg ratios that 
were superior to those seen in response to combination therapy with Flt3L (Fig. 9E). Using 
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tetramer staining to track the known immunodominant SPAS-1 neoepitope expressed in 
TRAMP-C2 (468), we found that combination therapy with CDG enhanced the density of 
SPAS-reactive CD8+ T-cells at the injected tumor and exhibited a trending capacity to mobilize 
these cells to the distal tumor, which was not observed in mice receiving Flt3L therapy (Fig. 
9F). Local CDG synergized with checkpoint modulation to reduce the percentage of SPAS-
specific T cells within the total pool of infiltrating CD8+ T-cells, suggesting that this therapeutic 
approach may diversify the T-cell receptor repertoire to more effectively target subdominant 
epitopes in addition to SPAS-1 compared to checkpoint modulation alone or combination 
therapy with Flt3L (Fig. 9G). These data indicate a mechanistic basis underlying the 
discrepancy in efficacy between local combination therapy incorporating CDG and Flt3L 
wherein CDG elicits numerous and diverse CD8+ T-cell responses against injected and 
uninjected tumors, whereas the efficacy of Flt3L is limited by the tendency to promote CD4+ 
T-cell responses. 
The dense myeloid infiltrate characteristic of TRAMP-C2 tumors poses a barrier to the 
function of infiltrating cytolytic T cells.  Even in this context, we found that local priming with 
3XCDG promoted improved CD8:TAM ratios relative to the untreated animals (Fig. 9H).  This 
was also evident for 1xCDG vs Flt3L for CD8:MDSC ratios; however, this data for the 3xCDG 
group was confounded by the large neutrophil infiltration in response to the skin inflammation 
shown in Fig. 7, and our inability to distinguish these neutrophils from PMN-MDSC using the 
antibodies in our panel (Supplementary Fig. S5A). Overall though, few, if any, tumors reached 
ratios at which CD8+ T-cells are expected to fully escape myeloid suppression. Therefore, we 
hypothesize that intratumoral delivery of myeloid agonists can reprogram tumor myeloid 
populations to reduce their immunosuppressive activity, creating a microenvironment that is 
amenable to T-cell effector function despite unfavorable relative cellular ratios. Supporting this 
hypothesis, we observed downregulation of the M2 macrophage marker CD206 on TAM in 
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tumors receiving CDG concurrently with all three doses of anti-CTLA-4, anti-PD-1, and anti-
4-1BB, potentially indicating repolarization of TAM in response to CDG combined with 
checkpoint modulation (Fig. 9I). Although combination therapy with Flt3L promoteed DC 
expansion and a reduction in MDSC populations, Flt3L failed to induce CD206 downregulation 
on TAM, suggesting this effect is specific to CDG. We conclude, therefore, that relative to 
Flt3L, CDG better potentiates intratumoral anti-CTLA-4, anti-PD-1, and anti-4-1BB activity by 
increasing infiltration and diversification of tumor-specific CD8+ T cells at local and distal 
tumors, enhancing CD8:Treg ratios, and by reprogramming suppressive TAM to a pro-
inflammatory phenotype.  
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  Figure 9: Analysis of the TRAMP-C2 immune infiltrate at local and distal tumors 
following intratumoral therapy at a single lesion. (A) To obtain cell numbers sufficient 
for flow analysis, TRAMP-C2 tumors were established for 31 days, exposed to three doses 
of intratumoral therapy at the right flank, then were harvested for multi-parameter flow 
cytometry as described in Methods. See Supplementary materials for antibodies used and 
gating strategy. (B) Relative proportions of unique cell subsets within the CD45+ immune 
infiltrate, normalized to the total number of gated cells. (C) Relative proportions of T-cell 
subsets within the CD3+ lymphocyte infiltrate, normalized to the total number of gated T 
cells. (D) Relative proportions of MDSC subsets within the CD11b+Gr-1+ immune infiltrate. 
(E) Calculated ratios of CD8+ T-cells to Treg, (F) density of SPAS-1 tetramer+ CD8+ T-cells, 
(G) percentage of SPAS-1 reactive T cells within all infiltrating CD8 T-cells, and ratio of 
CD8+ T-cells to (H) macrophages are shown. (I) Percentage of macrophages expressing 
the M2 macrophage marker CD206. Data is cumulative of 2 independent experiments with 
5 mice per group. Statistical significance was calculated using Student’s T test. ns = not 
significant, * = P < 0.05, ** = P < 0.01, *** = P < 0.001, **** = P < 0.0001. 
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Supplemental Figure S5: TIL flow analysis experimental setup and gating strategy. 
As described in the treatment schedule, 31-day established subcutaneous TRAMP-C2 
were exposed to 3 IT injections 4 days apart, and tumors were harvested for flow analysis 
3 days following the final therapy. Sample gating strategy displays all analyzed cell 
populations from a fully-stained naïve spleen sample. 18-color compensation was 
performed using single stained spleen controls and the compensation matrix from TreeStar 
FlowJo ® version 7.6.5, and all gating was performed in FlowJo ® version 10.1. 
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  Supplemental Figure S6: TIL Flow Population Quantifications. Cell populations 
harvested from TRAMP-C2 tumors as described in Supplemental Fig S6 were enumerated 
using tumor suspension cell counts and relative percentages defined by flow cytometry, 
and densities were calculated by dividing population cell count by tumor volume. (A) Ratio 
of CD8 T cells to CD11b+Gr-1+ MDSC. Individual cell populations shown are (B) CD8 
cytotoxic T cells (CD45+ CD3+ CD8+), (C) CD4 effector T cells (CD45+ CD3+ CD4+ FoxP3-
), (D) CD4 regulatory T cells (CD45+ CD3+ CD4+ FoxP3+), (E) myeloid derived suppressor 
cells (CD45+ CD3- CD11b+ Gr-1+), (F) dendritic cells (CD45+ CD3- CD11c+ CD11b-), and 
(G) tumor associated macrophages (CD45+ CD3- CD11b+ F4/80+ Gr-1-). Data is cumulative 
of 2 independent experiments with 5 mice per group. Statistical significance was calculated 
using Student’s T test. ns = not significant, * = p<0.05, ** = p<0.01, *** = p<0.001, **** = 
p<0.0001. 
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3.2.6: Summary 
Simultaneous manipulation of multiple, non-redundant immune regulatory systems 
can activate potent antitumor immune responses in mouse and man. Translation of this 
approach, however, has been limited by cumulative inflammatory side effects which limit the 
tolerability of high-order combination therapies in patients. At the time of this writing, the only 
combination immunotherapy with FDA approval consists of ipilimumab (Yervoy®; anti-CTLA-
4) and nivolumab (Opdivo®; anti-PD-1) for patients with Braf V600 wild-type unresectable or 
metastatic melanoma. Though effective and tolerable in this indication, a number of solid 
tumors, including castration-resistant prostate cancer, remain resistant to these therapies. In 
this chapter, I report that an optimized cocktail of immunomodulators engaging both innate 
and adaptive immunity mediates efficient rejection of poorly immunogenic murine prostate 
cancer. Although local stimulation of the STING or Flt3 pathways can complement checkpoint 
modulating antibodies targeting CTLA-4, PD-1, and 4-1BB to delay tumor growth and enhance 
survival of mice with multi-focal TRAMP-C2, I find that the STING agonist CDG mobilizes 
abscopal immunity more efficiently than Flt3L. In an effort to mitigate the toxicity of these high-
order combinations, I report that intratumoral injection of low-dose checkpoint modulators 
together with CDG, but not Flt3L, is sufficient to induce curative abscopal immunity in ~50% 
of mice. I identify a potential mechanistic basis for the discrepancy in synergy between 
checkpoint modulators and CDG vs Flt3L, as CDG promotes CD8 skewing, infiltration of tumor 
specific T cells, and enhanced intratumoral ratios of CD8+ T cells to Treg, TAM, and MDSC, 
while Flt3L facilitates expansion of CD4 T cells, including Treg, in both local and distal tumors. 
Combination therapy with CDG may reduce the suppressive capacity of TAM in TRAMP-C2 
tumors, as I observe downregulation of the M2 macrophage marker CD206 in response to 
this therapy. These data suggest STING-mediated myeloid programming can potentiate 
intratumoral T-cell checkpoint modulation to render multi-focal prostate cancer sensitive to 
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immunotherapy. 
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Chapter 4: Intratumoral Delivery of a Novel STING Agonist Repolarizes 
Suppressive Myeloid Cells and Sensitizes Pancreatic Ductal Adenocarcinoma 
to Checkpoint Blockade 
4.1: Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy whose defining 
characteristics render it resistant to available therapies. Over 80% of PDAC patients present 
with metastatic disease precluding surgical resection, and relapse occurs in the majority of 
early-stage surgical candidates within one year (68, 118). First-line chemotherapy regimens 
consisting of gemcitabine and albumin-bound paclitaxel (Abraxane®) or a cocktail of 
leucovorin, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) extend median overall 
survival up to 11 months, yet 5-year survival rates remain dismal (~7%) and treatment related 
toxicities can be severe (120, 121). The PDAC genome bears few actionable targets, as the 
characteristic genetic alterations common to nearly all PDAC patients (KRAS, TP53, 
CDKN2A, and SMAD4) are considered “undruggable” by current targeted therapies. A 
uniquely desmoplastic tumor microenvironment also contributes to the refractory nature of 
PDAC tumors. High interstitial pressures from densely-deposited extracellular matrix limits 
drug perfusion into the tumor bed, and restriction of the sparse tumor vasculature creates 
regions of deep hypoxia (137, 138). While oncogenic Kras drives metabolic adaptions to 
sustain tumor growth under these conditions (141-144), many anti-tumor components of the 
PDAC stroma, chiefly cytotoxic CD8 T cells, are excluded or rendered locally dysfunctional by 
this hostile environment (146). As a result, PDAC tumors are generally considered 
immunologically “cold”, and immunotherapies targeting T cell checkpoints CTLA-4 or PD-1 
have failed in clinical evaluation in this indication (162, 164, 165, 469). 
However, contrary to its perception as an immunologically silent tumor, PDAC relies 
on numerous intimate interactions with the host immune system from its earliest discernable 
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pre-invasive stages through metastatic disease (146). Early activation of oncogenic Kras 
drives tumor-intrinsic production of colony stimulating factors including GM-CSF and CSF-1, 
which stimulates myelopoiesis and recruits monocytes that undergo polarization to an “M2-
like” macrophage phenotype in situ (151, 330). Further release of Kras-driven cytokines 
including IL-6 can induce aberrant activation of immature myeloid precursors, which 
accumulate as myeloid derived suppressor cells (MDSC) within tumors and lymphoid organs 
(147-149). Once recruited, these myeloid cells can participate in crosstalk with cancer-
associated fibroblasts (CAF) that construct fibrotic barriers that interfere with CD8 T cell 
infiltration (57, 151). Moreover, any CD8 T cells which gain entry to the tumor bed are subject 
to the myriad mechanisms of immunosuppression by both tumor associated macrophages 
(TAM) and MDSC, which include local nutrient deprivation, secretion of suppressive 
cytokines, release of reactive oxygen and nitrogen species, engagement of inhibitory T-cell 
checkpoint receptors, and promotion of FoxP3-driven CD4 regulatory T cell (Treg) 
phenoconversion (470). Thus, an early proclivity towards myeloid recruitment and polarization 
is an intrinsic property of PDAC which cloaks developing and established neoplasms from 
immune sensing and rejection (146). As a result, a number of approaches are currently under 
preclinical and clinical evaluation to target myeloid cells in PDAC, including interference with 
myeloid recruitment and signaling through blockade of chemokine receptors CCR2 and 
CXCR2 (301, 305) or key macrophage signaling molecules CSF-1R or PI3Kγ (330, 338, 339), 
as well as activation of tumor macrophages through agonism of the TNF superfamily receptor 
CD40 (341, 342). However, it remains to be determined which method of myeloid modulation 
engenders optimal conditions to sensitize PDAC tumors to immunotherapy. 
Myeloid cells are canonically activated through a repertoire of pattern recognition 
receptors (PRR), which sense molecular patterns associated with infection or cellular stress 
and induce transcriptional programs associated with acute inflammation and antigen 
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presentation. Recently, stimulator of interferon genes (STING) was identified as a novel 
sensor of cytosolic nucleic acids that is capable of liberating potent type I interferon responses 
to cytosolic DNA (358). Signaling through STING, rather than any other innate PRR, was 
shown to be required for spontaneous immunity against immunogenic tumors, suggesting the 
STING pathway may uniquely engender tumor-antagonistic phenotypes and function in tumor 
myeloid populations (348). STING is specifically activated by cyclic dinucleotide (CDN) 
compounds, initiating a signaling cascade through IRF3 and NFκB pathways to elaborate 
inflammatory cytokines including IFN-β and TNFα, chemokines including CXCL10 and CCL5, 
and surface molecules associated with antigen presentation including MHC-II, CD86, and 
CD40 (360, 373, 429). Intratumoral delivery of CDN has shown preclinical efficacy across an 
array of ectopically-implanted tumor models as monotherapy and in combination with 
checkpoint blockade (114, 389, 429, 434, 437, 439, 440, 442), and synthetic CDN with 
enhanced stability and potency relative to the mammalian CDN 2’3’ cyclic guanine 
monophosphate-adenosine monosphosphate (cGAMP) are currently under early-phase 
clinical evaluation in solid tumors with superficial involvement (NCT02675439, NCT03172936, 
NCT03010176). Unknown, however, remains the feasibility and efficacy of local delivery of 
CDN to visceral tumors such as PDAC, as well as a comprehensive analysis of the effects of 
CDN on suppressive myeloid cell phenotypes at the transcriptional, translational, and 
functional levels. In the following study, we describe and characterize a novel, highly potent 
STING agonist IACS-8803, and perform in depth profiling of its effects relative to other known 
CDN on in vitro polarized populations of MDSC and M2-like macrophages of murine and 
human origin. Furthermore, we demonstrate that CDN can be locally delivered within 
orthotopically-implanted pancreatic lesions, and provide preclinical evidence that local STING 
activation can potentiate the effects of checkpoint blockade immunotherapy in a highly 
aggressive, refractory model of PDAC. 
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4.2: Results 
4.2.1: In vitro characterization of IACS-8803, a novel highly potent STING agonist 
STING activation via cyclic dinucleotide (CDN) compounds is one of the most efficient 
means of generating a type I interferon response in both hematopoietic and non-
hematopoietic cells, making CDNs an attractive therapeutic modality for tumors which lack a 
T cell inflamed signature. A number of CDNs are produced naturally, including cyclic di-
guanine monophosphate (CDG) and cyclic di-adenosine monophosphate (CDA), which are 
broadly conserved second messenger molecules in bacteria (360). Mammalian cells utilize 
the cytoplasmic DNA sensor cGAS to synthesize cyclic guanine-monophosphate adenosine 
monophosphate (cGAMP), which possesses higher affinity for STING due to a non-canonical 
3’5’-2’5’ phosphodiester “mixed” linkage that results in deeper binding within the STING CDN-
binding pocket and more potent induction of downstream signaling relative to bacterial CDN 
(364-366). Recently, synthetic CDNs have been designed bearing 2’3’ mixed linkages in 
addition to bisphosphothionate substitutions that inhibit CDN enzymatic degradation by 
phosphodiesterases such as ENPP1 (431). The molecule ML-RR-S2-CDA (ML-RR) bears 
these modifications and is the first CDN under clinical evaluation in cancer (ADU-S100; 
Novartis) (429, 437). We designed and synthesized a number of novel CDNs containing 
additional proprietary alterations to ML-RR, and evaluated these CDNs for the capacity to 
activate STING in human THP-1 Dual reporter monocytes and murine J774 Dual reporter 
macrophages (Invivogen). We identified a novel CDN IACS-8803 that induces downstream 
IRF3 and NFκB signaling with enhanced potency relative to ML-RR, with a specific advantage 
at reduced concentrations below 1µg/mL (Figure 10A-B, Supplementary S7A). To confirm 
these data, we quantified STING-mediated release of Type I IFN by parental THP-1 
monocytes and murine splenocytes by ELISA, and found that stimulation with 8803 induced 
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higher IFN-β release relative to ML-RR or cGAMP in both conditions (Fig 10C, Supplemental 
Fig S7B). STING-deficient splenocytes from STINGgt/gt mice failed to induce IFN-β in response 
to 8803, suggesting the enhanced potency of 8803 is not due to promiscuous activation of 
non-STING targets (Supplemental Fig S7B). Structurally, 8803 is a 2’3’-2’5’ mixed linkage 
CDA molecule with identical bisphosphothioate substitutions of R,R chirality as found in ML-
RR-S2-CDA. However, IACS-8803 contains an additional fluorine substitution in place of the 
2’ hydroxyl group on the 3’ linked ribose residue (Fig 10D). These data demonstrate 8803 is 
a highly potent novel CDN capable of efficiently activating STING in both murine and human 
myeloid cell lines in vitro. 
A number of unique germline variants of the human STING gene have been described, 
with the HAQ and R232H alleles each being found in 10-20% of the human population (430). 
As these isoforms may possess unique CDN binding characteristics compared to wild-type 
STING, we next evaluated the capacity of 8803 to activate the most common human STING 
variants. We utilized STING-deficient HEK-Blue reporter cells stably transduced with WT, 
HAQ, R232H, or G230A STING alleles, and measured induction of STING signaling in 
response to 8803. We found 8803 sufficient to robustly activate each isoform (Fig 10E). While 
ML-RR can activate the HAQ and G230A alleles as previously described, we found ML-RR 
incapable of activating the R232H allele at the concentrations evaluated, suggesting 8803 
may be more broadly effective than ML-RR in 13.7% of the human population known to 
express the R232H isoform of STING. 
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Figure 10: In vitro characterization of IACS-8803. (A) 1x105 THP-1 Dual and 5x104 J774 
Dual reporter cells (Invivogen) were stimulated for 20 hours with 1μg/mL of indicated CDN. 
IRF3 activity was measured by luciferase assay according to manufacturer’s instructions. 
(B) CDN titration assay using the THP-1 Dual reporter cell line as in (A). (C) 1x105 THP-1 
parental cells were plated in flat-bottom 96 well plates and were incubated with 10μg/mL 
indicated CDN. After 72 hours, IFN-β levels in the supernatant were measured by ELISA 
(PBL Assay Science). (D) Chemical structures of 2’3’ cGAMP, ML-RR-S2-CDA, and IACS-
8803. (E) 5x104 HEK-Blue reporter cells expressing the indicated human STING allele 
were incubated with 100μg/mL of the corresponding CDN for 24 hours. IRF3/9 activity was 
measured by SEAP assay according to manufacturer’s instructions. Statistical significance 
was calculated using Student’s T test. ns = not significant, * = p<0.05, ** = p<0.01, *** = 
p<0.001, **** = p<0.0001. 
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Supplemental Figure S7: Extended in vitro characterization of IACS-8803. (A) 1x105 
THP-1 Dual reporter cells (Invivogen) were stimulated for 20 hours with a range of indicated 
CDN. NF-κB activity was measured by SEAP assay according to manufacturer’s 
instructions. (B) Splenocytes were harvested from WT C57BL/6 or STINGGt/Gt mice and 
2x105 cells were plated in flat bottom 96-well plates in the presence of 10μg/mL CDN. After 
72 hours, IFN-β levels in the supernatants were measured by ELISA (PBL Assay Science). 
Statistical significance was calculated using Student’s T test. ns = not significant, * = 
p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
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4.2.2: In vivo characterization of 8803 relative to known CDNs 
To determine whether the superior potency of 8803 in in vitro cell lines translates to 
enhanced in vivo anti-tumor efficacy compared to other known CDNs, we performed 
intratumoral injection of CDNs into subcutaneously-implanted PDAC tumors using a 
Kras+/G12DTP53+/R172HPdx1-Cre (KPC) derived cell line mT4-2D (445). Tumors were harvested 
following three successive injections with 5µg of indicated CDN for mass measurement and 
analysis by multi-parameter flow cytometry, probing for compositional and functional 
modulation of the tumor immune microenvironment (Fig 11A). We find that relative to PBS 
vehicle injection, CDG and cGAMP at this dose have minor effects on tumor mass. However, 
ML-RR and 8803 induce regression of mT4-2D tumors, with 8803 delivering superior efficacy 
over ML-RR (Fig 11B). Local delivery of 8803 triggers expansion of the CD45+ immune 
infiltrate (Fig 11C), which is dominated by recruitment of CD11b+Ly6G+Ly6CmidF4/80- 
granulocytes that likely consist largely of inflammatory neutrophils (Fig 11D). This 
granulomatous response occurs at similar or reduced levels in tumors exposed to ML-RR or 
CDG, but interestingly is not as prominent in cGAMP-treated mT4-2D tumors. Nearly all other 
analyzed immune cell populations exist at higher densities following injection with 8803 
relative to vehicle (Fig 11E), however among lymphocytes, particular expansion occurs within 
the CD8 T cell compartment, with these cells exhibiting increased expression of functional 
markers including Ki67 and Ly6C (Fig 11E-G). In the myeloid compartment, expansion of 
CD11b+Ly6C+Ly6G-F4/80mid/- monocytes occurs in response to 8803, with resulting 
monocytes bearing reduced expression of the functional M2-like marker Arginase (Fig 11E,I). 
Tumor associated macrophages (TAM) as defined by CD11b+Ly6C-Ly6G-F4/80+ marker 
expression do not significantly expand in response to 8803, yet undergo phenotypic 
conversion through downregulation of CD206 (Fig 1H). Together, these data describe in vitro 
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stimulatory capacity and in vivo therapeutic effects of a novel STING agonist IACS-8803, and 
detail its high relative potency compared to natural STING ligands CDG and cGAMP and the 
clinical compound ML-RR-S2-CDA. 
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Figure 11: In vivo characterization of 8803 in subcutaneous KPC-derived PDAC. (A) 
Mice received subcutaneous injection of 2.5x105 mT4-2D cells in 30% matrigel, then were 
injected intratumorally with 5μg CDN on days 15, 18, and 21 before tumor harvest on day 
23. Tumors were massed, counted, and processed for flow cytometry analysis as 
described in methods. Data shown represent (B) tumor mass, (C) CD45+ infiltration, (D) 
overall composition of analyzed CD45+ cells, (E) cellular densities, (F) Ki67 and (G) Ly6C 
expression on tumor CD8 T cells, (H) normalized CD206 expression on macrophages, and 
(I) arginase expression in MO-MDSC. Data are cumulative of 2 independent experiments 
with 5 mice per group. Statistical significance was calculated using Student’s T test. ns = 
not significant, * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
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4.2.3: Profiling effects of CDNs on murine bone marrow-derived MDSCs 
STING agonists are known to act on a number of different cell types within the tumor 
microenvironment, including dendritic cells, macrophages, endothelial cells, and 
radioresistant stromal cells (414, 429, 443), and induction of CD8 T cell priming by activated 
professional antigen presenting cells (APCs) is thought to be central to the efficacy of CDNs. 
Phenotypic “M2 to M1” conversion of macrophages following STING activation has been 
documented (442, 471), suggesting repolarization of suppressive myeloid populations may 
contribute to the efficacy of CDNs in tumors with high myeloid infiltrates. However, it is 
currently unknown whether CDNs modulate the phenotype or function of myeloid derived 
suppressor cells (MDSC), which are numerous and highly immunosuppressive in many tumor 
types. Therefore, we sought to describe the effects of CDNs on MDSC signaling and T cell 
suppressive function.  
We chose to study in vitro differentiated populations of bone marrow-derived MDSCs 
(BM-MDSCs) due to the sensitivity of tumor MDSCs to ex vivo culture and the lack of definitive 
phenotypic markers to differentiate bona fide MDSCs from mature neutrophils or monocytes 
recruited following intratumoral CDN injection. Culture of murine bone marrow aspirates with 
recombinant GM-CSF and IL-6 for 4 days yields consistent populations of both 
polymorphonuclear (PMN-) and monocytic (MO-) MDSCs as defined by expression of CD11b, 
Ly6G, and/or Ly6C (Fig 12A, Supplemental Fig S8) (199). In these cultures, PMN-MDSCs 
predominate numerically over MO-MDSC at a ~2:1 ratio, which reflects the relative abundance 
of these populations observed in many tumor models (Supplemental Fig S8). We found this 
mixed population of MDSCs capable of efficiently suppressing proliferation of naïve CFSE-
labeled splenic CD8 T cells in the presence of polyclonal αCD3/αCD28 stimulation, indicating 
they are functionally valid MDSC as has been previously published (Fig 12B). To evaluate 
112 
 
whether CDN are capable of modulating the suppressive function of MDSCs, we harvested 
BM-MDSCs following 4-day in vitro differentiation and stimulated them with increasing 
concentrations of 8803 for 1-2 days, then evaluated their suppressive function by T cell 
suppression assay (Fig 12A). In comparison to unstimulated BM-MDSCs, 8803-treated BM-
MDSCs exhibit reduced suppressive function in a dose-dependent manner, with maximum 
repolarization occurring at 10µg/mL 8803 (Fig 12B). These data suggest STING-activating 
CDNs can reduce the suppressive function of BM-MDSCs in a dose-dependent manner. To 
evaluate the relative capacity of different STING agonists to modulate MDSC function, we 
stimulated BM-MDSCs with 2.5µg/mL of indicated CDN, then evaluated suppressive function 
by T cell suppression assay. Under these conditions, CDG has no observable effects on BM-
MDSC function, while cGAMP stimulation yields BM-MDSCs with a trending decrease in 
suppressive capacity at a 1:1 MDSC:T cell ratio. In contrast, both ML-RR and 8803 mediate 
significant reversal of MDSC suppression, with a majority of T cells escaping suppression by 
treated BM-MDSC at the equivalent 1:1 ratio (Fig 12C). Compared to ML-RR, 8803-treated 
BM-MDSCs exhibit a trending, but not significant reduction in suppressive function. Together, 
these data indicate the CDN can reverse the T-cell suppressive activity of in vitro differentiated 
MDSC populations, and synthetic dinucleotides 8803 and ML-RR-CDA are superior to natural 
STING ligands at mediating these effects. 
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Figure 12: STING activation reduces the suppressive capacity of bone marrow-
derived MDSC. (A) Generation of BM-MDSC and repolarization protocol as described in 
detail in methods. (B) Evaluation of MDSC suppression by CD8 T cell suppression assay 
following MDSC repolarization using indicated concentration of 8803. (C) Evaluation of 
MDSC suppression by CD8 T cell suppression assay following repolarization with 
2.5μg/mL indicated CDN. Data are representative of at least two independent experiments. 
Statistical significance was calculated using Student’s T test. ns = not significant, * = 
p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
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Supplemental Figure S8: MDSC subsets in unstimulated BM-MDSC cultures. Bone 
marrow harvested from WT C57BL/6 mice was cultured in the presence of GM-CSF and 
IL-6 for 4 days to induce differentiation of suppressive BM-MDSC as described in methods. 
Flow cytometric analysis of untreated BM-MDSC revel ~95% expression of CD11b, and a 
2:1 ratio of Ly6G+Ly6Cmid PMN-MDSC (49.4%) to Ly6C+Ly6G- MO-MDSC (24.0%). 
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4.2.4: Profiling effects of CDNs on human M2c-polarized macrophages 
A number of studies indicate a capacity for STING-activating CDN to facilitate “M2 to 
M1-like” phenotypic conversion of in vitro-differentiated and tumor associated macrophages. 
However, in depth profiling of CDN-mediated macrophage repolarization in controlled in vitro 
settings has not been reported. Additionally, analysis of myeloid polarization by CDNs has 
predominately focused on murine macrophage populations, leaving little known about the 
potential for STING agonists to modulate macrophages of human origin. We generated 
human macrophages through magnetic bead isolation of healthy donor peripheral blood 
mononuclear cell (PBMC) CD14+ monocytes, which were cultured in the presence of M-CSF 
for 6 days to induce macrophage differentiation. Polarization to an “M2c-like” phenotype was 
induced through addition of IL-10 and TGF-β cytokines for 2 days as previously described 
(447), yielding macrophages with high expression of CD163, CD206, PD-L2, and IRF4. 
Following differentiation and polarization, resulting M2c-like macrophages were exposed to 
CDNs at 10 µg/mL concentration for 3 days in the presence of supportive M-CSF (Fig 13A). 
We found unstimulated M2c macrophages to exhibit classical M2-like morphology 
characterized by firmly adherent, elongated cellular architecture (Fig 13 B). In contrast, 
addition of CDNs results in a shift in morphology towards a less-adherent, “fried egg” M1-like 
shape (343, 472). Interestingly, the degree to which this morphological shift occurs is 
correlated with CDN potency, which can be measured roughly by side scatter characteristics 
upon analysis by flow cytometry (Fig 13C). Exposure to ML-RR or 8803 induce potent 
upregulation of M1-like markers CD86, HLA-DR, and IL-6 relative to unstimulated, CDG-
treated, or cGAMP-treated M2c macrophages, concomitant with downregulation of classical 
M2-like markers CD206 and CD163. Furthermore, 8803 is superior to ML-RR in inducing 
expression of CD80 and PD-L1, which are generally unresponsive to natural CDNs at the 
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dose examined (Fig 13C). These markers are expressed at lower levels than CD86 or IL-6, 
thus we speculate that their expression may be a result of secondary effects from CDN-
induced primary secretion of IFNβ, IFNγ, or TNFα cytokines. In addition, we observe a 
profound proliferative block in M2c macrophages responding to ML-RR or 8803 as measured 
by Ki67 downregulation. Interestingly, proinflammatory triggers such as LPS were recently 
shown to block proliferation controlled by Myc, which also governs M2-like polarization in 
macrophages (473-475). Thus, it is tempting to speculate that potent STING activation by ML-
RR or 8803 counteracts Myc-dependent proliferation and suppressive polarization. Together, 
these data indicate that CDNs are capable of mediating direct inflammatory repolarization of 
human M2c-like macrophages at morphological and phenotypic levels. 
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Figure 13: STING activation phenotypically repolarizes human M2c macrophages. 
(A) Protocol for generation of M2c polarized macrophages from CD14+ PBMC-derived 
monocytes and subsequent CDN stimulation, as detailed in methods. (B) Representative 
images of morphological changes in M2c macrophages following 3 day exposure to 
indicated CDNs. (C) Analysis of macrophage phenotypic polarization following 3 day CDN 
stimulation by flow cytometry. Data are cumulative of two independent experiments with 3 
unique donors each. Statistical significance was calculated using Student’s T test. ns = not 
significant, * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001.  
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4.2.5: Combination therapy with 8803 and checkpoint blockade cures multi-focal mT4-LS 
PDAC. 
Given the capacity of 8803 to induce phenotypic and functional repolarization of 
suppressive myeloid cells – which pose a major barrier to the efficacy of immunotherapy in 
PDAC – we hypothesized that intratumoral delivery of 8803 could remodel the tumor 
microenvironment to permit CD8 T cell cytotoxicity, creating an opportunity for checkpoint 
blockade to be of benefit in PDAC. Furthermore, we tested whether local STING activation in 
the context of checkpoint blockade could promote systemic antitumor immunity against distal 
uninjected PDAC lesions, as we previously demonstrated in a bilateral model of TRAMP-C2 
prostate cancer. For this, we utilized mT4-2D, a C57BL/6 syngeneic PDAC cell line derived 
from Kras+/G12DTP53+/R172HPdx1-Cre (KPC) tumor organoid cultures. We found mT4-2D to 
possess an extremely low mutational burden, as is common of KRAS-driven spontaneous 
murine tumor models (Supplemental Fig S9A-B). Retroviral transduction of an optimized firefly 
luciferase gene facilitated longitudinal monitoring of orthotopically-implanted mT4-2D-
Luciferase (termed mT4-LA) using IVIS bioluminescent imaging. We found low doses of 
<5x104 mT4-LA cells capable of aggressive local invasion and metastatic spread to the liver, 
peritoneum, and mesentery, with mice succumbing to disease within three weeks on average. 
Additionally, we isolated a single cell clone from the mT4-LA population that exhibits reduced 
growth kinetics compared to mT4-LA in vivo following both subcutaneous and orthotopic 
implantation (Termed mT4-LS for its characteristically “slow” growth pattern; Supplemental 
Fig S9C). We leveraged the larger therapeutic window afforded by mT4-LS to screen potential 
combination approaches, and performed validation of effective therapies in the highly 
aggressive orthotopic mT4-LA model. 
 To evaluate the efficacy of intratumoral 8803 alone and in combination with checkpoint 
blockade against multi-focal PDAC, we simultaneously implanted mice with both orthotopic 
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and subcutaneous mT4-LS tumors to model a primary and metastatic lesion, respectively. 
Mice received localized 8803 or PBS vehicle within the orthotopic tumor by survival surgery 
on days 10 and 22 post-implantation, and received checkpoint blockade antibodies targeting 
CTLA-4 or PD-1 by intraperitoneal (IP) injection on days 10, 14, and 18 (Fig 14A). We found 
monotherapy with αCTLA-4, αPD-1, or intra-pancreatic 8803 capable of curing 50% of mice 
of both lesions in this model, with combination αCTLA-4/αPD-1 not demonstrating significant 
benefit over individual checkpoints. However, the combination of intratumoral 8803 with 
concurrent checkpoint blockade cures all mice tested of both lesions, regardless of the 
checkpoint being targeted (Fig 14B-C). IVIS imaging reveals a rapid kinetic of tumor 
regression following combination therapy, with tumors falling below the level of detection 
within six days of initiating treatment. These data demonstrate that local STING activation by 
8803 within orthotopically-implanted PDAC lesions can potentiate checkpoint blockade and 
induce robust curative immunity against both injected and distal uninjected mT4-LS tumors. 
  
120 
 
 
  
Figure 14: Intra-pancreatic 8803 potentiates checkpoint blockade to cure mice with 
multi-focal mT4-LS. (A) Implantation and treatment schedule. Intra-pancreatic delivery of 
8803 involves survival surgery to inject 8803 directly into primary mT4-LS lesions. (B) 
Representative longitudinal IVIS imaging of mice treated as in (A). (C) Survival data 
indicating therapeutic additivity between 8803 and CTLA-4 or PD-1, or the combination of 
CTLA-4 and PD-1. Data are cumulative of two independent experiments with 5-10 mice 
per group. Statistical significance was calculated using the Log-rank Mantel-Cox test. ns = 
not significant, * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
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Supplemental Figure S9: Mutational analysis and tumor growth kinetics of mT4 
PDAC model. (A) Whole genome sequencing was performed on parental mT4-2D in 
collaboration with Colm Duffy of the Allison lab. Identified exonic nonsynonymous 
mutations were analyzed for predicted neoantigen epitopes using the NetMHC 4.0 
algorithm. (B) Comparison of nonsynonymous mutational burden of mT4-2D relative to 
PancO2 (data adapted from Bhadury et al 2013) and B16-F10 (data adapted from Castle 
et al 2012). (C) Subcutaneous tumor growth kinetics and survival following orthotopic 
implantation of mT4-LA and mT4-LS cells. For subcutaneous implantation, 2.5x105 cells 
were implanted in 3 mice each. For orthotopic implantation, 0.35x105 cells were implanted 
in 30% matrigel v/v in the head of the pancreas by survival surgery in 10 mice each. 
Survival endpoint indicates death from tumor burden or observed overt morbidity. 
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4.2.6: Analysis of orthotopic and subcutaneous mT4 tumors following 8803 + checkpoint 
therapy by flow cytometry 
 To understand how this combination approach achieves such rapid and robust 
clearance of multi-focal PDAC, we performed multi-parameter flow cytometry on both 
pancreatic and subcutaneous tumors four days following delivery of intra-pancreatic 8803. For 
this early timepoint, we modified the checkpoint antibody schedule as detailed in Fig 15A, and 
utilized the parental mT4-2D cell line to obtain sufficient tumor tissue for analysis. We found 
local 8803 sufficient to increase CD8 T cell density within orthotopic tumors, which can be 
further potentiated by αCTLA-4 or the combination of αCTLA-4/αPD-1 (Fig 15B). This 
correlates with a decreased proportion of Foxp3+ Tregs in tumors exposed to 8803 and 
αCTLA-4, resulting in improved CD8:Treg ratios within the pancreatic microenvironment (Fig 
15C). This is expected, given the well-documented capacity for the 9H10 clone of αCTLA-4 
to facilitate Treg depletion in murine tumors. In contrast, αPD-1 does not appear to drive CD8 
T cells into PDAC tumors as single agent or in combination with 8803, or productively 
modulate tumor T cell composition to numerically favor CD8 T cells over Tregs (Fig 15C). 
However, Tregs within all tumors locally-exposed to 8803 exhibit reduced expression of 
CD103, a marker that has been associated with Treg effector function (Fig 15D). Thus, direct 
effects of 8803 may reduce the suppressive capacity of Tregs and promote CD8 T cell 
cytotoxicity even in αPD-1 treated mice which retain poor CD8:Treg ratios. This is 
substantiated by the observation that phenotypic changes within CD8 T cells associated with 
enhanced cytotoxicity – including expression of the cytotoxic granule Granzyme B and 
proliferation marker Ki67 – are observed in response to 8803 and αPD-1 (Fig 15E-F). While 
similar effects are noted in response to 8803 and αCTLA-4 or the combination of αCTLA-
4/αPD-1, we do observe a unique capacity for 8803 and αPD-1 to most efficiently upregulate 
Ly6C expression on CD8 T cells within pancreatic tumors (Fig 15H). Interestingly, we also 
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observe analogous induction of Granzyme B in CD8 T cells within distal subcutaneous tumors 
in mice treated with intra-pancreatic 8803 and systemic checkpoint blockade, which indicates 
local 8803 can exert systemic effects on T cell function (Fig 15G). However, it is unclear 
whether this is bona fide “abscopal” immunity, or due to diffusion of small CDN molecules into 
the circulation that can induce residual STING activation within the uninjected lesion. 
Downregulation of CD206 is observed on TAM from orthotopic lesions exposed to 8803 alone 
or together with checkpoint blockade, however the degree of downregulation is minor relative 
to that seen in the subcutaneous model (Fig 15I). This may be due to the transient polarizing 
effects of CDN in vivo following a single – rather than multiple – injections. Infiltrating DCs 
exhibited increased proliferation through Ki67 staining in response to 8803 and checkpoint 
blockade, possibly indicating expansion of the DC compartment by 8803 (Fig 15J). Together, 
these data describe early modulation of the PDAC TME by intra-pancreatic 8803 alone and 
together with checkpoint blockade, and suggest distinct mechanisms by which 8803 may 
potentiate checkpoint blockade by αCTLA-4 vs αPD-1 to modulate the quantity and quality of 
CD8 T cells within PDAC tumors following therapy.  
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Figure 15: Analysis of orthotopic and subcutaneous mT4 tumors following 
combination 8803 + checkpoint blockade therapy. (A) Implantation and treatment 
schedule. Both orthotopic and subcutaneous tumors were harvested following local 8803 
into the orthotopic lesion only. Data are from pancreatic lesions unless otherwise indicated, 
and represent (B) density of CD8 T cells, (C) CD8:Treg ratios, (D) CD103 expression on 
Tregs, (E) functional markers Ki67 and (F) granzyme B on CD8 T cells, (G) granzyme B 
expression on CD8 T cells within the uninjected subcutaneous tumor, (H) Ly7C on CD8 T 
cells, (I) CD206 expresssion on F4/80+ macrophages, and (J) Ki67 expression on CD11c+ 
dendritic cells. 
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4.2.7: 8803 potentiates checkpoint blockade against orthotopic mT4-LA and does not require 
chemotherapy. 
Given the therapeutic additivity observed between intratumoral 8803 and systemic 
checkpoint blockade in the responsive mT4-LS model, we sought to test whether synergy 
would be observed in the mT4-LA model which more accurately reflects the aggressive and 
refractory nature of late-stage PDAC. We implanted mice simultaneously with orthotopic and 
subcutaneous mT4-LA to model primary and metastatic lesions, and performed intratumoral 
injection of 8803 or PBS vehicle within the orthotopic tumor by survival surgery on days 10 
and 22 post-implantation. Mice received αCTLA-4 and/or αPD-1 IP on days 10, 14, 18, 22, 
and 26 (Fig 16A). In this model, local 8803 induces transient regressions that moderately 
extend survival compared to PBS-treated mice, however no mice are cured. Monotherapy 
checkpoint blockade with αCTLA-4 or αPD-1 do not deliver significant survival benefit over 
PBS-treated mice, and the combination of αCTLA-4 or αPD-1 with 8803 does not significantly 
extend survival compared to monotherapies (Fig 16B, Supplemental Fig S10A). Therefore, in 
contrast to the mT4-LS model, 8803 does not synergize with individual checkpoint blockade 
against aggressive mT4-LA tumors. However, dual blockade of CTLA-4 and PD-1 extends 
survival compared to PBS-treated mice, and the combination of local 8803 with αCTLA-
4/αPD-1 shows significant survival benefit over 8803 or αCTLA-4/αPD-1 alone (Fig 16B, 
Supplemental Fig S10A). Additionally, this combination alone leads to a trend towards 
reduced growth kinetics at the uninjected subcutaneous tumor (Supplemental Fig S10B). 
These data demonstrate that 8803 can be delivered into late-stage, aggressive tumors and 
synergize with dual αCTLA-4/αPD-1 checkpoint blockade to mediate local and systemic 
control of mT4-LA PDAC tumors. 
 Longitudinal IVIS imagining of orthotopically implanted tumors indicates the 
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combination of local 8803 and dual checkpoint blockade can achieve significant, but 
incomplete regression of mT4-LA tumors. We hypothesized that concurrent administration of 
first-line chemotherapy agents gemcitabine (Gem) and Abraxane (nab-paclitaxel; nP) could 
further enhance tumor control by (i) curtailing tumor growth kinetics and metastasis at initiation 
of immunotherapy, (ii) mediating immunogenic tumor cell death, increasing tumor antigen 
availability to APCs being activated by local CDN, and (iii) promoting depletion or further M1-
like polarization of tumor myeloid cells, which has been reported in response to nab-Paclitaxel 
(476). While gemcitabine has controversial effects on macrophage polarization (477, 478), it 
has been successfully combined in preclinical models with myeloid-targeting agents including 
CD40 agonists, CCR2 and CXCR2 inhibitors, and CSF-1R inhibitors (305, 330, 341). 
Therefore, we implanted mice orthotopically with mT4-LA and evaluated whether Gem/nP 
administered IP (120mg/kg) on days 10 and 22 could enhance the efficacy of intratumoral 
8803 and αCTLA-4/αPD-1 dual checkpoint blockade. In this experiment, mice were not 
inoculated with subcutaneous “pseudo-metastatic” lesions due to the highly metastatic nature 
of orthotopic mT4-LA and the tendency of subcutaneous tumors to ulcerate before reaching 
1000mm3 in volume, requiring early euthanasia of long-term responders (Supplemental Fig 
S10C). Chemotherapy with Gem/nP alone delivers no observable benefit by IVIS imaging or 
survival, and does not significantly boost the efficacy of 8803 or αCTLA-4/αPD-1 
(Supplemental Fig 10D). When combined with both 8803 and αCTLA-4/αPD-1, Gem/nP 
promotes early survival, with no mice succumbing to disease until day 41 post-implantation. 
However, this early benefit does not translate to long-term survival advantage, as the median 
overall survival rate of this cohort is identical to mice treated with 8803 and αCTLA-4/αPD-1 
without chemotherapy (Fig 16C). Additionally, we observe signs of increased treatment-
related toxicity in mice exposed to Gem/nP, with 31.5% of mice failing to recover from the final 
therapeutic surgery (Supplemental Fig S10E). A smaller proportion of mice receiving Gem/nP 
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with 8803 or αCTLA-4/αPD-1 exhibit similar morbidity, while all mice receiving combination 
8803 and αCTLA-4/αPD-1 recover without incident. Therefore, we conclude that standard of 
care chemotherapy is not required to achieve maximum therapeutic benefit when combining 
local 8803 with systemic dual checkpoint blockade with αCTLA-4 and αPD-1 against 
orthotopic mT4-LA PDAC tumors. 
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Figure 16: Intra-pancreatic 8803 synergizes with dual checkpoint blockade to 
prolong survival in mT4-LA independent of chemotherapy. (A) Implantation and 
treatment schedule. (B) Survival of mice bearing orthotopic and subcutaneous mT4-LA 
treated as described in (A), with n=5-10 mice per group. (C) Mice bearing only orthotopic 
mT4-LA (0.35x105 cells) were treated as described in (A) with additional standard of care 
chemotherapy consisting of gemcitabine (120mg/kg) and nab-paclitaxel (120 mg/kg) 
(Gem/nP) administered on days 10 and 22 in indicated groups. Longitudinal tumor growth 
by IVIS imaging and overall survival are shown. Data are cumulative of two independent 
experiments with 5-10 mice per group. Statistical significance was calculated using the 
Log-rank Mantel-Cox test. ns = not significant, * = p<0.05, ** = p<0.01, *** = p<0.001, **** 
= p<0.0001. 
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  Supplemental Figure S10: Extended data on combination 8803 and checkpoint 
blockade in mT4-LA PDAC. (A) Longitudinal IVIS imaging for mice treated as described 
in Fig 16A. (B) Growth kinetics of subcutaneous mT4-LA tumors in mice shown in (A) and 
treated as described in Fig 16A. (C) Enumeration of mice deemed moribund due to 
ulceration >5mm in diameter at the uninjected subcutaneous tumor in the experiment 
shown in (A). (D) Survival of mice shown in Fig 16C in control groups consisting of Gem/nP 
and 8803 or Gem/nP and CTLA-4/PD-1 compared to relevant controls. (E) Percent of mice 
that failed to recover from final survival surgery on day 22 in experiments shown in Fig 16C. 
Statistical significance was calculated using the Log-rank Mantel-Cox test. ns = not 
significant, * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
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4.2.8: Summary 
 Targeting the suppressive myeloid stroma of pancreatic ductal adenocarcinoma 
(PDAC) is an attractive approach to sensitize these tumors to checkpoint blockade 
immunotherapy. Given the capacity for STING to control innate immune activation in both 
pathogenic and malignant settings, we investigated the effects of cyclic dinucleotide (CDN) 
agonists of STING on suppressive myeloid populations in vitro and in in vivo models of PDAC. 
We characterized a novel CDN IACS-8803, which exhibits equivalent – if not superior – activity 
in all settings relative to the first-in-class clinical CDN ML-RR-S2-CDA (ML-RR). As a single 
agent, local delivery of 8803 mediates efficient regression of subcutaneous PDAC tumors 
compared to ML-RR or natural CDNs cGAMP or CDG, inducing a profound inflammatory 
remodeling of the PDAC tumor microenvironment. In isolated in vitro settings, 8803 reduces 
the T cell suppressive capacity of murine bone marrow-derived MDSCs, and mediates 
morphological and phenotypic M1-like repolarization of human M2c-like macrophages. Using 
a novel transplantable model of KPC-derived PDAC, we find that intratumoral administration 
of 8803 into visceral orthotopically-implanted tumors potentiates the effects of checkpoint 
blockade immunotherapy, leading to the rapid eradication of an early-stage responsive 
disease model and extending survival in the context of a late-stage aggressive disease model. 
We find that standard of care chemotherapy is not required to achieve maximal survival benefit 
with this approach. Therefore, intratumoral delivery of potent STING agonists is an effective 
approach to sensitize aggressive PDAC tumors to checkpoint blockade in murine preclinical 
models, suggesting this combination may be of benefit in a clinical setting in urgent need of 
effective treatment options. 
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Chapter 5: Discussion 
 Castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma 
(PDAC) are terminal diseases that constitute a large proportion of all cancer-related deaths 
each year (68). Though immense progress has been made over the last decade identifying 
immune-based treatments that can be curative for patients with otherwise lethal malignancies, 
CRPC and PDAC remain refractory to these modalities. Therefore, new approaches must be 
developed based upon a deep understanding of the underlying barriers to immunological 
detection and rejection in these settings. A growing consensus in the world of immuno-
oncology attributes poor tumor immunogenicity in large part to the wayward activities of innate 
immune cells within the tumor microenvironment, prompting the discovery of therapeutic 
regimens capable of depleting or reprogramming these cells to support – rather than suppress 
– T cell-mediated antitumor immunity. In this dissertation, I studied the general hypothesis 
that activation of the STING pathway in suppressive tumor myeloid cells could mediate their 
functional repolarization, creating a context in which checkpoint blockade immunotherapy 
could liberate significant antitumor T cell responses in the context of poorly immunogenic 
cancers. In the course of these studies, I learned how intratumoral delivery of cyclic 
dinucleotide (CDN) STING agonists in combination with checkpoint modulators affects their 
ability to generate systemic immunity against multi-focal tumor burden, and how modulating 
CDN dosing frequency can alter the balance between efficacy and inflammatory pathology. I 
had the opportunity to characterize a novel STING agonist, IACS-8803, which consistently 
outperformed the first-in-class clinical CDN ML-RR-S2-CDA in both in vitro and in vivo testing. 
I further established a novel transplantable model of orthotopic PDAC in mice, and used this 
model to evaluate whether surgical delivery of 8803 into malignant pancreatic tissue could 
sensitize PDAC to checkpoint blockade or synergize with standard of care chemotherapy. In 
this chapter, I will discuss how my findings support, contradict, or advance the knowledge of 
134 
 
the field, and speculate about the potential future implications and applications of this work. 
 The strong preclinical foundation for targeting STING in cancer has spurred interest in 
translating CDNs as clinical compounds. To this end, a number of synthetic CDNs such as 
ML-RR-S2-CDA have been created for potent activation of both murine and human STING 
and reduced sensitivity to enzymatic degradation (429, 431). This effort was made with the 
assumption that greater CDN potency in vitro directly correlates with optimal therapeutic 
benefit in vivo, a theory that has been partially substantiated by dose titrations experiments 
(429) but has not been rigorously tested in the literature through comparison of different CDNs 
at equivalent concentrations. Some groups have argued that excessive STING activation can 
be a negative influence in cancer by upregulating counter-regulatory suppressive molecules 
such as IDO and PD-L1 (479) or through inhibition of T cell proliferation and survival (404, 
405). Moreover, I found that cyclic di-GMP (CDG), one of the weakest agonists of STING 
utilized in the literature, possesses significant efficacy in the TRAMP-C2 model of prostate 
cancer, and that reduced dosing of CDG suppresses local pathologies without significantly 
blunting efficacy. These results would argue that the “more is better” approach may not 
universally apply to STING agonists. Our identification of a novel CDN with even greater 
potency than ML-RR-S2-CDA (ML-RR) gave me the opportunity to ask with a panel of unique 
agonists whether greater in vitro CDN potency does in fact correlate with ultimate therapeutic 
benefit in PDAC tumors. In the context of a non-saturating dose of CDN, I found that CDN 
potency does correlate, albeit imperfectly, with tumor regression following intratumoral 
injection. Synthetic CDNs ML-RR and 8803 are clearly superior to natural CDNs CDG and 
cGAMP in the subcutaneous mT4 model. However, cGAMP does not outperform CDG, and 
in fact may trend towards inferiority at the dosage tested. An intriguing observation with these 
data is that cGAMP, unlike CDG or synthetic CDNs, fails to induce a substantial granulocytic 
infiltrate upon local injection. Though the nature of this granulomatous response has not been 
135 
 
fully described in the literature, it has been suggested that these cells may contribute to 
hemorrhagic necrosis at the injection site, possibly through TNFα release (442, 443). Whether 
recruitment of inflammatory neutrophils is a critical component of the CDN-mediated antitumor 
response remains an open question for further investigation. Nevertheless, in in vitro myeloid 
polarization experiments, I found that phenotypic and functional myeloid reprogramming 
correlates directly with CDN potency. Thus, with the corollary that CDG and cGAMP don’t fit 
perfectly within the paradigm, my results argue that translating CDNs with high in vitro potency 
is more likely to lead to more effective tumor control in vivo.  
Knowing this, an interesting area of investigation moving forward would be to 
determine exactly why synthetic CDNs possess such greater potency than cGAMP. It is not 
currently clear that these molecules bind with higher affinity to STING. The modifications that 
differentiate natural and synthetic CDNs tend to be associated with phosphodiesterase 
resistance, indicating that enhanced stability may underlie their greater efficacy (431). 
However, CDNs are very small molecules that can be rapidly cleared from the circulation, so 
it is not established that enzymatic degradation is rate-limiting in this context. An alternative 
explanation could be that synthetic CDNs exhibit differential rates of cellular uptake relative 
to natural CDNs, or are preferentially internalized by different cell types. Little is known about 
how unformulated CDNs ultimately gain access to the cytoplasm, thus greater understanding 
of the mechanisms controlling CDN uptake would be fruitful for the field. In addition, the 
enhanced potency of synthetic CDNs may also be explained by a capacity to engage 
qualitatively disparate signaling pathways relative to natural CDNs. One may imagine that 
CDNs bearing unnatural thiol substitutions or fluorinated sugar residues induce unique 
conformations in STING that affect recruitment of downstream signaling adaptors. Or, the 
rapid activation of STING by synthetic CDNs may elaborate primary cytokine release with 
faster kinetics compared to natural CDNs, leading to autocrine or paracrine signaling and 
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activation of secondary pathways that diversify the cytokine output. Experiments in this vein 
are an area of current investigation in follow up of my dissertation studies. 
In comparing the efficacy of known CDNs in vivo and in in vitro functional assays, my 
results have both corroborated and deepened our understanding of the effects of CDNs on 
suppressive myeloid populations. Polarization of macrophages along the M1/M2 spectrum 
has been studied in response to DMXAA and RR-CDG, focusing on the level of RNA 
transcription of selected genes such as arginase and iNOS (471) or release of cytokines 
including IL-10 or TNFα (442). My studies are the first to monitor in detail the broad phenotypic 
changes in human M2c polarized macrophages at the protein level by a panel of common 
CDNs. These experiments illuminated the tendency of CDNs to potently induce CD86 on 
suppressive macrophages, while CD80 can only be upregulated to a physiologically relevant 
level by 8803 at the dose examined. Moreover, these studies were the first to describe 
downregulation of M2-like markers CD163 and CD206 by human macrophages, coincident 
with a clear morphological shift away from M2-like morphology (343, 472). Importantly, my 
studies were also the first to describe detailed effects on MDSC function in response to CDN 
exposure. By establishing an assay system to quantitatively evaluate T cell suppression by 
homogenous populations of in vitro-differentiated bone marrow-derived MDSCs following 
CDN repolarization, I was able to demonstrate that STING activation reduces the suppressive 
capacity of MDSCs, with the most pronounced effects achieved by the more potent CDNs. 
Further studies into the nature of this reversal of function are warranted, as it is unclear 
whether observed functional changes are due to a shift in the relative contributions of PMN-
MDSCs versus MO-MDSCs in the culture, preferential cytotoxic effects on the most 
suppressive cells in the culture, or outright downregulation of factors responsible for 
ROS/RNS production, metabolic deprivation, or cytokine-mediated suppression of T cells. 
Detailed analysis of signaling programs engaged by CDNs in human M2c macrophages and 
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murine MDSCs through RNA sequencing and RPPA protein analysis are currently underway, 
which should shed light on these questions. At present, however, it appears that CDNs can 
achieve phenotypic and functional reprogramming of suppressive myeloid populations, which 
is likely to bolster the therapeutic effects of these molecules when delivered locally into 
myeloid-rich suppressive tumor microenvironments. 
The requirement for local delivery of CDNs presents a number of interesting questions 
and obstacles for successful translation into humans. Chief among these are the issues of 
dosing and applicability to visceral tumor settings. There is currently no consensus 
concentration at which CDNs should be used in preclinical settings, with published reports 
ranging from 5 µg to 100 µg per injection (429, 440). It can be argued that traditional “mg/kg” 
dosing is irrelevant in the context of intratumoral therapy, where therapies are intended to act 
at the site of injection rather than throughout the body. Rather, dosing based upon the size of 
the injected tumor may be more relevant, in light of the relationship I found between tumor 
size and the extent of inflammation at the site on injection with a flat dose of CDG. There is 
currently one FDA approved therapy administered by intratumoral injection in cancer; the 
oncolytic virus talimogene laherparepvec (T-VEC) (480). This drug is administered with a 
hybrid flat dosing scheme, in which patients receive either 106 pfu/mL or 108 pfu/mL T-VEC, 
but receive different injection volumes according to tumor size; starting at 0.1 mL for lesions 
under 0.5cm in diameter, ranging up to 4.0 mL for lesions greater than 5.0 cm in diameter 
(481). Experience with T-VEC may be useful in guiding clinical dosing strategies for CDNs. 
Additionally, few studies have evaluated different dosing frequencies, in terms of the number 
of CDN injections or days between injections, if multiple are used. My studies were the first to 
directly report on the effects of reducing CDN dosing frequency, as I found that a single CDN 
injection invokes less toxicity without significantly sacrificing systemic efficacy compared to 
three injections when combined with local checkpoint modulators in the bilateral TRAMP-C2 
138 
 
model. Francica et al found that within 24 hours following CDN injection, tumors exhibit 
widespread cleaved caspase 3 expression, indicative of a rapid apoptotic response in the 
TME (443). As STING activation is known to exert toxicity in the T cell compartment (404, 
405), one can imagine that use of frequent successive CDN injections may prove counter-
productive if this results in apoptotic death of newly primed and recruited T cells. In this case, 
frequent high-dose CDNs may deliver favorable cytoreduction of large bulky tumors, but this 
may occur at the expense of a maintained memory T cell response as a result of T cell toxicity. 
Thus, the relationship between CDN dosing, tumor reduction, and generation of memory T 
cell response is an important area of investigation for the field moving forward.  
Irrespective of this biology, the use of multiple CDN injections may be practically 
untenable in the clinic for the majority of patients that would require delivery of these agonists 
to sites of visceral disease. In theory, any organ in the body can be accessed through 
endoscopic, laparoscopic, or interventional radiologic means, and these are regularly utilized 
to biopsy human tumors (482). However, these procedures are associated with significant 
cost and risk, especially if multiple injections are preferred. My studies indicate that a single 
or two CDN injections are sufficient to elicit significant therapeutic benefit in both 
subcutaneous TRAMP-C2 or orthotopically-implanted mT4 PDAC, suggesting that local 
administration at the time of biopsy may be feasible and effective for patients even with late 
stage disease. Though rare in PDAC, the adjuvant setting presents an intriguing place to test 
the effects of local CDNs in patients already undergoing surgery for resectable or borderline 
resectable disease, especially given the high rate of relapse in these patients (68). Two 
innovative approaches have been proposed to prolong or optimize the benefit associated with 
local innate agonists in this setting through slow-release formulations. Smith and colleagues 
developed a biopolymer film that could be loaded with CDNs and CAR T cells and placed 
within the peritoneal cavity in proximity to growing PDAC tumors, allowing for extended 
139 
 
release of both constituents after a single procedure (483). In this study, the biopolymer 
approach outperformed local injection of naked CDN, and was sufficient to cure a portion of 
mice with aggressive orthotopically implanted KPC-derived tumors. While striking, the efficacy 
of this therapy was heavily dependent on CAR T cells, which have not been successfully 
utilized in the context of solid cancers and thus have many barriers preventing their use in 
human PDAC, for example. An alternative approach involves formulating CDNs or other 
innate agonists into a biodegradable hydrogel matrix, which can be locally implanted and allow 
for slow release of CDNs into tumors over one to two weeks. To date, two studies have 
incorporated CDNs into hydrogels for use in cancer therapy, and have demonstrated immune 
potentiating effects and therapeutic benefit in 4T1 breast cancer and MOC2 head and neck 
cancer models (484, 485). This approach, combined with checkpoint blockade therapy, may 
enhance the efficacy of my local injection method without requiring use of CAR T cells as used 
in the study by Smith et al. This is thus an area of active investigation with exciting translational 
potential. 
 Ultimately, the holy grail of any intratumoral immunotherapy is generation of abscopal 
immunity. A number of studies have reported that local delivery of STING agonists in the 
single agent setting is sufficient to induce systemic immunity against distal uninjected tumors 
(429, 439). In contrast, a number of other reports have found the opposite to be true; that 
STING agonists alone are insufficient to generate abscopal immunity on their own, but only 
affect outgrowth of distal tumors when used in combination with other systemic 
immunotherapies (438, 440, 442). My results have indicated that either can be true. In all 
likelihood, the ability of CDNs alone to generate abscopal immunity may be dependent on 
tumor antigenicity as well as the size and composition of the tumor at the time of therapy. For 
example, using the less aggressive mT4-LS model of PDAC, I found that single agent 8803 
delivered into orthotopic lesions can elicit curative responses against the injected tumor as 
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well as the uninjected subcutaneous tumor in 50% of mice tested. However, in the aggressive 
mT4-LA model, no curative responses are observed using the equivalent treatment schedule. 
Thus, in two models which are theoretically equivalent in terms of antigen burden but differ in 
in vivo growth kinetics, abscopal immunity was only generated in the context of lesser tumor 
burden. Interestingly, this too may be context-dependent, as no significant abscopal immunity 
could be generated using CDG against small ~25mm3 TRAMP-C2 tumors, which are known 
to exhibit relatively slow growth kinetics in vivo. In this context, CDN potency and the immune 
composition of distal TRAMP-C2 tumors may be critical in dictating responsivity of the 
uninjected tumor to abscopal T cell-mediated immunity. A final factor to be considered in this 
discussion is that the small size and highly-diffusive nature of CDNs makes systemic 
distribution likely even following local intratumoral injection. Without rigorous evaluation of the 
levels of CDN reaching the uninjected tumor that may have direct immune-potentiating effects, 
it is difficult to make firm conclusions about abscopal immunity, especially when large doses 
(~50-100 µg) are administered one or more times (429, 443). Therefore, while CDNs are 
theoretically capable of promoting priming of systemic T cell responses, it is difficult to predict 
under which circumstances these responses will be seen, and detailed validation needs to be 
provided to determine whether any such response is the result of bona fide abscopal 
immunity. 
 Together, my results help lay the groundwork to test CDNs in combination with 
checkpoint blockade therapy in patients with CRPC or PDAC, two settings with urgent need 
for effective treatment modalities. These studies have contributed to the field at large by 
providing insight into CDN dosing strategies and local pathologies when combined with 
checkpoint modulating therapies, by identifying a novel potent CDN and demonstrating that 
CDN potency does correlate with efficacy in both in vitro functional assays and in vivo tumor 
models, by enriching our understanding of the effects of CDNs on M2c polarized macrophages 
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and bone marrow-derived MDSCs of human and murine origin, and by providing proof of 
concept that CDNs can be delivered into visceral PDAC tumors and synergize with checkpoint 
blockade immunotherapy in the setting of highly aggressive and metastatic disease. The 
coming years should see rapid clinical translation of therapies targeting myeloid cells in many 
cancers including CRPC and PDAC, where the myeloid infiltrate is numerous and functionally 
corrupt. My hope is that, in some part due to the work presented in this thesis, these powerful 
STING-targeting therapies may help lead the way in this endeavor, and that patients in need 
of hope may find it as a result.   
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